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1. Coronary artery disease
In the beginning of the 20th century coronary artery disease was the fourth 
cause of death in the USA behind tuberculosis, pneumonia or influenza and 
gastrointestinal infections, but in ensuing decades this would change[1]. In 1900 a 20 
year old adult had a remaining life expectancy of just 41 years, the impact of an age 
related condition such as coronary artery disease was consequently limited. But in 
the following decades treatment for infectious diseases improved and life expectancy 
increased dramatically and so did the risk of dying by a cardiovascular related illness. 
By the end of the Second World War coronary artery disease (CAD) was already 
the primary cause of death in the USA and accounted for more deaths than the 
next 3 highest causes of death combined. In the western world this increase would 
peak around 1960 to 1980 at which time the number of deaths per 100.000 due to 
cardiovascular disease started to decrease[1]. In other parts of the world particularly 
in rapidly developing countries the same trend that western countries saw in the 
beginning of the 20th century can currently be observed and a large increase in 
cardiovascular disease related deaths is witnessed[2,3]. At present cardiovascular 
disease is the number one cause of death worldwide and future projections indicate 
that this is unlikely to change in the coming decades[3–5]. Although in the western 
world the number of cardiovascular disease related deaths is decreasing the actual 
prevalence of cardiovascular disease is increasing due to better management of 
cardiovascular disease and primarily due to a better survival rate after myocardial 
infarction. The increasing prevalence of cardiovascular disease in the western 
population imposes a heavy and increasing burden on the health care system[6–9]. 
The pressure is still on for researchers and physicians to develop new and better 




Atherosclerosis is the main cause of cardiovascular disease and as such it 
is essential to improve the knowledge of mechanisms leading to atherosclerotic 
disease development and progression[10,11]. The first stages of atherosclerosis are 
already observed in childhood[12,13]. Atherosclerosis is prone to develop at specific 
sites in the cardiovascular system and develops primarily at branch points of arteries 
and at the inner curvatures of coronary arteries[14].
2.1 Early lesion development
Endothelial cell dysfunction is the first step in the development of an 
atherosclerotic plaque[15]. Even before the start of atherosclerosis, endothelial 
cells at sites of low or oscillatory shear stress show an altered gene expression 
profile and phenotype[14,16,17]. Cardiovascular risk factors such as smoking and 
diabetes mellitus can increase endothelial cell dysfunction leading to accelerated 
atherosclerotic development[18,19].
The first atherosclerotic plaque, called a fatty streak, develops when LDL 
Figure 1:
Fatty streak Pathological intimal thickening Fibroatheroma
Foam cells Lipid pool/Necrotic core
Fibrous cap
Angiogenesis
 Development of atherosclerotic lesion. Already during adolescence the first stages of 
atherosclerosis development are visible. The earliest atherosclerotic lesion is called the fatty streak 
and is characterized by an accumulation of foam cells in the intima of the vessel wall. The next 
step is the development of a pathological intimal thickening lesion in which lipid pools develop 
without an apparent necrotic core. With the appearance of a necrotic core the lesion transitions to a 
fibroatheroma which can also contain calcified nodules and newly formed microvessels as depicted. 
Figure adapted from Bentzon JF et al. Circ Res 2014; 114(12): 1852–66.
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enters the intimal layer[20–22]. Modifications such as oxidation of LDL (oxLDL) can 
further aggravate the endothelial dysfunction and induce expression of vascular 
cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-
1), E-selectin and P-selectin[23–25]. Furthermore, oxLDL also increases expression of 
inflammatory factors such as CCL2, MCSF and GMCSF[26,27]. Both the increased 
expression of adhesion molecules on endothelial cells as well as the increased 
expression of inflammatory factors leads to recruitment of primarily innate immune 
cells such as monocytes and neutrophils to the early plaque. Due to the increased 
selectin expression on endothelial cells monocytes attach to or are “captured” by 
the endothelial layer and start rolling along the vessel wall, binding of VCAM1 and 
ICAM1 on the endothelial layer to LFA1 and VLA4 on the monocytes causes arrest 
and firm adhesion of the monocyte to the vessel wall[28]. The monocyte then migrates 
through the endothelial layer into the atherosclerotic plaque. Upon entering the 
fatty streak the monocytes differentiate into macrophages and start taking up oxLDL 
forming so called lipid laden foam cells which are characteristic for atherosclerotic 
plaque development (Figure 1)[29,30]. When multiple layers of foam cells develop the 
plaque becomes visible by the unaided eye as a yellow streak in the vessel wall. The 
fatty streak can already be present in infants younger than six months, in the later 
years these disappear[31,32]. In adolescence fatty streaks reappear at predisposed sites 
in the vascular system. Fatty streaks are clinically silent and fully reversible if the 
cause of atherosclerotic development is removed.
LDL is essential for the first initiation of atherosclerotic plaque development, 
data from randomized statin trails suggest that below a threshold of approximately 
70 mg/ml LDL-cholesterol (LDL-C) atherosclerotic plaque progression is virtually 
halted and coronary heart disease events are minimized[33]. As the disease progresses 
however the endothelial dysfunction increases and the vessel wall becomes 
increasingly “leaky” allowing easier migration of LDL particles and inflammatory 
cells into the newly developing plaque[34]. As such a higher concentration of LDL 
might be needed for initiation of atherosclerosis in contrast to the progression of 
atherosclerotic plaque development. In accordance with this view studies have found 
5
Introduction
that high LDL-C levels early in life are a risk factor for developing cardiovascular 
disease later in life[35,36].
2.2 Advanced lesion development
Many early lesions will not progress beyond this stage of development, but 
especially at predisposed sites in the coronary, carotid and femoral artery some 
lesions will advance to a more complex lesion types. Macrophages and T cells 
recruited to the early atherosclerotic plaque will produce cytokines, chemokines 
and growth factors that stimulate smooth muscle cells (SMC) to start migrating 
from the media, the middle layer of the vessel wall, to the intima[37]. In the intima 
SMCs will start to proliferate and produce extracellular matrix protein forming a 
fibrous cap over the macrophage and lipid rich plaque. The defining characteristic 
of pathological intimal thickening (PIT) lesions is the appearance of lipid rich pools 
below the layer of foam cells, these types of lesions are often seen in the coronary 
arteries of young adults (Figure 1)[22,38,39].
Due to stress factors such as endoplasmic reticulum stress in combination 
with possible other stressors, cells, primarily foam cells and SMCs, go into 
apoptosis[40,41]. Apoptosis can in some cases lead to a decrease in atherosclerosis and 
inflammation when the apoptotic bodies are cleared efficiently by other phagocytes 
(efferocytosis)[42,43]. When efferocytosis is inadequate, as is often the case in more 
advanced atherosclerosis, the apoptotic bodies go into secondary necrosis which 
increases inflammation and adds to the creation of the so called necrotic core within 
the atherosclerotic plaque[44,45]. The necrotic core primarily contains cholesterol 
esters, free cholesterol and cellular debris, the formation of the necrotic core leads to 
disruption and destruction of the intima of the vessel wall[43,46]. With the appearance 
of the necrotic core the plaque becomes a fibroatheroma.
At this stage of plaque development angiogenesis, new vessel formation, may 
occur. Oxygen deprivation in the inner plaque region can induce a signaling cascade 
that leads to new microvessel formation into the interior of the plaque[47–49]. Most 
of these vessels originate from the vasa vasorum, the small vessel formation around 
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the larger artery[50–52]. These new vessels into the plaque expedite inflammatory 
cell recruitment and due to the “leaky” nature of these vessels this also leads to an 
increase in intra-plaque hemorrhages[53]. In an experimental atherosclerosis model, 
migration of inflammatory cells was up to 100 times more efficient through newly 
formed microvessels (per endothelial area) compared to the arterial vessel wall[52]. 
Both increased inflammatory cell infiltration as well as increased plaque hemorrhage 
can increase the formation of the necrotic core[54].
Increases in the size of the fibrous cap and the necrotic core of the plaque 
can obstruct the lumen of the artery (Figure 2). Initially the artery can remodel its 
outer structure limiting the incursion of the plaque into the lumen. The formation 
of large advanced atherosclerotic plaques as well as negative arterial remodeling in 
the presence of a smaller plaques can result in regression of lumen area (stenosis)[55]. 
Severe stenosis can result in stable angina pectoris, a clinical manifestation in which 
coronary blood flow is obstructed and which results in chest pain during exercise 
for the patients, but does not necessarily lead to myocardial infarct[56].
The progression from fatty streak to fibroatheroma does not advance at the 
same pace for every lesion. An interesting finding is that while men and women 
develop the same number of fatty streak lesions at a young age men have significantly 
more advanced lesion by the age of 30[57].
2.3 The vulnerable plaque
An acute coronary syndrome, such as a myocardial infarct (MI), is in almost 
all cases caused by luminal thrombosis[58]. In the case of an MI the luminal thrombosis 
is persistent and the occlusion of the artery leads to oxygen deprivation of the 
myocardium and damage to heart tissue. In contrast in non-ST segment elevation 
MI (non-STEMI) and unstable angina the thrombus formation is intermittent 
and leads to temporary or partial occlusion of the lumen. The difference between 
unstable angina and non-STEMI is the presence of biomarkers in blood indicating 
damage to the myocardium, such as creatine kinase or cardiac troponins[59].
7
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There are two main initiators of thrombus formation, rupture and so called 
erosion of the plaque, and in about 75% of cases rupture is the cause of coronary 
thrombosis[60,61]. Research has shown that plaques that have ruptured often have a thin 
fibrous cap and a large necrotic core, plaques with these morphological features are 
called thin cap fibroatheroma (TCFA, Figure 2)[22]. Degradation of the fibrous cap is 
likely caused by loss of SMCs in the cap and infiltration of inflammatory macrophages 
into the cap. SMCs are the main producers of extracellular collagen which provides 
stability to the plaque and loss of these cells leads to a loss of maintenance of the 
fibrous cap[46,62]. SMC apoptosis is induced by pro-inflammatory cytokines produced 
by a range of cells including lymphocytes, macrophages and mast cells[63–65]. Human 
autopsy samples of coronary plaques have shown that ruptured plaques are heavily 
infiltrated by macrophages[66,67]. Infiltrating macrophages produce matrix degrading 
protein such as matrix metalloproteinases (MMP) which destabilize the plaque by 
degrading the fibrous cap, increasing the risk of plaque rupture[68]. Although 95% of 
Figure 2:
TCFA Ruptured plaque Healed plaque
Lumen Thin fibrous cap Thrombus Stenosis
 Rupture and healing of atherosclerotic plaque. Thin cap fibroatheromas (TFCA) are 
vulnerable to rupture and typically are heavily inflamed atherosclerotic plaques with a large necrotic 
core and a thin fibrous cap. After rupture of the fibrous cap material from inside the plaque will enter 
the blood stream leading to thrombus formation. The thrombus can occlude flow directly on top of 
the plaque or can dislodge and get stuck in other part of the vasculature. In the process of healing the 
rupture, vessel remodeling can result in obstruction of blood flow (stenosis). Figure adapted from 
Bentzon JF et al. Circ Res 2014; 114(12): 1852–66.
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ruptures are seen in TCFAs, only a minority of TCFAs cause an actual cardiovascular 
event according to the recent PROSPECT study[69].
Erosion of the plaque is the other main cause of arterial thrombosis, in 
contrast to plaque rupture little is known about plaque erosion[22]. Plaque erosion 
is described as the formation of a thrombus in the absence of plaque rupture or 
loss of endothelial cells covering the plaque[66]. Other features sometimes associated 
with an eroded plaques are the fact that these lesions are smaller and less inflamed 
compared to ruptured plaques and show negative arterial remodeling although 
there is no consensus on these features[60]. Interestingly, although rupture is the 
main cause for arterial thrombosis in both males and females, it is much less 
prevalent in females (approx. 55%) in contrast to males (approx. 76%)[60,66,70]. 
Particularly in pre-menopausal women plaque erosion seems to be the main cause of 
coronary thrombosis[71].
It is unknown whether the thinning of the fibrous cap is a fast or a slow 
process, but observations suggest it may be a relatively slow process taking years 
or even decades. Fibroatheromas are prevalent in men in their thirties, in contrast, 
cardiovascular events are rare in this age group indicating that degradation of the 
fibrous cap is a protracted process[38]. Recently a research project determined the 
average age of specific plaque components using a novel carbon dating method and 
they describe that the average age of the fibrous cap is 6.4 years[72].
3. Atherosclerosis and the immune system
For the primary initiation of atherosclerosis lipid accumulation is essential but 
during progression of the atherosclerotic plaque inflammation becomes increasingly 
more important and is the crucial modulator of plaque destabilization[73,74]. 
Classically the immune system is divided into two complimentary systems: the 
innate and the adaptive immune response (Figure 3). The innate immune response 
acts as the first rapid but non-specific response of the immune system to invasion 
by a foreign pathogen, the innate response can recognizing foreign pathogen and 
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local damage associated molecular patterns and their recognition can initiate a 
rapid inflammatory response. The pathogen can be internalized and processed by 
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 Overview of innate and adaptive immune cells involved in the development and 
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Kidney Int 2011; 80(5): 453–63.
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which are part of the innate immune system. APCs can present processed pathogen-
derived molecules on specialized receptors on the cell surface and these can then 
be recognized by lymphocytes, such as T and B cells, which are part of the adaptive 
immune system. Lymphocytes can consequently initiate a specific inflammatory 
response towards the pathogen, besides the inflammatory response memory T and 
B cells are induced which can retain the molecular pattern information for a faster 
targeted response in future infections by the same pathogen.
3.1 Monocytes and macrophages
The discovery of a previously unknown subdivision of monocytes into two 
functionally distinct cell subsets led to renewed interest in monocyte development 
and their involvement in disease[75]. In mice two monocyte subsets are identified that 
are denoted by their cell surface expression of the glycoprotein Ly6C, in contrast in 
humans three distinct monocyte subsets have been identified by their expression of 
the pattern recognition receptor CD14 and the Fcγ receptor CD16[76,77]. Ly6Chigh 
monocytes are referred to as classical monocytes which represent majority 
(approx. 80%) of all monocytes, they are short lived cells that upon inflammation 
rapidly migrate towards the site of inflammation where they can differentiate into 
macrophages or dendritic cells[75]. The homologous monocyte cell subset in humans 
is CD14highCD16-. In contrast Ly6Clow monocytes are longer lived and continually 
survey the integrity of the vessel wall by crawling along the endothelial cell layer, 
these are called the non-classical monocytes[78,79]. Cell fate mapping studies have 
confirmed that Ly6Clow monocytes differentiate from L6Chigh monocytes outside the 
bone marrow[80–82]. The corresponding human monocyte cell subset is identified by 
CD14lowCD16+ expression. A third human monocyte cell subset exists designated 
by CD14highCD16+ which is called the intermediate monocyte cell subset, there is no 
equivalent mouse monocyte cell subset known[77].
A clear association has been shown between classical monocytes and 
atherosclerotic plaque progression. As experimental atherosclerosis in mice 
worsens the number of circulating classical monocytes increases[83]. In multiple 
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animal models on a hypercholesterolemia background monocytosis has been 
described, also in patients with familial hypercholesterolemia increased circulating 
monocyte counts have been observed[84–86]. The CCR2 receptor is exclusively 
expressed by classical monocytes, blockade of the CCR2 receptor disrupts exit of 
monocytes from the bone marrow resulting in greatly reduced atherosclerotic lesion 
development in mice[87]. While CCR2 is important for monocyte homeostasis there 
are multiple other chemokines described that mediate direct homing of monocytes 
to the atherosclerotic lesion, these include CCL5, CXCL1 and CX3CL1[88]. Blockade 
of the chemokine receptors CCR2, CCR5 and CX3CR1 reduces atherosclerotic 
development to such a degree that it is practically abolished[89].
In contrast to the clear relationship between classical monocytes and 
atherosclerosis, for the non-classical monocytes the relationship is ambiguous. 
While non-classical monocytes can take up cholesterol and become foam cells in 
vitro they do not seem to contribute to lesional macrophage content[90–92]. Knock 
out of non-classical monocytes in experimental atherosclerosis shows contradicting 
results, while some see an increase in atherosclerosis others do not[91–94]. Non-classical 
monocytes have rarely been shown to extravasate into tissue, as such non-classical 
monocytes might only play a minor role in the development of atherosclerosis[79].
Until recently macrophages were thought to exclusively originate from 
monocytes that differentiate in tissue to macrophages[95]. A recent spate of papers has 
shown that under normal circumstances tissue resident macrophages do not originate 
from monocytes but from progenitor cells distributed during embryogenesis[82,96–101]. 
Another recent paper suggests that local macrophage proliferation is of great 
importance to lesional macrophage content especially in advanced atherosclerotic 
lesions[102]. Although a clear correlation is observed between classical monocyte 
and atherosclerotic plaque development this is especially strong in initial lesion 
development. Blockade of monocyte recruitment in advanced lesions does not 
have a pronounced effect on lesion development[103–105]. As such the initial batch of 
macrophages might be directly derived from circulating monocytes while later on 
in atherosclerotic development most lesional macrophages might be derived from 
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local proliferation. If and what part tissue resident progenitor cells add the lesional 
macrophage content is still not known and more research is needed to clear this up.
As with monocytes, macrophages are also known to have multiple 
functionally different subsets, until recently two subsets were described, M1 and M2 
macrophages[106]. Recent research has shown that there are many more than just these 
two subsets of macrophages and new nomenclature has been proposed to encompass 
this new spectrum of macrophage subsets[107]. In this new nomenclature the M1 and 
M2 macrophage describe the two extremes of the spectrum. M1 or M(IFNγ) as these 
are called in the new nomenclature produce large amounts of pro-inflammatory 
cytokines such as TNFα, IL-6 and IL-12, MMP-1, reactive oxygen species, oxygen 
intermediates and promote a Th1 type T cell inflammatory response[108–111]. In 
contrast M2 (or M(IL-4)) macrophages produce anti-inflammatory cytokines such 
as IL-10, TGFβ, and IL1RA and promote wound healing, tissue remodeling and 
efferocytosis[112,113]. Research has shown that both M1 and M2 macrophages are 
present in atherosclerotic lesions[114]. Furthermore subsequent in vitro research 
has found additional macrophage subsets possibly involved in atherosclerotic 
development[115,116]. The activation of macrophages is likely microenvironment 
dependent and very dynamic, the functional impact of these macrophage 
subsets on the development of atherosclerosis is still unclear[117]. Interestingly, in 
atherosclerotic regression studies, where mice are put on a low cholesterol diet a shift 
can be seen in the activation of macrophages in the atherosclerotic lesion towards a 
more M2 like phenotype[118].
3.2 Neutrophils
Neutrophils are one of the first cells to initiate the immune response upon 
infection or tissue damage and release a large amount of anti-microbial compounds 
and signaling molecules, as such neutrophils are sometimes characterized as a rapid 
but untargeted and blunt response which can induce collateral damage to heathy 
tissue[119]. This classification of neutrophils has recently been challenged by new 
findings of immune regulatory roles of neutrophils[120–122]. The main mechanism 
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of action for neutrophils is the release of their granules, which are preformed 
intracellular vesicles that upon fusion with the cell membrane can release their intra-
vesicle content very rapidly. Neutrophils contain a spectrum of granules which can 
roughly be divided into four subsets, each type contains a unique mix of cytokines, 
chemokines and anti-microbial compounds[119]. For many years the importance of 
neutrophils in the development of atherosclerosis was underestimated, likely because 
of the difficulty of studying neutrophils in vivo. Neutrophils are very short-lived cells 
especially when they are in circulation, their half-life is 6-8 hours[123]. Furthermore 
until recently no specific markers were available to identify neutrophils in tissue. 
New markers such as Li6G in mice and CD66b in humans and new microscopy 
techniques simplified the study of neutrophils[124]. Recent papers reveal that 
extravasation of neutrophils into inflamed tissue increases their half-life significantly 
(1-4 days) leading to an increase in time during which neutrophils can produce and 
excrete inflammatory factors, exacerbating the local inflammatory response[123].
Experimental mice models have shown that neutrophils are present in the 
plaque in the initial stage of atherosclerosis development as well as in the rupture 
prone plaque[125,126]. Endothelial dysfunction is the first sign of atherosclerosis 
development and new data indicates that neutrophils might aggravate endothelial 
dysfunction leading to monocyte recruitment into the fatty streak. Research has 
shown that neutrophils have more transient contact with endothelium covering 
the atherosclerotic plaque than any other immune cell[127]. Upon binding of 
neutrophils to the endothelium neutrophils will release granules containing 
azurocidin and proteinase-3 which can increase vascular adhesion molecule and 
CCL2 expression[128–130]. Furthermore myeloperoxidase (MPO), a protein primarily 
produced by neutrophils, decreases availability of nitric oxide which greatly increases 
endothelial dysfunction[131,132]. Both these mechanisms could induce increased 
recruitment of monocytes to the early fatty streak. This view is further corroborated 
by research in an experimental mice model which shows that in the absence of 
neutrophils (neutropenia) there is a decreased number of classical monocytes 
and macrophages in the aorta of mice with hyperlipidemia[125]. Once neutrophils 
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extravasate into the atherosclerotic lesion they can produce a whole range of pro-
inflammatory cytokines and chemokines some of which can recruit monocytes 
by themselves others can induce other immune cells to start a pro-inflammatory 
reaction, initiating a cascade of increasing inflammation in the lesion[133].
In later stages of plaque development neutrophils have also been identified 
in the lesion, both in mice as well as in men. They are primarily associated with 
highly inflamed plaques in mice and locate close to the fibrous cap and in humans 
neutrophils are associated with rupture prone (TCFA) plaques[126,134]. Neutrophils 
produce multiple MMPs that can induce plaque destabilization including MMP-8 
and MMP-9[124]. In an experimental mice model MMP-9 has been shown to induce 
plaque destabilization[68,135]. Further research is needed to determine if neutrophils 
are causally linked to plaque rupture.
3.3 T cells
For the immune system to initiate an adaptive immune response APCs 
are essential. APCs engulf and process antigens and present them on their cell 
surface through specialized proteins expressed on the cell surface called the major 
histocompatibility complex (MHC). Dendritic cells are the immune systems primary 
antigen presenting cell type and it is thought they take up the antigen and transport it 
to the draining lymph node where T cells with the corresponding T cell receptor can 
recognize the presented antigen, depending on co-stimulation and cytokines in the 
environment T cell can become activated effector, anergic, regulatory or memory T 
cells[136]. There are two classes of MHC molecules, which are recognized by different 
T cells, CD8+ T cells can interact with MHC class I molecules while CD4+ T cells can 
interact with MHC class II molecules. Activated T cells proliferate and travel to the 
site of inflammation where they can again encounter APCs which present the same 
antigen inducing the T cell to start inflammatory functions, at the site of infection 
macrophages, endothelial cells, mast cells as well as dendritic cells can function as 
APCs. Depending on environmental factors T cells can differentiate into specific T 
cell subsets such as T helper, T regulatory or cytotoxic T cells[137].
15
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3.3.1 CD4+ T cells
In experimental mouse models the majority of T cells found in the 
atherosclerotic plaque are CD4+ and in humans CD4+ T cells are present in all stages 
of plaque development[138–141]. Reconstitution of immune deficient mice with CD4+ 
T cells significantly aggravated atherosclerotic plaque development[142]. T cells can 
differentiate into different T cell subsets depending on environmental cues, for a long 
time it was thought that there were two mutually exclusive T helper cell subsets, Th1 
and Th2 cells. Since the start of this millennium this view has changed significantly 
with the introduction of new T cell subsets such as Th17, Th9, Th22 and Treg cells 
and there is evidence for considerable plasticity between these subsets in vivo[143,144].
3.3.2 T helper 1 cells
Naïve T cells commit to Th1 differentiation under influence of IFNγ and 
interleukin 12 (IL-12). Binding of IL-12 to its receptor initiates an intracellular 
signaling cascade that lead to induction of two transcription factors, STAT4 and 
Tbet. Tbet in turn blocks production of IL-4 and IL-5 and induces production of 
IFNγ and a high affinity IL-12 receptor, which leads to terminal differentiation 
towards the Th1 lineage T cells.
IFNγ is the defining cytokine for Th1 cells and the identification of 
IFNγ mRNA and protein in the atherosclerotic plaque as well as the finding 
that T cells isolated from plaques produce IFNγ shows that Th1 cells are present 
in atherosclerotic plaques[145,146]. Ablation of IFNγ or its receptor attenuates 
plaque development and results in a more stable plaque phenotype, in contrast 
administration of IFNγ aggravates atherosclerotic plaque development[147–149]. 
IFNγ promotes a pro-inflammatory environment by inducing other cells like 
macrophages and endothelial cells to produce pro-inflammatory factors as well as 
express increased adhesion molecules. In conjunction with these findings treatment 
of hypercholesterolemic mice with IL-12 increased IFNγ concentration and 
accelerated plaque development[150]. Other cytokines connected with the Th1 cell 
subset IL-18, TNFα and IL-1β are associated with aggravation of atherosclerosis in 
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a mouse model[151–154]. Consequently the Th1 cell subset is seen as pro-atherogenic 
by enhancing atherosclerotic plaque growth, increasing inflammation and reducing 
plaque stability.
3.3.3 T helper 2 cells
The Th2 lineage differentiation is initiated by IL-4 and IL-13 in combination 
with OX40-OX40L co-stimulation by dendritic cells and possibly basophils. IL-4 
stimulation induces STAT6 activation and in combination with T cell receptor 
(TCR) signaling stimulates expression of the transcription factor GATA-3. GATA-3 
is essential for Th2 differentiation and blocks IL-12 signaling repressing Th1 
differentiation as well as inducing IL-4 and IL-5 production which in an autocrine 
loop solidifies Th2 differentiation[155].
When T helper cell diversity was still considered a dichotomy between Th1 
and Th2, Th2 cells were considered anti-atherogenic. This was a consequence of 
observations that when the T helper cell response switched to a Th2 paradigm a 
decrease was seen in atherosclerosis development. Hypercholesterolemia was shown 
to be associated with a shift in T cell subsets to Th1 cell response and further more Tbet 
deficient mice shifted the T cell response towards a Th2 response and a significant 
reduction was seen in atherosclerotic plaque development in these mice[156,157]. 
Research into the relationship between the characteristic cytokine produced by 
Th2 cells IL-4 and atherosclerosis is inconsistent. Some papers report an athero-
protective effect of the absence of IL-4 while another paper reported no difference 
when IL-4 was administered to mice prone to develop atherosclerosis[158–160]. These 
studies indicate that IL-4 might play no part in atherosclerosis or might even be pro-
atherogenic, contrasting with the view of Th2 cells as athero-protective. In a recent 
study on another Th2 cytokine,IL-23, showed that the absence of this cytokine had 
an adverse effect on atherosclerotic plaque development in atherosclerotic prone 
mice thus indicating a protective effect of this cytokine[161]. Blockade of the OX40-
OX40L co-stimulatory pathway lead to a significant reduction of Th2 of activation 
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which corresponded with less plaque development, pointing to a pro-atherogenic 
role of Th2 cells[162].
No consistent conclusion can be made about the protective or aggravating 
effect of Th2 cell on atherosclerosis development. In contrast research has clearly 
shown that Th1 cells are considerably more pro-atherogenic than Th2 cells and thus 
a shift towards a Th2 response is likely to attenuate plaque development.
3.3.4 T helper 17 cells
TGFβ and IL-6 are essential for a naïve T cells to differentiate into a Th17 
cell[163]. First TGFβ blocks differentiation towards the other major T helper subsets 
and subsequently IL-6 can initiate Th17 differentiation[164]. IL-6 activates STAT3 
which in turn induces RORγt which is the central regulator of IL-17 production by 
Th17 cells[165].
Th17 cells are involved in many inflammatory and autoimmune diseases, 
such as inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis 
and psoriasis[166]. After the discovery of Th17 cells it was thought that Th17 cells 
aggravated immune disease progression by increasing inflammation but recently in 
other disease settings it has been shown that Th17 can also attenuate inflammatory 
disease progression. In arthritis, conversion of T regulatory (Treg) cells into Th17 
cells aggravated disease progression while in a colitis model the inhibition of the Th1 
differentiation by Th17 cells limited disease progression[167,168]. In the atherosclerosis 
field there is contradictory evidence on the role of Th17 cells. Blockade of IL-17 
signaling through antibody blockade or genetic ablation seems to be mostly athero-
protective or had no effect on progression of atherosclerosis, but one group found 
the opposite that ablation of IL-17 increased atherosclerosis[169–172]. Extrapoling from 
these results, it would be expected that stimulation of the IL-17 signaling pathway 
would then be atherogenic. In contrast, this was found to also be athero-protective 
by the majority of studies which researched administration or increased expression 
of IL-17, again one paper found that IL-17 administration was atherogenic[172–174]. 
It is interesting to note that when IL-17 is seen to be athero-protective in a study 
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this is mostly associated with a decrease in IFNγ and an increase in IL-5 and IL-
10[172,174]. This possibly could indicate that the influence of IL-17 on atherosclerosis 
progression depends on its ability to shift T cells towards Th1 or Treg subsets 
depending on environmental factors.
3.3.5 T regulatory cells
The counterbalance to the T helper cell response is the T regulatory (Treg) 
cell response. In contrast to the T helper cells, Treg cells do not directly provide 
protective immunity but modulate the inflammatory response. The primary function 
of Treg cells is to induce self-tolerance toward indigenous antigens to protect against 
autoimmunity[175]. Not surprisingly failure to induce an adequate Treg response is 
shown in several autoimmune and inflammatory diseases[176].
Treg cells achieve their immunosuppressive effect by three different 
mechanisms. First by direct cell-to-cell contact, which is mediated by CTLA-4 
and membrane bound TGFβ. Second the binding of IL-2 to CD25 reduces the 
availability of this proliferation factor for other T cells. And third by producing 
immunosuppressive cytokines such as TGFβ and IL-10, which are the signature 
cytokines for Treg cells[177,178]. Treg cells not only target other CD4+ T cells for 
immunosuppression but also CD8+ T cells, DCs, macrophages, natural killer 
cells and endothelial cells. Treg cells are observed in all stages of atherosclerotic 
plaque development in humans, albeit in much lower numbers than observed in 
other inflamed tissues[179]. Although initially an increase is seen in Treg numbers 
during atherosclerotic plaque development in a hyperlipidemic mouse model , a 
large reduction is seen in more advanced plaques with a greatly increased effector 
T cell to Treg ratio[180]. This increase in effector T cell to Treg ratio can be reversed 
by placing the mice on a low cholesterol diet. Depletion of Tregs increased plaque 
formation in a hypercholesterolemic mouse model, another model where Treg 
cell development was blocked also showed an increase in plaque formation[181–183]. 
Furthermore blockade of IL-10 or TGFβ through antibody blockade or through 
genetic ablation showed increased atherosclerotic plaque formation[184–189]. In 
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contrast, adaptive transfer of Tregs or Treg induction reduced atherosclerotic plaque 
progression, more so administration of IL-2 or IL-2/anti-IL-2 complex to mice with 
pre-established atherosclerotic plaque saw plaque regression which coincided with 
a significant increase in Treg cells[183,190–197]. In aggregate this research clearly shows 
that Treg cells are athero-protective and modulation of Treg cells or Treg induction 
is an interesting novel therapy for the treatment of cardiovascular disease.
3.3.6 CD8+ T cells
Compared to CD4+ T cells much less is known about the influence of CD8+ 
T cells on atherosclerotic plaque development. CD8+ T cells kill their target APC 
directly by releasing granzyme B and perforin, in this way CD8+ cells are very 
important for the protection against viruses. Upon continued activation CD8+ T cells 
can also produce large amounts of IFNγ[198]. Although in humans CD8+ T cells can 
account for up to 50% of T cells in the plaque in mice plaque resident CD8+ T cells are 
much rarer than in humans[199]. MHC I receptors on APCs are necessary for antigen 
presentation to CD8+ T cells, mice lacking MHC I show reduced atherosclerotic 
plaque formation suggesting a role for CD8+ T cells in plaque formation[200]. Results 
from hyperlipidemic mice studies lacking CD8+ T cells are contradictory, while two 
studies find no significant difference, a third study finds that CD8+ T cells increase 
lesion inflammation and lesion vulnerability[200–202]. Taken together these reports 
indicate that if CD8+ cells have an effect on atherosclerosis it is likely to be atherogenic 
but the significance of their influence in atherosclerotic development still needs to be 
determined. Interestingly a recent study has found that immunization using ApoB-100 
derived peptides, which protect against atherosclerosis, is mediated by CD8+ T cells, 
as such CD8+ cells could also play a protective role in certain situations[203].
3.3.7 Cytokines
Proliferation, differentiation, activation and migration of immune cells are 
controlled by extracellular signals, cytokines play an essential role in these processes. 
Cytokines are small signaling molecules that are produced and excreted by cells, 
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they can have effects on other cells in the local environment but also on distant 
cells and they can also target the excreting cell themselves. Depending on the target 
cell and environmental factors, cytokines can have a range of different sometimes 
opposing effects[204]. More than 100 different cytokines have been identified, some 
cytokines have already been mentioned in relation to atherosclerosis such as IFNγ 
produced by Th1 cells, IL-4 produced by Th2 cells and IL-10 produced by Tregs. 
Cytokines are commonly grouped into two categories those that tend to increase 
inflammation (e.g. IFNγ, IL-1β) and those that tend to decrease inflammation 
(e.g. IL-10, TGFβ), pro-inflammatory cytokines are usually atherogenic while anti-
inflammatory cytokines are usually athero-protective.
3.4 Chemokines
A crucial stage in atherosclerotic plaque development is the migration of 
inflammatory cells into the plaque, chemokines are a subset of cytokines which 
organize the recruitment of these immune cells and are structurally related 
proteins that are categorized based on their N-terminal cysteine residue sequence 
(CC, CXC, CX3C, XC)[205]. Initially chemokines were thought to have their main 
function in recruitment of cells but research has shown that chemokines can have 
multiple functions including in cell homeostasis, cell survival, angiogenesis and 
cell activation[206,207].
Monocytes migrate into the plaque where they can differentiate into 
macrophages and ultimately foam cells. Homeostasis of monocytes is governed 
by the chemokine CCL2 and its corresponding receptor on monocytes CCR2[208]. 
Ablation of CCR2 results in a decrease in circulating monocytes and consequently a 
decrease in monocyte infiltration in the plaque[208]. The chemokine receptor CCR5 
is important for local recruitment of monocytes to the plaque and CX3CR1 is 
important for survival of monocytes, a combined blockade of these three chemokine 
receptors leads to a dramatic reduction in atherosclerotic plaque formation in 
hypercholesterolemic mice[89]. More chemokines are involved in recruitment of 
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monocytes like CXCR2(receptor)-CXCL1(ligand) and CCR1-CCL5, disruption of 
these chemokine signaling cascades leads to reduced lesion formation[88,209,210]. 
There is a lot of overlap between the chemokine receptors expressed by 
monocytes to the chemokines receptors expressed by neutrophil (e.g. CCR2, 
CCR5), as such neutrophils use many of the same chemokines for recruitment to 
the plaque although with different affinities[125]. The CXCR4:CXCL12 axis seems 
to be primarily important for the homeostasis of neutrophil cells as interference 
with this axis shows an increase in neutrophil mobilization from the bone marrow 
and increased neutrophil aggregation in the plaque[211,212]. This is also one of the 
few chemokines that protects against atherosclerotic plaque formation as most 
chemokines attract inflammatory cells to the plaque while CXCL12 helps retain 
leukocytes in the bone marrow[213].
T helper cells express CXCR3, which can bind three chemokines CXCL9, 
CXCL10 and CXCL11. Blockade of this chemokine receptor leads to an increase in 
Treg cells in the lesion as well as an increase in anti-inflammatory cytokines such as 
IL-10 and a shift towards a less inflammatory plaque environment[214,215]. Ablation of 
CXCL10 or CXCR3 blockade results in decreased CD4+ T cells but increased Treg 
cells in the lesion and these mice show a reduction in plaque formation[216].
Many more chemokines have recently been shown to be involved in plaque 
formation, as such chemokines have become a keen subject for drug target studies 
in cardiovascular disease by modulating the trafficking of leukocytes to and from 
the atherosclerotic plaque[206,217].
4. MicroRNAs
microRNAs (miRNA) are a relatively recent discovery in the field of 
biology, in the 1990s the first miRNA was discovered in the early 1990s but only 
since (approximately) 2000 the large influence on biological processes of miRNAs 
was appreciated[218–223]. The last decade has seen a massive undertaking in the 
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scientific field to understanding the influence of miRNAs on biological and also 
disease processes.
miRNAs are small non-coding RNA strands of approximately 21 nucleotides 
(nt) in length, that can post-transcriptionally down-regulate gene translation (Figure 
4)[224,225]. The seed region of miRNAs is a short sequence of approximately 7 nt in 
length that can bind non-perfectly to a complementary region on the 3’ untranslated 































Figure 4: Mechanism by which miRNAs induce translational repression. The microRNA is first 
transcribed into pri-miRNA and then processed into pre-miRNA by a protein complex (Drosha-
DGCR8). Subsequently the pre-miRNA is transported out of the nucleus into the cytoplasm where it is 
cut into two complementary RNA strands by Dicer, one of the strands combines with a multi-protein 
complex called RISC. The miRNA in combination with the RISC complex can bind complimentary 
sequences on mRNA strands and downregulate mRNA translation. The main mechanism by which 
miRNA downregulates translation is through binding of the 3’UTR but it has also been shown that 
binding of the coding region or the 5’UTR is possible. Figure adapted from Ling H et al. Nat Rev 
Drug Discov 2013; 12(11): 847–65.
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the mRNA while non-perfect binding will induce down-regulation of translation 
and eventual destruction of the mRNA through different mechanisms. miRNAs 
can have multiple mRNA targets and mRNAs can be targeted by multiple miRNAs, 
miRNAs can thus influence the expression of multiple proteins potentially shifting 
whole cellular pathways into a different states.
4.1 MicroRNAs and immunity
Many different miRNAs are involved in the differentiation and activation 
of myeloid cells and especially lymphoid cells[226–230]. The first indication that 
miRNAs played a role in T cell biology was when parts of the miRNA repression 
machinery were disrupted, abolishing miRNA repression of translation. Survival 
and proliferation were greatly reduced in activated T cells, but surprisingly also 
the differentiation to T effector cells was increased indicating that miRNAs had 
substantial influence on transition from naïve T cell to effector T cell[231–236]. Specific 
miRNAs that are involved in the activation of naïve T cells are miR-125 and 
miR-29, while miR-29 seems to block the differentiation to specific T helper cell 
subsets such as Th1 cells, miR-125 blocks general differentiation into effector T cell 
state[235,237–239]. Both miRNAs are down-regulated upon activation thus opening the 
way to differentiation of naïve T cells. miRNAs can also have more subtle influences 
by blocking or promoting differentiation of specific T cell subsets or expression of 
certain cytokines. miR-21 can induce Th2 differentiation when overexpressed and 
miR-27 and miR-128 can influence the expression of Th2 specific cytokines IL-4 and 
IL-5[240,241]. Th17 cell differentiation can be influenced by expression of miR-326 and 
miR-10a, while miR-10a has been shown to block Th17 differentiation, conversely 
miR-326 promotes Th17 cell differentiation in vitro[242,243]. Treg cell differentiation is 
supported by miRNAs, Treg specific disruption of the miRNA machinery resulted 
in a severe spontaneous autoimmunity in experimental models indicating that 
miRNAs were important for the proper functioning of Treg cells[234,244,245]. In Treg 
cells miR-155 is highly expressed and it has been shown that this is due to FOXp3, 
the central transcription factor in control of Treg differentiation which directly 
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induces miR-155 expression[246–248]. SOCS1 is targeted by miR-155 and consequently 
IL-2 signaling is down-regulated which is important for Treg development[249]. The 
miRNA signaling mechanism is very complex and many of the miRNAs mentioned 
are also expressed in and have influence on different myeloid cells like DCs and 
macrophages which can indirectly influence T cell differentiation[250]. As such 
miRNAs are essential for the proper working of the immune system and especially 
for T cell plasticity.
4.2 MicroRNAs and atherosclerosis
Accumulating evidence has shown that miRNAs have an important 
modulatory role in all stages of atherosclerotic plaque progression from initiation 
to ultimately rupture of the plaque. The areas where miRNAs influence plaque 
progression can be roughly separated into three groups, endothelial dysfunction, 
inflammation and lipid metabolism.
It has long been known that atherosclerotic plaques predominately develop 
at sites of disturbed flow which causes dynamic shear stress on the vascular wall 
inducing endothelial dysfunction[251]. Recent evidence shows that miRNAs are 
important regulators of this process. In ECs miR-126-5p is down regulated upon 
disturbed blood flow and this induces up regulation of DLK1 which decreases 
proliferation of ECs and increase atherosclerotic plaque formation[252]. At the same 
time miR-126 induces CXCL12 expression which is shown to be protective for 
atherosclerosis development[253]. Contrary to miR-126, miR-92a is up-regulated in 
regions with dynamic shear stress and is highly expressed at atherosclerotic prone 
sites[254]. Furthermore oxLDL increases miR-92a expression and disruption of miR-
92a activity leads to reduced lesion formation[255,256]. A potentially therapeutically 
important target in vascular inflammation is miR-181b, which has shown to down-
regulate the vascular inflammatory response[257]. miR-181b down-regulates adhesion 
proteins on the cell surface of ECs thus reducing infiltration of inflammatory cells, 
miR-182b administration resulted in decreased lesion formation in a hyperlipidemic 
mouse model with decreased macrophage and T cell infiltration[258].
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Macrophage accumulation and inflammation is central to advancement of 
the atherosclerotic plaque. An important mediator of monocyte and macrophage 
inflammation is miR-155 for which the expression is increased in macrophages in the 
atherosclerotic plaque[259]. Increased miR-155 results in NF-κβ activation, a central 
regulator of pro-inflammatory cellular response. In accordance with these results 
one study in a hyperlipidemic mouse model found miR-155 ablation in myeloid cells 
resulted in reduced atherosclerotic plaque formation and a different study found 
that administration of anti-miR-155 resulted in reduced lesion formation[260,261]. 
Confusingly in a study with a different hyperlipidemic mouse model ablation of 
miR-155 resulted in increased lesion formation in conjunction with increased 
macrophage inflammatory status[262]. Another miRNA that is involved with 
macrophage inflammation is miR-342-5p which in conjunction with miR-155 can 
increase macrophage inflammation, consequently ablation of miR-342-5p resulted 
in reduced lesion formation[263]. As mentioned miRNAs are essential for the proper 
functioning of the immune system and as such there are many more that can induce 
changes in inflammation and possibly alter atherosclerotic plaque formation.
Lastly, miRNAs can induce changes in lipid metabolism, the best studied 
miRNAs in this regard is miR-33a and miR-33b. miR-33a/b represses expression 
of the ABCA1 and ABCG1 cholesterol transporters, reducing cholesterol efflux out 
of macrophages to HDL particles[264–266]. Administration with anti-miR-33 resulted 
in regression of the atherosclerotic plaque in a hyperlipidemic mouse model and 
in a primate model anti-miR-33 increased HDL-cholesterol (HDL-C) plasma 
concentration[267,268]. It is unclear if long-term treatment with anti-miR-33 decreases 
atherosclerotic plaque development, one study found decreased plaque progression 
while another found no differences in the same mouse model[269,270]. While miR-33 is 
the most studied miRNA in connection with lipid metabolism many other miRNAs 
have recently been found to be involved as well, such as miR-10b, miR-27, miR-144, 
miR-145, miR-223, miR-302a and miR-758[271–279].
miRNAs are an interesting therapeutic target for treatment of cardiovascular 
disease and potential miRNA targets have already been identified such as miR-
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181b[280]. The complexity of miRNA signaling and the limited ability to target 
miRNAs to specific cell types might be roadblocks that still need to be overcome 
before widespread use of a miRNA based drug therapy for cardiovascular 
disease is possible.
5. Biomarkers in coronary artery disease
Correct risk stratification of cardiovascular disease patients based on risk of 
subsequent cardiovascular events is essential for a fitting personalized therapeutic 
approach. Conventional risk factors such as diabetes, smoking, hypertension and 
dyslipidemia have been incorporated into the risk assessment for cardiovascular 
disease, still a large portion of patients with cardiovascular disease have only one or 
even none of these risk factors[281]. These risk factors do therefore not fully explain 
cardiovascular risk and there is a substantial need to identify novel biomarkers that 
can increase the accuracy of risk assessment[281–283].
Biomarkers are “a characteristic that is objectively measured and evaluated as 
an indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention” as defined by NIH working group in 
2001[284]. Current biomarkers for cardiovascular disease can be categorized into two 
groups, biomarkers that can stratify the current disease state of patients (diagnostic) 
or biomarkers that can differentiate patients for disease development (prognostic). 
Diagnostic biomarkers are used for therapeutic choices and prognostic biomarkers 
can be used for preventative measures, biomarkers can and often do fall in both 
categories. A biomarker in current use for diagnosis of cardiovascular disease is 
cardiac troponin. Cardiac troponin is released when myocardial necrosis occurs 
and is used to identify acute myocardial infarction and stratify risk for unstable 
angina and non-STEMI patients[285,286]. A prognostic biomarker that is used for risk 
stratification of cardiovascular patients is C-reactive protein (CRP) which can be 
used to more accurately stratify risk in patients that are determined to be low to 
intermediate risk by conventional risk factors[287,288]. The limitation of CRP is that 
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it is a general inflammation markers which thus may indicate an inflammation 
unrelated to cardiovascular disease, as such some studies have found limited added 
benefit over conventional risk factors[289,290]. Many more biomarkers are in use for 
assessing risk in coronary artery disease patients, such as LDL-C, HDL-C, fibrinogen 
and creatinine but even with these biomarkers much of the risk for cardiac events 
remains unexplained[291].
6. Outline of this thesis
The aim of this thesis is to find new cellular biomarkers in whole blood, 
which improve the risk stratification of cardiovascular disease patients. Chapters 2 
to 5 respectively investigate monocyte subsets, T cell subsets, neutrophil subsets and 
cytokines as potential biomarkers for cardiovascular disease, furthermore chapter 
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Background- Previous studies have shown associations between circulating 
monocyte subsets and the progression of coronary artery disease (CAD). Given 
confirmed sex differences in CAD-development, we assessed whether the 
distribution of monocyte subsets differed between male and female patients with 
CAD and whether the subsets correlated with manifestation and progression of 
cardiovascular disease.
Methods and Results- Using a multi-color flow cytometry protocol assessing 
14 myeloid cell markers, monocyte subsets were assessed in peripheral blood of 479 
CAD patients scheduled for coronary angiography. In both sexes, total monocytes 
(TMs) and the classical monocyte (CM) to non-classical monocyte (NCM) ratio were 
increased in unstable CAD compared to stable CAD. Monocyte subsets between 
sexes showed different prognostic values for major adverse cardiac events (MACE), 
with females showing an association with CMs, while in males no significant 
associations with monocyte subsets was found. However, when HDL-cholesterol 
(HDL-C) levels were taken into account, in males increased CM/HDL-C and 
Intermediate monocyte (IM)/HDL-C ratios were associated with MACE. In females 
increased TM/HDL-C and CM/HDL-C were strongly associated with MACE.
Conclusion- In patients with CAD, monocyte subsets and HDL-C each 
showed a modest predictive value for the development of MACE. However, by 
calculating the ratio of monocyte subsets and HDL-C, odds ratios were synergistically 
increased, showing a predictive value of CM/HDL-C and IM/HDL-C in males and 
a highly predictive value of TM/HDL-C and CM/HDL-C in females for MACE. 
These data show the differential involvement of the various monocyte subsets in the 
progression of CAD in men and women.
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Introduction 
The notion that coronary artery disease (CAD) is a disease that generally 
affects men is rapidly disappearing. For instance, CAD-related mortality before 
the age of 75 is now more common in women (21%) compared to men (20%) in 
Europe[1]. Clinical studies have observed intrinsic differences in the progression 
and manifestation of CAD between males and females[2–5]. Although the underlying 
pathophysiological drivers of the sex-specific progression of CAD are incompletely 
understood, recent studies have involved phenotypic differences in cells of the innate 
immune system between men and women. For instance, estrogen[6] or incomplete 
X-chromosome silencing[7] can impact monocyte differentiation and macrophage 
polarization. Likewise, differences in monocyte phenotypes between men and women 
could possibly explain sex-biased differences of statins on monocyte chemotaxis[8].
In atherosclerosis, the endothelial cells lining the arteries become activated 
by adverse metabolic and hemodynamic factors and pro-inflammatory oxidized 
lipoproteins accumulate in the sub-endothelial space. As a consequence, circulating 
monocytes infiltrate the vessel wall and differentiate into macrophages, where they 
serve to scavenge the modified lipids as present in oxidatively modified low density 
lipoprotein (LDL). This results in the conversion of macrophages into foam cells 
that initiate fatty streak development, priming the region for the development of 
stenotic atherosclerotic plaques.
Numerous studies have been initiated aiming to explore the therapeutic 
potential of modulating monocyte phenotypes in patients at risk for atherosclerosis[9]. 
Circulating monocytes form a heterogeneous population of cells with subsets that 
can be distinguished based on functional properties as well as expression of cell 
surface markers[10]. In humans, three subpopulations have been defined based 
on the differential expression of the LPS co-receptor CD14 and the Fcγ-receptor 
III, CD16[11–13]. Classical monocytes (CM, CD14++CD16-) generally encompass 
approximately 80% of all circulating monocytes, while non-classical (NCM, 
CD14+CD16+) and intermediate (IM, CD14++CD16+) monocytes each account for 
approximately 10% of the total monocyte (TM) population.
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These three monocyte phenotypes show distinctive expression patterns of 
chemokine receptors[14–16] and, consistent with these differences, show substantially 
different behavior in circulation[17–20]. CMs and IMs accumulate at sites of 
inflammation, where they rapidly differentiate into macrophages and dendritic 
cells[21]. NCMs on the other hand patrol the vasculature to survey endothelial 
integrity[17]. Similar to CMs and IMs, they can rapidly respond to inflammation 
or injured cells by secreting inflammatory cytokines and chemokines that serve to 
recruit additional neutrophils and CMs[22].
Given the diverse actions of monocyte subsets in the pathogenesis of 
atherosclerosis, several groups have postulated that causal relationships exist 
between the composition of circulating monocyte subsets and clinical cardiovascular 
outcomes. For instance, increased numbers of IMs were found to independently 
predict cardiovascular death, myocardial infarction and stroke in a prospective 
cohort of 951 patients referred for elective coronary angiography[23]. In contrast, in 
a general population cohort of 659 subjects, increased numbers of circulating CMs 
predicted cardiovascular events[24]. Although these prospective studies correlated 
different monocyte subsets to cardiovascular outcome, they clearly indicate that 
circulating monocytes could act as cellular protagonists of atherogenesis.
High numbers of IMs have been shown to predict an increased risk of a 
cardiovascular events in CKD patients[25]. Recent studies in patients with chronic 
kidney disease (CKD) suggest that monocyte subsets are affected by circulating levels 
of HDL-C[26]. In line with the close relationship between the number of monocytes 
and HDL-C, the ratio of monocytes/HDL-C was recognized as an independent 
predictor of fatal and composite cardiovascular events in CKD patients[27].
To assess whether sex-differences in monocyte subsets play a role in the 
difference in pathophysiology between male and female CAD patients, we performed 
a detailed flow cytometric analysis of the monocyte subset distribution in 479 CAD 
patients that were enrolled into the CIRCULATING CELLS study[28], which was 
designed to explore the use of cellular effectors of atherosclerosis as biomarkers for 
CAD. We demonstrate that differences in monocyte subset distribution observed 
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between unstable- and stable CAD are similar for males and females. In contrast, 
monocyte subsets prospective for major adverse cardiovascular events (MACE) 
differed between males and females. The observed sex-differences between 
prognostic monocyte subsets were even more pronounced when monocyte/HDL-C 
ratios were taken into account. Moreover our study provides strong support for a 
causal role of the sex-specific differences in the innate immune response for the 





The study population consists of a subgroup of 479 patients from the 
CIRCULATING CELLS study cohort[28]. In brief, CIRCULATING CELLS is 
a prospective multi-center study in which patients scheduled for coronary 
angiography due to CAD were included. To minimize the potential influence of 
the presence of profound acute myocardial ischemia, patients with ST-elevation 
myocardial infarction (STEMI) were excluded. Additional exclusion criteria were: 
age < 18 years, inability to give informed consent, suspected drug- or alcohol abuse, 
serious concomitant disease, serious recent infectious disease in the last 6 weeks 
or suspected elevated state of the immune system, and non-cooperativeness. The 
study was approved by the medical ethical committees of the participating centers 
and conforms to the Declaration of Helsinki. All patients received oral and written 
information about the objectives of the study and provided written informed 
consent. MACE within 9 months after inclusion is the primary endpoint of this study 
and is defined as death, myocardial infarction, percutaneous coronary intervention, 
coronary artery bypass grafting and cardiovascular accident. The cohort consists 
of 17 non-significant atherosclerosis, 385 stable angina, 52 unstable angina and 42 
non-STEMI diagnosed patients. The non-significant atherosclerosis patients were 
removed for unstable vs stable CAD analysis. For 33 patients there was no follow-up 
data available; these patients were excluded from primary endpoint MACE analysis.
Flow cytometry
Whole blood fluorescence-activated cell sorting (FACS) analyses was 
performed to identify and quantify monocyte subsets with antibodies directed 
against the cell surface antigens CD14, CD16, CCR2, CX3CR1, CXCR4, CD11b, 
CD11b activation epitope (MAC-1), CD143, CD162, CD68, CD89, IL15 (membrane-
bound), TIE2 and CD115. See supplementary methods for specifications and 
combinations of antibodies for staining (Table S1).
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Figure 1:
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Gating strategy monocyte subsets. (A) Leukocytes are gated on forward/side scatter 
characteristics. (B) Total monocytes and lymphocytes are selected using CD14 and sides scatter. (C) 
CD14 and CD16 plots allow gating of classical- (CD14++CD16-), intermediate- (CD14++CD16+) and 
non-classical (CD14+CD16+) monocyte subsets that form the basis of the gating of all additional 
markers as depicted for CCR2, CX3CR1 and CD162 (D-F). Additional markers that display distinct 
(positive, negative, high or low staining) populations were gated separately. (G) The tree plot is used 
to generate all possible combinations of the employed cellular markers, the figure shows the tree plot 
for the classic (CD14++CD16-) monocyte population.
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Blood was collected in EDTA-containing vacutainer blood collection tubes 
(Becton Dickinson, Breda, The Netherlands) and 50 μl whole blood samples were 
stained with selected antibody sets for 30 minutes at 4oC. Cells were washed with 
FACS solution (1% bovine serum albumin and 0.01% Na-azide in PBS). Red blood 
cells were lysed in 8.3 g/L ammonium chloride (168320; Merck), 1.0 g/L potassium 
bicarbonate (1048540500; Merck) and 37.2 mg/L EDTA (E4884-100G; Sigma-
Aldrich) solution at 4oC for 30 minutes. Cells were then washed and fixed with 
0.2% formaldehyde and 0.9% NaCl solution immediately followed by FACS analysis 
(FC500, Beckman Coulter, Fort Lauderdale, USA) calibrated with fluorosphere setup 
kits (Beckman Coulter). Data analysis was performed on Kaluza 1.3 flow cytometer 
analysis software (Beckman Coulter). 
FACS gating strategy
CM (CD14++CD16-), IM (CD14++CD16+) and NCM (CD14+CD16+) were 
defined according to Ziegler-Heitbrock et al.[12] and gated as described in Figure 1A-
C. For the additional markers, subsets were defined based on the presence or absence 
of expression (e.g. CX3CR1+ vs. CXC3R1-, Figure 1D-F) or the presence of distinct 
populations that display high (e.g CX3CR1high) or low expression (e.g. CX3CR1low). 
The Kaluza FACS analysis software was used for the automated generation of tree 
plots for all possible combinations of the used monocyte markers (Figure 1G).
 Statistics
Statistical calculations were performed using R for windows (version 3.0.2). 
A P<0.05 was considered significant. Categorical data was compared using the chi-
square test. For continuous data the nonparametric Mann-Whitney U test was used.
For logistic regression the patients were divided into 3 equal sized groups 
(tertiles) according to the measured values for each variable. Firth’s penalized 
likelihood logistic regression was used to analyze stratified data. Firth’s method was 
used to handle small sample sizes. The odds ratio (OR) was adjusted for potential 
CAD risk factors such as age (Model 1) and age, hypertension, diabetes mellitus, 
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current smoker, BMI and HDL-C level (Model 2).
To identify variables that could potentially stratify patients into separate 
groups (e.g. stable vs. unstable CAD patients) we used a machine learning method 
called Random Forest[29]. The Random Forest modeling method and its application 
in this project is further explained in the supplementary methods section.










Age 62 (56-69) 60 (56-68) 64 (58-71) 63 (56-71)
BMI 27 (25-30) 27 (25-30) 28 (25-31) 25 (23-28)*
SBP (mm Hg) 135 (125-145) 130 (115-141)* 139 (125-150) 135 (120-145)
DBP (mm Hg) 80 (70-85) 80 (70-87) 77 (70-85) 79 (70-82)
Glucose (mmol/L) 6.00 (5.40-6.79) 6.38 (5.52-7.46) 5.90 (5.40-6.83) 7.00 (5.97-7.82)*
Hemoglobin (mmol/L) 8.90 (8.50-9.40) 8.95 (8.60-9.60) 8.20 (7.80-8.60) 8.30 (7.60-8.55)
Cholesterol (mmol/L) 3.90 (3.35-4.64) 4.61 (3.90-5.27)‡ 4.27 (3.77-5.21) 4.82 (3.85-5.39)
LDL-C (mmol/L) 2.22 (1.75-2.85) 2.77 (2.38-3.50)‡ 2.41 (1.90-3.12) 2.73 (1.98-3.50)
HDL-C (mmol/L) 1.01 (0.88-1.19) 0.96 (0.79-1.14) 1.17 (1.00-1.45) 1.09 (0.95-1.31)
Triglycerides (mmol/L) 1.28 (0.93-1.80) 1.60 (1.21-2.20)‡ 1.38 (1.00-1.80) 1.58 (1.25-2.11)
hsCRP (ng/mL) 2423 (1640-5473) 5952 (1865-18624)‡ 3867 (1620-7245) 3669 (2136-7495)
WBC (X1000 cells/µL) 6.80 (5.80-8.00) 8.40 (7.20-10.00)‡ 6.90 (5.40-8.25) 8.80 (7.30-9.90)‡
Current smoker 20% (57) 25% (16) 16% (17) 52% (15)‡
Diabetes 22% (62) 20% (13) 24% (25) 28% (8)
Hypertension 62% (175) 57% (37) 74% (77) 59% (17)
Beta-blocker 76% (214) 62% (40)* 84% (87) 48% (14)‡
Ca-antagonist 31% (88) 20% (13) 37% (38) 21% (6)
Aspirin 84% (235) 69% (45)* 91% (95) 66% (19)†
Vitamin K antagonist 10% (29) 22% (14)* 10% (10) 17% (5)
ADP receptor blocker 52% (145) 42% (27) 57% (59) 41% (12)
ACE inhibitor 36% (102) 29% (19) 28% (29) 28% (8)
ATII receptor blocker 17% (47) 9% (6) 33% (34) 17% (5)
Diuretic 20% (55) 15% (10) 27% (28) 14% (4)
Statin 84% (237) 66% (43)† 83% (86) 45% (13)‡
Baseline characteristics table, values are median (interquartile range) or percentage (n). Stable and 
unstable CAD was compared within each sex, categorical data was compared using the chi-square 




Monocyte subset associations in CAD:
Baseline cohort characteristics
Baseline characteristics, patient history and medication use upon study 
inclusion are shown in Table I. Patients with unstable angina and non-STEMI patients 
were combined into the unstable CAD group and compared to the stable CAD 
patient group. The use of beta-blockers, aspirin and statins was significantly higher 
in both male and female stable CAD patients while use of Vitamin K antagonists 
was higher in males in the unstable CAD group. Consistent with the more frequent 
use of statins, total cholesterol, triglycerides and LDL-cholesterol (LDL-C) plasma 
levels were significantly lower in the stable CAD compared to unstable CAD group 
in males, but not in females. Systolic blood pressure was slightly, yet significantly, 
decreased in male unstable CAD patients compared to male stable CAD patients. In 
females smoking was more frequent in unstable CAD group (52%) in comparison 
to the stable CAD group (16%). White blood cell (WBC) count was significantly 
increased in patients with unstable CAD in both sexes but hsCRP plasma levels were 
only significantly increased in male unstable CAD patients in comparison to male 
stable CAD patients.
Comparison of the baseline characteristic between male and female patients 
(Table S2) showed significant differences in hemoglobin, LDL-C, HDL-C and 







TM (cells/µL) 578 (467-695) 626 (507-785) p<0.01
CM (CD14++CD16-, cells/µL) 472 (378-598) 525 (429-658) p<0.01
IM (CD14++CD16+, cells/µL) 40 (28-53) 41 (28-62) N.S.
NCM (CD14+CD16+, cells/µL) 47 (33-64) 48 (35-69) N.S.
Cell counts in blood for total monocytes (TM), classical monocytes (CM), intermediate monocytes 
(IM) and non-classical monocytes (NCM). Values are median (interquartile range).
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total cholesterol. Also TM and CM (CD14++CD16-) counts (cells per µL) were 
approximately 10% higher (p< 0.01) in males as compared to females (Table II).
Elevated CM/NCM ratios in unstable CAD in both males and females
To address sex differences in monocyte subset distribution in relation to 
























































































































































































































































































































































































Stable CAD Unstable CAD
 Sex-stratified quantification of (A) classic (CM, CD14++CD16-), (B) intermediate (IM, 
CD14++CD16+) and (C) non-classical (NCM, CD14+CD16+) monocyte populations in stable versus 
unstable CAD. (D) Classical- to non-classical monocytes ratios. * p<0.05, ** p<0.01, ***p<0.001. 
Correlation matrices of the 10 highest ranked cell subsets determined by Random Forest modeling 
of stable and unstable CAD patients for the male (E) and female (F) cohort. The variables were 
clustered using hierarchical clustering. Blue indicates a positive correlation while red indicates a 
negative correlation. Color intensities indicate the magnitude of the correlation.
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patients was examined in separate male and female cohorts. CM (CD14++CD16-) 
counts were significantly increased in unstable CAD patients compared to stable 
CAD patients in both males and females (Figure 2A). Only in males were IM 
(CD14++CD16+) counts found to be significantly increased in unstable CAD patients 
in comparison to stable CAD patients (Figure 2B). In contrast to the rise in CMs, the 
circulating NCM (CD14+CD16+) count decreased in male unstable CAD patients 
(Figure 2C). Similar trends were observed in the female cohort for both IMs and 
NCMs, but these did not reach statistical significance. Interestingly, the ratios of 
CM to NCM were elevated in unstable CAD compared to stable CAD both in males 
and females (Figure 2D), indicating a skew towards CD16-negative monocytes in 
unstable CAD patients.
Differential cell surface marker expression on monocyte subsets in males and females
To extend our search for sex bias in circulating monocyte subsets, we 
enlarged our flow cytometry panel with antibodies that all have been described to 
relate to specific monocyte phenotypes (Table S1). With these additional markers 
we generated an extensive data set that potentially allows the identification of 839 
monocyte subsets. Since Random Forest has been shown to be highly effective in 
the processing of complex FACS data (supplementary methods)[29], we utilized this 
software to select 10 monocyte subsets that best stratify stable and unstable CAD 
patients. Using this approach, different marker combinations can identify the same 
cell subset, e.g. CD14+CD16+CX3CR1++ and CD14+CD16+CCR2-. As such, to select 
for different marker combinations that describe largely similar monocyte subsets, 
we generated a correlation matrix and subsequently used hierarchical clustering 
to determine clusters of highly correlating cell subsets (Figure 2E and F). The 
correlation matrix shows five clusters in the male cohort (Figure 2E) and six clusters 
in the female cohort (Figure 2F). The marker combinations that cluster likely identify 
similar cell subsets and thus one marker combination from each cluster was chosen 
for further analysis (with the shortest combination of markers and the highest rank 
in the model, see Table S3 and S4).
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In males, 4 of the 5 clustered cell subsets showed a significant difference 
between stable and unstable CAD patients (Table S3). Circulating CD14++CD16-
CD89+ cells (Cluster E) displayed 33% higher counts in unstable CAD patients (535 
cells/µL (452-670) in unstable CAD vs. 400 cells/µL (284-530) in stable CAD) (Table 
S3). CD14+CD16+IL15- cells (Cluster A) overlap with NCMs and were 27% decreased 
in unstable CAD patients (32 cells/µL (24-51) in unstable CAD vs. 44 cells/µL (32-
65) in stable CAD). CD14+CD16+CCR2+CD162-/low (Cluster B) and CD14++CD16-
CD162-/lowCX3CR1high (Cluster C) fractions show extremely low numbers (cells/
mL) that nonetheless show a significant difference between male stable and unstable 
CAD patients (Table S3).
In females, 4 of the 6 clustered selected cell subsets showed a significant 
difference between stable and unstable CAD. CD14++CD16-ACE-CD162high (Cluster 
B) and CD14+CD16+IL15- (Cluster F) populations largely overlapping with CM 
and NCM, respectively (Table S4). CD14++CD16-CX3CR1highTIE2- (Cluster D) 
and CD14++CD16+CD115- (Cluster A) are minor cell subsets that are elevated in 
female unstable CAD patients compared to stable CAD patients. In both males and 
females, cell subsets that overlap with CMs show higher numbers of circulating 
cells in unstable CAD patients, while in male patients, cell subsets that overlap with 
NCMs displayed significantly lower numbers in unstable CAD patients compared 
to stable CAD patients.
Prognostic features of monocyte subsets:
Baseline cohort characteristics
To investigate whether intrinsic sex-specific differences in monocyte subsets 
relate to clinical outcome in CAD patients, we assessed the prognostic value of the 
monocyte subsets with respect to major adverse cardiac events (MACE). Table S5 
depicts the baseline characteristics of patients with MACE compared to control 
cases. Both in male and female patients, HDL-C was found to be significantly 





































































































































































































































































































































































Figure 3: Odds ratios (OR) for classic (CM, CD14++CD16-), intermediate (IM, CD14++CD16+) 
and non-classical (NCM, CD14+CD16+) monocytes in the male (A) and female (B) cohort adjusted 
for age (Model 1). ORs for major blood based biomarkers such as hsCRP, LDL-C and HDL-C and 
novel monocyte subsets in the male (C) and female (D) cohort adjusted for age. Median value with 
corresponding 95% confidence interval (CI) for each variable, dotted vertical line indicates no effect. 
Correlation matrix of the 10 highest ranked cell subsets determined by Random Forest modeling 
of MACE and control patients for the male (E) and female (F) cohort. The variables were clustered 
using hierarchical clustering. Blue indicates a positive correlation while red indicates a negative 
correlation. Color intensities indicate the magnitude of the correlation.
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in female control patients compared to male control patients while being similar 
in MACE patients, indicating that the decrease in HDL-C in females with MACE 
versus without MACE is more substantial than in males.
Female CMs are predictive for MACE
To assess whether monocyte subsets associate with clinical outcome, logistic 
regression was performed on the monocyte subsets for their ability to predict MACE. 
The subjects were distributed into three approximately equal sized groups (tertiles) 
based on monocyte subset counts. The first tertile includes subjects with the lowest 
values measured (e.g. lowest monocyte count), the second tertile contains subjects 
with medium measured values and the third tertile contains subjects with the highest 
measured values. Logistic regression analysis was performed comparing the risk of 
MACE in the second and the third tertile to the risk of MACE in the first tertile, which 
served as a reference value. Odds ratios (OR) were calculated after adjusting for age 
(Model 1) or for several cardiovascular risk factors, including age, hypertension, 
diabetes mellitus, current smoker, BMI and HDL-C (Model 2). When logistic 
regression was performed on ratios of monocyte (subset)/HDL-C, the regression 
model was not adjusted for HDL-C and HDL-C was excluded from Model 2.
In males (Table S6) the monocyte subsets did not show a significant correlation 
with MACE when the third tertile was compared to the first tertile. However, in 
females (Table S7) a significant OR of 4.36 (95%CI: 1.14-23.94, p=0.030, Model 1) 
was found for the CM subset for the third tertile compared to the first tertile (Figure 
3B), which remained significant when adjusted for additional cardiovascular risk 
factors (Model 2, Table S7).
For the extended ontology analysis, we used Random Forest modeling to 
identify 10 monocyte subset-descendants that can best classify patients that develop 
MACE. Overlapping cell subsets were identified by correlation matrix clustering 
(Figure 3E and F).
In the female cohort (Table S9) an increased number of NCM-descendant 
CD14+CD16+CD162highCX3CR1-/low cells (Cluster A) associated with MACE with 
60
Chapter 2
an OR of 5.31 (1.39-29.26; p=0.013, Model 1), which remained significant when 
adjusted for additional cardiovascular risk factors (Model 2). Although the cell 
count of the NCM-descendant CD14+CD16+CCR2+CX3CR1- (Cluster C) also 
shows a significant OR (OR: 3.69, 95%CI:1.02-16.09, p=0.047, Model 1), due to a 
large proportion of patients having 0 cells/µL for this cell subset, the patients were 
unable to be equally distributed among tertiles and the calculated ORs for this cell 
subset are unreliable (Table S9).
Monocyte subset/HDL-C ratios are highly predictive of MACE in a sex-specific fashion
Amongst the classic blood-based biomarkers, only the HDL-C level was 
statistically different between males and females. Furthermore, HDL-C was the only 
discriminating factor between males and females with and without MACE (Table 
S5). Moreover, reduced HDL-C level in the male cohort significantly associated 
with MACE (Figure 3C), while in the female cohort this association approached 
significance (Figure 3D). 
Recently, the TM/HDL-C ratio emerged as an indicator of inflammation and 
oxidative stress and was described as being predictive for cardiovascular events in 
a chronic kidney disease cohort[27]. Therefore, the logistic regression analysis was 
extended with the ratio monocyte (subsets)/HDL-C. Here we find that in males 
(Table S6), the highest tertile of TM/HDL-C ratio was not associated with MACE 
(OR: 2.31, 95%CI: 0.91-6.50, p=0.080, Model 1), while the CM/HDL-C ratio was 
(OR: 2.72, 95%CI: 1.03-8.27, p=0.044, Model 1). Interestingly, the IM/HDL-C ratio 
was even more predictive of MACE (OR: 3.40, 95%CI: 1.32-10.16, p=0.010, Model 
1) and remained significant after adjusting for multiple cardiovascular risk factors 
(Model 2). Of note is the fact that in females (Table S7) both the TM/HDL-C ratio 
(OR: 8.46, 95%CI: 1.84-81.09, p=0.004, Model 1) and the CM/HDL-C ratio (OR: 
10.81, 95%CI: 2.39-103.22, p=0.001, Model 1) were significantly predictive of MACE, 
but only the CM/HDL-C ratio remained significant after adjusting for multiple 
cardiovascular risk factors (OR: 15.50, 95%CI: 1.91-239.00, p=0.008, Model 2).
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Discussion
In this study, we sought to investigate whether intrinsic differences in 
circulating monocyte subsets play a potential role in the sex-specific pathophysiology 
of CAD. Using a detailed multi-color flow cytometric approach on blood samples 
taken from 479 CAD patients from the CIRCULATING CELLS cohort, we 
demonstrated in agreement with a previous report that males have a 10% increased 
TM count compared to females[30], which is mainly attributable to an increase in 
CMs. Despite the constitutively higher TM count in males, the TM changes observed 
between stable- and unstable CAD were similar for both sexes. With regard to 
monocyte subsets, the male cohort exhibited an increased CM population and a 
decreased NCM population in the unstable CAD patients, while the females showed 
a trend in the same direction.
As unstable CAD is a coronary syndrome associated with acute ischemic 
insults, the increase in CMs in these patients is consistent with earlier reports 
detailing the rapid elevation of CMs following acute myocardial infarction[31]. 
Though highly speculative, as NCMs are known to patrol the vasculature resolving 
damage to the vascular wall, their concomitant decreased number could be due to 
their increased interaction with the injured vascular wall[22].
Following the above, we argued that the relatively strong monocytotic signals 
associated with acute insults in unstable CAD patients could mask more subtle 
intrinsic sex-specific differences in monocyte subsets that we postulated would have 
a greater impact on long-term sex-specific pathophysiology. Given the above, we 
determined the prognostic values of the monocyte subsets for MACE. Indeed, we 
found that the CM subset was strongly predictive of cardiovascular events for the 
female cohort, but that this association was absent in the male cohort. In contrast, 
for the male cohort the IM subset displays a trend towards a significant OR for 
MACE. These data suggest that monocyte subsets may differ in their impact on 
cardiovascular outcome in men and women.
In order to identify potentially new monocyte subsets, 12 additional surface 
markers were added, yielding several monocyte descendants of which in the males 
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only one CM-descendant (CD14++CD16-CD162-/lowCX3CR1-) showed predictive 
value for the development of MACE, while in females only one NCM-descendant 
(CD14+CD16+CD162highCX3CR1-/low) was also found to predict MACE. Since the 
number of these new monocyte-descendants was very low, the added benefit of 
expanding the ontology of monocyte subsets beyond CD14 and CD16 was minimal, 
certainly in relation to the amount of work and materials needed for this analysis. 
However, these data do indicate that different monocyte subsets are involved in the 
development of MACE in males and females.
Two previous studies also investigated the prognostic value of CM, IM and 
NCM subsets on cardiovascular events, but the outcome of these studies appeared 
inconsistent[23,24]. While Berg et al.[24] found that CM counts were predictive for 
cardiovascular events, Rogacev et al.[23] came to the same conclusion for IMs. 
Although these contradicting findings could be the result of differences in study 
setup[32], our data suggest an alternative explanation in the form of sex-bias in the 
contribution of monocyte subset to cardiovascular outcome. In the study by Berg 
et al.[24] the cohort was female dominated (59% female versus 41% male), while the 
cohort in the study by Rogacev et al.[23] males dominated (68% male versus 32% 
female). Our finding that females have a ‘classical monocyte predictive phenotype’ 
and males may have an ‘intermediate predictive phenotype’ could be an alternative 
explanation for their results.
Recently, the TM/HDL-C ratio emerged as an indicator of inflammation 
and oxidative stress and was described as being predictive for cardiovascular events 
in a chronic kidney disease cohort[27]. Furthermore, lower levels of HDL-C and 
ApoA-I (the major protein component of HDL) were shown to be associated with 
higher IM counts, which predicted cardiovascular events in patients with chronic 
kidney disease[25].
Interestingly, HDL not only affects monocyte number by altering cholesterol 
efflux pathways, leading to reduced hematopoietic stem cell proliferation, 
myelopoiesis and monocytosis[26,33], but may also affect monocyte function. HDL 
has been found to inhibit the adhesion of monocytes to endothelial cells by both 
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reducing the activation of the integrin CD11b[34] and by down-regulating the 
expression levels of the endothelial cell adhesion molecules VCAM-1, ICAM-
1 and L-Selectin[35]. These data imply that HDL likely influences monocyte and 
endothelial cell function, as well as their interaction and consequently HDL may 
repress recruitment of monocytes to the atherosclerotic lesion reducing overall 
CAD progression. In line with the relation between monocytes and HDL-C, Kanbay 
et al. showed that the TM/HDL-C ratio was a strong biomarker for cardiovascular 
events in a chronic kidney disease cohort[27]. Our findings confirm these results only 
in females, where indeed TM/HDL-C ratio was highly predictive for MACE, but is 
however lost when taking more than one risk factor into account (Table S7; Model 
2). Nevertheless, the ratio CM/HDL-C was even more predictive for MACE, which 
remained highly significant after correcting for additional risk factors (Model 2).
In males, only the ratios CM/HDL-C and IM/HDL-C were predictive of 
MACE (in both models) and HDL-C by itself was predictive for MACE, while the 
absolute numbers for CMs or IMs were not. These data illustrate the strong additive 
effect of relating the monocyte subsets with HDL-C levels and again show the 
importance of discriminating between sexes.
Interestingly, our data show that HDL-C in males with MACE was on 
average 7% lower compared to males without reported MACE, while in females 
with MACE this reduction was 15%, leading to equal HDL-C levels in males and 
females experiencing MACE. Since all females were of post-menopausal age, these 
variations in HDL-C levels cannot be sex-hormone-driven. Nevertheless, this large 
difference is obviously reflected in the monocyte (subset)/HDL-C ratio and will 
influence the predictive values between males and females, further emphasizing the 
importance of discriminating between sexes.
A few limitations of this study warrant consideration. First, the number 
of patients that experienced MACE is limited, especially in the female cohort and 
secondly, the follow-up time of 9 months was short compared to other similar 
studies[23,24]. As such these findings need to be validated in cardiovascular disease 
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cohort studies that are specifically designed to find sex differences in monocyte 
subset distribution.
To the best of our knowledge, this is the first report that describes a predictive 
value of the ratio of monocyte subsets per HDL-C for the development of MACE 
and the predictive differences in males and females.
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For analyses of circulating monocyte subsets stainings were performed in 
nine combinations (supplementary table 1) of five antibodies selected from the 
antibodies listed below. 
CD14-PC7 (A22331; Beckman Coulter, Fort Lauderdale, USA), CD16-PC5 
(A07767; Beckman Coulter, Fort Lauderdale, USA), CCR2-PE (FAB151P; R and D 
Systems, Minneapolis, Minn., USA), CX3CR1-FITC (D070-4; MBL International, 
Nagoya, Japan), CXCR4-FITC (D123-4; MBL International, Nagoya, Japan), 
CD11b-PE (IM2581U; Beckman Coulter, Fort Lauderdale, USA), CD11b activation 
epitope (MAC-1)-PE (12-0113-73; eBioscience, San Diego, USA), CD143(ACE)-
FITC (MCA2057F; AbD Serotec, Oxford, UK), CD162-ECD (IM99512B; Beckman 
Coulter, Fort Lauderdale, USA), CD68-PE (12-0689-73; eBioscience , San Diego, 
USA), CD89-PE (IM1614; Beckman Coulter, Fort Lauderdale, USA), IL15-FITC 
(IC2471F; R and D Systems, Minneapolis, Minn., USA), Tie2-PE (FAB3131P; R 
and D Systems, Minneapolis, Minn., USA) and CD115-FITC (FAB329F; R and D 
Systems, Minneapolis, Minn., USA). 
Random forest modeling 
Random forest is an ensemble learning method that generates models 
of the provided data and then uses all models combined to get better predictive 
performance. Random forest generates many decision trees based on bootstrap 
samples from the original data and for each split in a decision tree a number of 
variables are randomly selected and tested for classification performance. From these 
variables the best performing variable is selected for the split. This randomization in 
sampling and variable selection makes the model very robust and unbiased; it has 
been shown to give good results in analyzing multivariate flow cytometry data1,2.
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As only part of the data is used to generate each individual decision tree, 
the remainder of the data can be used to test the performance of the decision tree 
and determine the importance of each variable. The importance of variables in the 
random forest is estimated by permuting one predictor variable while all else is kept 
unchanged and looking at how much prediction accuracy decreases. This is done 
per constructed decision tree and gives a mean decrease of accuracy per variable.
Because the dataset contains many hundreds of variables (all possible 
marker combinations) we first reduced the number of variables. Using random 
forest to estimate the importance of each variable and discarding variables with an 
importance of less than zero, we then generate a new random forest again discarding 
the variables with a negative importance score. This procedure is repeated until for 
a set amount of repetitions no variables with negative importance values are found. 
This technique is based on a similar technique implemented in random jungle3.
The random forest can determine similarity between patients by looking at 
how many times two subjects fall into the same terminal node over all the decision 
trees, as it is assumed that two subjects that are similar to each other will frequently 
end up in the same terminal node. This attribute of random forest was used to impute 
missing predictor data in the database, as similar subjects were used to estimate 
the missing data.
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Supplementary Tables
Table S1: Antibody combinations monocyte subset staining
FITC PE ECD PE-Cy5 PE-Cy7
IL-15 CD68 N.A. CD16 CD14
CX3CR1 CCR2 CD162 CD16 CD14
ACE MAC-1 CD162 CD16 CD14
ACE CD11b CD162 CD16 CD14
CD115 CD89 N.A. CD16 CD14
CD115 MAC-1 CD16 N.A. CD14
CD115 CD11b CD16 N.A. CD14
CX3CR1 Tie2 CD162 CD16 CD14
CXCR4 Tie2 CD162 CD16 CD14
FACS staining panel used for monocyte analysis.
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Age 62 (56-69) 64 (58-71) N.S.
BMI 27 (25-30) 27 (24-30) N.S.
Diastolic blood pressure (mm Hg) 80 (70-85) 77 (70-85) N.S.
Systolic blood pressure (mm Hg) 135 (123-145) 137 (124-150) N.S.
Glucose (mmol/L) 6.03 (5.48-7.10) 6.09 (5.40-7.23) N.S.
Hemoglobin (mmol/L) 8.90 (8.50-9.40) 8.25 (7.78-8.60) p<0.001
Cholesterol (mmol/L) 4.02 (3.40-4.80) 4.40 (3.77-5.28) p<0.001
LDL-C (mmol/L) 2.33 (1.81-2.98) 2.60 (1.92-3.23) p<0.05
HDL-C (mmol/L) 1.00 (0.86-1.18) 1.14 (0.99-1.44) p<0.001
Triglycerides (mmol/L) 1.30 (0.98-1.90) 1.40 (1.02-1.81) N.S.
hsCRP (ng/mL) 2578 (1680-6711) 3759 (1731-7339) N.S.
WBC (X1000 cells/µL) 7.10(5.90-8.40) 7.20(5.58-8.90) N.S.
Current smoker 21% (73) 24% (32) N.S.
Diabetes 22% (75) 25% (33) N.S.
Hypertension 61% (212) 71% (94) N.S.
Beta-blocker 73% (254) 76% (101) N.S.
Ca-antagonist 29% (101) 33% (44) N.S.
Aspirin 81% (280) 86% (114) N.S.
Vitamin K antagonist 12% (43) 11% (15) N.S.
ADP receptor blocker 50% (172) 53% (71) N.S.
ACE inhibitor 35% (121) 28% (37) N.S.
ATII receptor blocker 15% (53) 29% (39) p<0.001
Diuretic 19% (65) 24% (32) N.S.
Statin 81% (280) 74% (99) N.S.
Baseline characteristics comparison of male and female patients. Values are median (interquartile 
range) for continuous variables and percentage (total count) for categorical data.
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Age 62 (56-68) 64 (56-72) 64 (58-72) 62 (56-67)
BMI 27 (24-29) 28 (26-31) 27 (24-30) 27 (23-29)
DBP (mm Hg) 80 (70-85) 80 (70-90) 76 (69-83) 75 (69-84)
SBP (mm Hg) 135 (123-145) 132 (120-140) 135 (120-150) 137 (127-153)
Glucose (mmol/L) 6.01 (5.50-6.95) 5.81 (5.30-6.62) 6.08 (5.40-7.01) 5.60 (5.40-8.60)
Hemoglobin (mmol/L) 8.90 (8.60-9.40) 8.90 (8.40-9.30) 8.30 (7.80-8.63) 8.25 (7.85-8.53)
Cholesterol (mmol/L) 4.00 (3.40-4.80) 4.00 (3.53-4.58) 4.57 (3.80-5.30) 4.20 (3.70-4.90)
LDL-C (mmol/L) 2.30 (1.76-2.90) 2.40 (1.91-3.03) 2.60 (1.91-3.30) 2.70 (1.99-2.90)
HDL-C (mmol/L) 1.03 (0.88-1.20) 0.96 (0.84-1.04)* 1.20 (1.01-1.47) 1.02 (0.77-1.25)*
Triglycerides (mmol/L) 1.30 (0.96-1.88) 1.30 (0.98-1.70) 1.40 (1.00-1.81) 1.42 (0.90-1.80)
hsCRP (ng/mL) 2486 (1650-6695) 3200 (1735-7475) 3867 (1847-7984) 4678 (2020-7224)
WBC (X1000 cells/µL) 7.00 (5.80-8.20) 7.10 (6.30-8.10) 7.20 (5.50-9.08) 7.40 (6.00-8.40)
Current smoker 21% (58) 11% (4) 24% (29) 24% (4)
Unstable CAD 17% (46) 26% (9) 22% (26) 12% (2)
Diabetes 20% (54) 20% (7) 23% (27) 35% (6)
Hypertension 62% (170) 77% (27) 69% (82) 76% (13)
Beta-blocker 72% (199) 86% (30) 71% (85) 88% (15)
Ca-antagonist 29% (80) 34% (12) 29% (34) 53% (9)
Aspirin 82% (227) 74% (26) 82% (97) 94% (16)
Vitamin K antagonist 11% (29) 20% (7) 12% (14) 12% (2)
ADP receptor blocker 49% (134) 49% (17) 48% (57) 59% (10)
ACE inhibitor 34% (94) 46% (16) 26% (31) 35% (6)
ATII receptor blocker 15% (41) 26% (9) 27% (32) 35% (6)
Diuretic 17% (46) 31% (11) 26% (31) 12% (2)
Statin 82% (225) 71% (25) 70% (83) 88% (15)
Baseline characteristics table; values are median (interquartile range) or percentage (n). Patients that 
experienced major adverse cardiovascular event (MACE) and control patients that did not experience 
MACE were compared within each sex; categorical data was compared using the chi-square test and 
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Background- While a limited number of epidemiologic studies have 
addressed the biomarker potential of circulating T cells for coronary artery disease 
(CAD) none have looked at sex-specific differences in populations of T cells. The 
aim of the current study was to determine sex-specific associations of a wide range 
of T cell subsets with CAD.
Methods and Results- The cohort consisted of 550 CAD patients from the 
Circulating Cells study that were referred for coronary angiography. Flow cytometry 
analysis of blood samples was used to determine circulating T cell numbers. At 
baseline a significant 25% higher CD3+ T cell count was observed in female (p<0.001) 
but not in male unstable CAD compared to stable CAD patients. Furthermore, in 
females we observed large significant differences in a number of T cell subsets while 
in males only a few small differences were found in T cell subsets between stable 
CAD and unstable CAD patients.
Prospective analysis showed that none of the T cell subsets could 
independently predict major adverse CAD events in the female cohort. In the 
male cohort the CD4+CD127-CD46+ and CD4+CD46+CD25high T cell subset 
showed an age adjusted odds ratio of 2.54 (1.14-6.06 CI95%, p=0.02) and 
2.32 (1.05-5.47 CI95%, p=0.04).
Conclusion- We show that the number of circulating T cells are sex-specific 
in CAD patients. Only females showed significant differences in major T cell subsets 
between stable CAD and unstable CAD patients, but only in males T cell subsets 
may have potential value as a prognostic biomarker.
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Introduction
Both innate and adaptive immunity have a leading role in modulating 
the progression of atherosclerosis. In human lesions the ratio of macrophage to 
T cell is between 4:1 and 10:1, the dominant cell type in the plaque is therefore 
the macrophage but T cells are present at all stages of atherosclerosis[1]. The first 
experimental evidence that underlined the important role of adaptive immunity in 
atherosclerosis came from atherosclerosis prone apolipoprotein E deficient mice 
that were also lymphocyte deficient. In these double knockout mice a marked 
reduction in atherosclerotic plaque formation was shown[2], while reconstitution 
of these mice with CD4+ T cells aggravated atherosclerosis development[3]. 
Subsequent studies have focused on the specific contribution of T cell subsets to the 
development of atherosclerosis.
Th1 cells are the predominant T helper cell observed in the atherosclerotic 
plaque. IFNγ is the characteristic cytokine produced by Th1 cells, studies which 
show that deletion of IFNγ or its receptor attenuates experimental atherosclerosis 
implicate the Th1 cell subset in the progression of atherosclerosis[4,5]. In addition, 
in a mouse model deficient for the transcription factor Tbet, which mediates the 
differentiation of Th1, atherosclerosis formation is significantly decreased[6]. In line 
with these observations is the finding that treatment with the Th1 inducing cytokine 
IL-12 aggravates atherosclerotic lesion development, while blockade of IL-12 using 
a vaccination approach inhibits lesion development. As IL-12 is one of the primary 
cytokines driving Th1 differentiation this was further evidence that Th1 cells have a 
pro-atherogenic effect[7,8].
In contrast to Th1 cells, studies on Th2 cells show contradictory findings 
concerning their role in atherosclerosis. The characteristic cytokine IL-4 produced 
by Th2 lineage cells is rarely detected in plaques, in mice nor in humans[9,10]. Contrary 
to this observation some studies have found reduced lesion formation in mice 
deficient for IL-4. Others found increased lesion formation or that IL-4 deficiency 
had no influence on lesion formation[11–14].
Compared to the other two major T helper cell subsets, Th17 is a relatively 
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newly described subset and the role of Th17 in atherosclerosis is under active 
debate. Studies in experimental models for atherosclerosis have found aggravated 
inflammation and a pro-atherogenic effect of IL-17 and its receptor, whereas others 
describe an athero-protective role for Th17 and IL-17[15].
Regulatory T cells (Treg) can suppress proliferation of effector T cells by 
cytokine secretion and direct cell-to-cell contact. Initial studies of the group of 
Mallat show that Tregs reduce atherosclerosis development[16]. Subsequent research 
showed that induction of oral tolerance to several antigens, including oxidized 
LDL-C, induces an athero-protective response mediated by Tregs[17] via production 
of IL-10 and TGFβ[18–20].
The role of other T cell subsets is less well defined and the role of CD8 T cells 
in atherosclerosis is, despite their relatively large numbers in human atherosclerotic 
lesions, not fully understood[21,22].
Studies in humans are mostly restricted to epidemiological studies and have 
focused at associations between cardiovascular disease manifestations such as acute 
coronary syndrome, stable and unstable angina and T cell subset counts in peripheral 
blood[23–31]. In contrast, only two prospective studies have been performed on T cell 
subsets for biomarker discovery[32,33]. These studies show that circulating Tregs and 
Th2 cells could potentially be predictive for future cardiovascular events.
Research has shown that there are intrinsic differences between the immune 
system of males and females and this has consequences for the development of 
immune mediated diseases such as autoimmune diseases[34]. Also in coronary 
artery disease (CAD) there are large differences in symptoms, risk factors and the 
underlying pathology of CAD between men and women. New insights into sex-
specific differences in cardiovascular disease have led to adaptations in diagnostic 
testing and treatment regiments[35]. Cardiovascular disease development in women 
generally lags 7 to 10 years behind compared to men in the expression of clinical 
symptoms[36]. It is not fully understood what causes this delay but it is suggested that 
sex steroids have a protective effect on atherosclerotic plaque development during 
the pre-menopausal years of a woman’s life[37].
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Research into novel prognostic blood based biomarkers has not found any 
new biomarkers with substantial additive value over the classic biomarkers such 
as LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C) and hsCRP. Sex-specific 
factors have shown to influence CAD development and progression, we hypothesize 
that these factors influence lipid and inflammatory processes leading to differences 
in CAD biomarker expression between sexes. In this paper, a cohort of 550 patients 
scheduled for coronary angiography was analyzed by flow cytometry for sex-specific 
T cell subset distribution in blood both for the purpose of diagnosing CAD as well 





The study cohort consists of a total of 550 CAD patients between the age 
of 31 and 83 from the Circulating Cells Study cohort. The T cell flow cytometry 
panel was performed for logistic reasons only on part of the Circulating Cells Study 
cohort, therefore the study cohort is smaller than the whole Circulating Cells Study 
cohort. In brief, Circulating Cells is a multi-center study in which CAD patients 
scheduled for coronary angiography were included. Exclusion criteria were age 
< 18 years, inability to give informed consent, suspected drug or alcohol abuse, 
serious concomitant disease, serious recent infectious disease in the last 6 weeks 
or suspected elevated state of the immune system, and non-cooperativeness 
.The Circulating Cells study protocol was approved by the review board or ethics 
committee of each participating center[38]. Nine months after inclusion in the study, 
patients were contacted and any MACE that had occurred in the preceding months 
were recorded for outcome analysis. MACE is the primary endpoint of this study 
and is defined as death, myocardial infarction, percutaneous coronary intervention, 
coronary artery bypass grafting and cardiovascular accident. The cohort consists 
of 18 non-significant atherosclerosis, 438 stable angina, 53 unstable angina and 54 
non-STEMI diagnosed patients. The non-significant atherosclerosis patients were 
removed for unstable vs stable CAD analysis. Thirty-three patients were lost to 
follow-up and were subsequently excluded from primary endpoint MACE analysis.
Flow cytometry
Whole blood flow cytometry analysis was performed to identify and quantify 
T cell subsets. Cells were stained for the following markers: CD127, CD134, CD152, 
CD152, CD16, CD25, CD28, CD31, CD3, CD40, CD46, CD49b, CD4, CD56, 
CD62L, CD69, CD8, CXCR4, ICOS, IL12R, IL23R, NKG2c, TCRαβ and TCRγδ. 
See supplemental data for antibody information and staining combinations.
Blood was collected in a BD vacutainer EDTA blood collection tube and 50 
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μL whole blood was stained with the respective antibodies for 30 minutes on 4oC. 
Red blood cells were lysed in 500 µL Versalyse solution (IM3648; Beckman Coulter) 
for 5 minutes at room temperature immediately afterwards cells were analyzed by 
flow cytometry. Each center was equipped with an identical flow cytometer (FC500, 
Beckman Coulter) and before each run cytometers were calibrated with fluorosphere 
setup kits (Beckman Coulter). Analysis was performed on Kaluza 1.3 flow cytometer 
analysis software (Beckman Coulter).
Flow cytometry gating strategy
Figure 1A-G shows an example of the gating strategy that was used for the 
analysis of the flow cytometry data. T cell subsets were defined by the presence or 
absence of the expression of a cellular marker (e.g. CD8+ and CD8-). When there 
was a distinct population of cells that expressed the marker to a higher degree than 
other positive cells, that population is separately indicated as a high population 
(e.g. CD8high) and the population of cells that are positive for a certain marker but 
expresses it to a lower degree is indicated with low (e.g. CD8low). When a population 
of cells does not express a marker or only expresses it to a low degree this is indicated 
with a minus/low indicator (e.g. CD8-/low). The Kaluza flow cytometry analysis 
software tree plot was used for generating the data for all possible combinations of 
cell markers (Figure 1H).
Statistics
Statistical calculations were performed using R (version 3.0.2) for Windows. 
A P value lower than 0.05 was considered significant. Categorical data was compared 
using the chi-square test. For continuous data the nonparametric Mann-Whitney U 
test was used. 
For logistic regression the patients were divided into 3 equally sized groups 
(tertiles) according to the measured values for each variable. Firth’s penalized 
likelihood logistic regression was used to analyze stratified data. Two models were 
used, one simple model (Model 1) adjusted for age and an extended model (Model 
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2), which adjusted for age, hypertension, diabetes mellitus, current smoker, BMI 
and HDL-C level.
To identify variables that can classify patients into separate groups (e.g. 
stable vs. unstable CAD patients) we used the machine learning method Random 
Forest[39]. Taking advantage of combinations of predictor variables this algorithm 
classified subjects into different groups. The Random Forest method and the way it’s 
applied in this project are further explained in the supplemental material.
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Figure 1:
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 The T cell flow cytometry gating strategy. First cells were gated to exclude monocytes 
and granulocytes from the analysis by using the forward scatter, side scatter (A) and CD4 or CD3 
staining characteristics (B). Cells were subsequently gated on expression of different T cell related 
markers, if present a separate low and high populations were also gated (C-G). Finally a tree diagram 
was generated to calculate the amount of cells in each possible combination of markers (H).
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Age 62(56-69) 62(56-69) 64(58-72) 63(56-71)
BMI 27(25-30) 27(25-30) 28(25-31) 25(23-28)‡
SBP (mm Hg) 135(125-145) 130(120-141) 138(124-150) 135(120-148)
DBP (mm Hg) 80(70-85) 79(70-86) 76(70-85) 78(70-81)
Glucose (mmol/L) 6.00(5.40-6.70) 6.38(5.70-7.60)* 6.00(5.40-6.90) 6.70(5.64-7.40)
Hemoglobin (mmol/L) 8.90(8.50-9.30) 9.00(8.60-9.60) 8.20(7.73-8.60) 8.30(7.75-8.60)
Cholesterol (mmol/L) 3.90(3.40-4.65) 4.45(3.90-5.29)‡ 4.35(3.80-5.20) 4.82(3.85-5.63)
LDL-C (mmol/L) 2.22(1.73-2.84) 2.72(2.12-3.49)‡ 2.46(1.96-3.10) 2.72(2.00-3.52)
HDL-C (mmol/L) 0.99(0.88-1.19) 0.96(0.79-1.15) 1.18(1.00-1.47) 1.14(0.97-1.37)
Triglycerides (mmol/L) 1.30(0.96-1.87) 1.67(1.20-2.45)‡ 1.39(1.01-1.82) 1.53(1.18-2.05)
hsCRP (ng/mL) 2516(1685-5524) 5594(2044-18154)‡ 3626(1666-6976) 3669(2136-7281)
WBC (X1000 cells/µL) 6.80(5.78-8.00) 8.10(6.90-9.80)‡ 6.95(5.50-8.30) 8.80(7.20-9.90)‡
Current smoker 20%(64) 24%(18) 17%(21) 49%(18)‡
Diabetes 22%(70) 19%(14) 25%(31) 22%(8)
Hypertension 61%(191) 60%(45) 75%(94) 59%(22)
Beta-blocker 76%(237) 60%(45)† 83%(104) 54%(20)†
Ca-antagonist 32%(99) 23%(17) 31%(39) 14%(5)
Aspirin 83%(261) 68%(51)† 94%(117) 62%(23)‡
Vitamin K antagonist 10%(32)* 21%(16)* 7%(9) 16%(6)
ADP receptor blocker 50%(155)* 35%(26)* 51%(64) 46%(17)
ACE inhibitor 37%(116) 28%(21) 31%(39) 30%(11)
ATII receptor blocker 17%(52) 12%(9) 31%(39) 14%(5)
Diuretic 19%(61) 17%(13) 28%(35) 14%(5)
Statin 84%(264) 65%(49)‡ 82%(103) 49%(18)‡
Baseline characteristics table for the Circulating Cells cohort; values are median (interquartile range) 
or percentage (n). Stable CAD was compared to unstable CAD within each sex; categorical data was 
compared using the chi-square test and continuous data was compared with the Man-Whitney U 
test.  * p<0.05, † p<0.01, ‡ p<0.001.
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Results
Baseline cohort characteristics
Unstable angina, non-ST elevated myocardial infarction (non-STEMI) 
and stable angina are three distinct coronary syndromes. Stable angina often has a 
chronic character, unstable angina and non-STEMI are an acute form of a coronary 
syndrome. In this study non-STEMI and unstable angina patients were pooled and 
referred to as unstable CAD patients, this group was compared with stable angina 
patients (hereafter referred to as stable CAD patients).
Due to the chronic nature of stable CAD as compared to the more acute 
nature of unstable CAD, prescribed drug use was substantially higher in the stable 
CAD group both for males and females. Beta-blockers, aspirin, statins and in men 
also ADP receptor blockers are more commonly prescribed to stable CAD patients 
(Table 1). The only drug that did not follow this trend were Vitamin K antagonists, 
which were used more frequently in the unstable CAD group but only in males. 
Statin use was much higher in the stable CAD patients (males: 84%, females: 82%) 
compared to the unstable CAD patients (males: 65%, females:49%). The higher statin 
prescription in stable CAD patients might have contributed to the significantly lower 
total cholesterol, LDL-C and triglyceride levels in male stable CAD patients but in 
females the cholesterol levels did not differ between groups. In females smoking was 
significantly more common in the unstable CAD group. The inflammation marker 
hsCRP was significantly increased in male unstable CAD patients to more than 
twice the concentration in stable CAD patients, in contrast females did not show 
an increase in hsCRP. The increased level of inflammation was further confirmed 
by an increase in white blood cell (WBC) count in unstable CAD patients both in 
males and females.
Sex-specific differences in CD3, CD4 and CD8 T cell distribution
Analysis of the flow cytometry data showed significant sex-specific 
differences in immune cell distribution. Lymphocyte count was significantly higher 
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by 13% in females as compared to males (Table 2). Examining the T cell distribution 
we observed that the difference in lymphocyte population was primarily caused 
by a higher CD4+ and CD3+ T cell count, which was approximately 20% higher 
in women as compared to men. Concurrently with the higher number of CD4+ T 
cells, an increased number of naïve CD4 T cells (CD4+CD62L+CD69-) and Treg cells 
(CD4+CD25highCD172-) was seen in women.
Increased T cell numbers in female unstable CAD patients
Large differences in T cell distribution were observed between stable and 
unstable CAD patients within the female cohort; total lymphocyte counts as well as 
CD3+ and CD4+ T cell count were significantly increased by approximately 20% in 
female unstable CAD patients compared to female stable CAD patients. Surprisingly 
in the male cohort no significant differences were observed in lymphocyte, 
CD3+, CD4+ or CD8+ T cell count between stable and unstable CAD patients 
(Figure 2A-F, Table S2).
To extend our analysis for T cell subsets that have a sex-specific effect on 





Lymphocytes (cells/µL) 2151(1746-2715) 1943(1529-2459) p<0.001
CD3+ T cells (cells/µL) 1450(1182-1889) 1256(955-1666) p<0.001
CD4+ T cells (cells/µL) 1013(796-1328) 808(603-1063) p<0.001
CD8+ T cells (cells/µL) 306(213-451) 307(204-467) N.S.
Naïve CD4+ T cells (cells/µL) 696(528-963) 534(348-723) p<0.001
Naïve CD8+ T cells (cells/µL) 98(59-143) 88(50-141) N.S.
Activated CD4+ T cells (cells/mL) 3456(2333-6653) 3191(1876-5136) p<0.05
Activated CD8+ T cells (cells/mL) 7187(4317-12097) 7215(4368-11400) N.S.
T regulatory cells (cells/µL) 32(24-48) 26(17-40) p<0.001
Differences in T cell population between sexes; values are median (interquartile range). Treg 
cells, naïve and activated CD4 and CD8 cells were respectively identified by marker combinations 
CD4+CD25+CD127-, CD4+CD62L+CD69- , CD8+CD62L+CD69-, CD4+CD62L-CD69+ and 
CD8+CD62L-CD69+.
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Male cohort Female cohort
 Sex-specific comparison of number of circulating CD3+ (A), CD4+ (B), CD8+ (C), Treg 
(D), naïve CD4+ (E) and naïve CD8+ (F) cells between stable and unstable CAD patients. ** p<0.01, 
***p<0.001. Correlation matrix of the 10 top ranked cell subsets determined by Random Forest 
modeling of stable and unstable CAD patients for the male (G) and female (H) cohort. The variables 
were clustered using hierarchical clustering. Blue indicates a positive correlation while red indicates 
a negative correlation, the intensity of the color indicates the size of the correlation. 
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CAD development we enlarged the flow cytometry panel with 24 markers known 
to be associated with specific T cell subsets (Table S1). The gating strategy we used 
was not focused on specific T cell subsets but included all possible combinations 
using the markers present in the panel, the panel can identify approximately 4500 
cell subsets. Random Forest modeling was used to find T cell subsets that could 
discriminate between stable and unstable patients.
The ten T cell subsets best able to stratify patients into stable and unstable 
CAD groups were selected for further analysis for both the male and female cohort. 
A correlation matrix in combination with hierarchical clustering was used to identify 
overlapping cell subsets (Figure 2G, H). From each cluster the cell subset with the 
shortest marker combination and best able to stratify patients was chosen for further 
analysis. Using this strategy 7 cell subsets were selected for the male cohort and 5 
cell subsets were selected for the female cohort (Table S3, S4).
In the male cohort, 3 T cell subsets showed a significant difference between 
stable and unstable patients: a higher number of circulating CD3+CD31-CD28-, 
CD3+CD56+TCRαβ- and CD4+CD152+ T cells were observed in male unstable CAD 
compared to stable CAD patients (Table S3). The largest change was seen in the 
CD3+CD56+TCRαβ- T cell subset, which is a small cell subset with approximately 19 
cells/µL blood (10-38 IQR) and we observed a 33% increase in the number of these 
cells in male unstable CAD compared to stable CAD patients.
The female cohort displayed larger changes in T cell subsets compared to 
the male cohort (Table S4). In the female cohort, CD4+CD127+CD46+, CD4+CD40+, 
CD4+CD8high, CD4+CD8+CD62Lhigh and CD8+CD62Lhighcells were significantly up 
regulated in female unstable CAD patients (Table S4). The largest changes were seen in 
the CD4/CD8-double positive T cell subsets CD4+CD8high and CD4+CD8+CD62Lhigh, 
which showed an almost 2-fold increase in unstable female CAD patients.
Prognostic analysis of T cell subsets
When comparing patients that experienced MACE with control patients we 
observed in female MACE patients a significantly lower HDL-C concentration, this 
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Male cohort Female cohort
 Correlation matrix and odds ratios of potential prognostic T cells subsets. Correlation 
matrix of the 10 top ranked cell subsets determined by Random Forest modeling of MACE and 
control patients for the male (A) and female (B) cohort. The variables were clustered using hierarchical 
clustering. Blue indicates a positive correlation while red indicates a negative correlation, the intensity 
of the color indicates the size of the correlation. Forest plots of ORs from granulocyte cell subsets 
and major blood based biomarkers such as hsCRP, LDL-C and HDL-C in the male (C) and female 
(D) cohort. Median value with corresponding 95% confidence interval (CI) for each variable, dotted 
vertical line indicates no effect.
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difference was not significant in the male cohort (Table S5).
As with stable and unstable CAD patients, a model was generated using 
Random Forest for discriminating MACE patients from controls. The ten top-
ranked T cell subsets from the Random Forest model were used to generate a 
correlation matrix for the male and female cohort (Figure 3A, B). Overlapping cell 
subsets were identified using hierarchical clustering of the correlation matrix and 
one representative subset was selected from each cluster.
Logistic regression was subsequently used to determine the odds ratio 
(OR) to evaluate the biomarker potential of each T cell subset (Table S6 and S7). 
The patients were distributed into tertiles based on their respective cell subset 
measurements, odds of MACE in the first tertile (reference tertile) were compared 
with the second and third tertile to determine the respective ORs. Using a simple 
model that adjusts for age (Model 1) we found that 2 subsets in the male cohort 
had significant ORs (first compared to third tertile). The CD4+CD127-CD46+ and 
CD4+CD46+CD25high have an OR of 2.54 (1.14-6.06 95%IC, p=0.023) and 2.32 
(1.05-5.47 95%IC, p=0.037) respectively and are associated with an increased risk of 
MACE. The subsets represent small T cell subsets with circulating cell numbers for 
CD4+CD127-CD46+ of 14 cells/µL(9-23 IQR) and for CD4+CD46+CD25high 7 cells/
µL (3-13 IQR) accounting for approximately 1% of CD4 T cells. When this model 
was extended to adjust for hypertension, diabetes mellitus, current smoker, BMI and 
HDL-C in addition to age (Model 2) the ORs for both cell subsets were no longer 
significant (Table S6). In contrast, in the female cohort none of the T cell subsets 
showed a significant association with MACE (Table S7).
In the male cohort traditional blood-based biomarkers such as LDL-C, 
HDL-C and hsCRP performed poorly as predictive biomarkers for MACE. The 
T cell subsets CD4+CD127-CD46+ and CD4+CD46+CD25high performed better 
than the traditional biomarkers (Figure 3C). In contrast, in females HDL-C had a 
significant OR (first compared to third tertile) and an increased concentration of 
HDL-C was associated with a decreased chance of MACE, while none of the T cell 
subsets showed a significant OR (Figure 3D).
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Discussion
The concept that both the innate and the adaptive immune system are of 
central importance in the initiation and progression of atherosclerosis is widely 
accepted. Modulation of specific T cell subsets in mice has been shown to affect 
the progression of atherosclerosis and as such T cells have been shown to play a 
central role in atherosclerotic disease progression. The translation of experimental 
research performed in mouse models into human pathology has been complicated 
by the inherent limitations in human research. In this study we investigated a broad 
spectrum of T cells in circulation to determine whether a T cell subset could be 
identified that associated with severity of coronary syndrome or with the chance to 
develop adverse cardiac events.
One of the prominent findings of this study is the significant sex based 
difference in the association of the immune system and lymphocyte subsets 
with cardiovascular disease. It is well known that sex based differences in the 
manifestation of cardiovascular disease exist. Women tend to develop CAD later 
in life and present with angina pectoris or atypical symptoms more often than 
men, whereas men more often present with acute myocardial infarction or sudden 
death[36,40,41]. Morphologically, the plaque disruption is also different between sexes 
as women (primarily pre-menopausal women) more often show plaque erosion, 
while men more often show plaque rupture when presenting with acute coronary 
syndrome[42,43]. In the Circulation Cells cohort, we found a 20% higher number of 
CD3+ and CD4+ T cells in women compared to men, this in contrast to a lower 
number of monocytes observed in women. These numbers indicate that it might be 
advised in future observational studies to separate men and women when analyzing 
an immune mediated disease in a gender mixed cohort.
Unstable CAD is associated with an increased systemic inflammation[44]. 
Here we found significantly higher numbers of circulating CD3 and CD4 positive 
T cells in female unstable CAD patients compared to stable female CAD patients, 
however a corresponding effect was not observed in the male cohort. While the 
differences for most T cell subsets in males were relatively small, one exception was 
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CD3+CD56+TCRαβ- cells which was increased in male unstable CAD patients. The 
CD3+CD56+TCRαβ- cell subset partially corresponds to natural killer T cells, most 
evidence points toward a pro-atherogenic role of NKT cells[45–47]. In contrast to our 
results a previous study has found a decreased numbers of circulating NKT cells in 
patients with CAD[48]. The discrepancy in result could be due to a difference in study 
setup as they compared healthy subjects to CAD patients and we compare stable 
CAD to unstable CAD patients.
Females show particularly large changes in CD4/CD8 double positive T cell 
subsets where the number of circulating CD4+CD8high and CD4+CD8+CD62Lhigh 
cells almost doubled in female unstable CAD patients. Equivalent changes in these 
subsets were not found in the male cohort. Double positive cells are most commonly 
described in the thymus as immature T cells but multiple studies have shown the 
presence of a small subset in blood, less than 5% of the circulating T cells in the 
blood that are positive for both CD4 and CD8[49–51]. Several studies have found an 
increase in this double positive cell subset in cases of viral infection, cancer and 
autoimmune disease but very little is known on the function of this cell subset[52]. We 
now show for the first time a direct correlation between CD4/CD8 double positive 
T cells and coronary syndrome. Additional research will have to reveal whether 
the CD4/CD8 double positive T cells have a functional role in the development of 
atherosclerosis in females.
To our knowledge only two prospective studies have been performed on 
circulating T cells in relation to major adverse coronary events, one focused on 
Th2 cells and the second on Tregs and their association with cardiovascular events. 
Engelbertsen et al. showed a strong negative association between Th2 count in 
circulation and the incidence of coronary events in women but not in men. In the 
panel that was used in this study it was impossible to identify Th2 cells, but it is 
interesting to note that Engelbertsen et al. found a strong sex-specific effect, which 
we also observed in different T cell subsets[32]. Wigren et al. found that increased 
Treg counts associate with a decreased incidence of myocardial infarction and 
interestingly in males we find two T cell subsets that are very similar to Treg cells, 
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CD4+CD127-CD46+ and CD4+CD46+CD25high, which are predictive for MACE[33]. 
These subsets should partially overlap with the standard Treg CD4+CD25highCD127- 
cell subsets but in contrast to Wigren et al. we found an increased chance of MACE 
with an increase in these cell subsets. The study by Wigren et al. has a significantly 
longer follow-up time of 15 years compared to the 9 months follow-up in the current 
study and in their study blood samples had been stored for many years before 
analysis, whereas in comparison we used fresh blood for flow cytometry analysis. 
These differences in the setup of the study could have contributed to the different 
findings in comparison to Wigren et al.
Classic blood based biomarkers such as LDL-C, HDL-C and hsCRP 
performed poorly in this study as a predictive biomarker for the development of 
MACE. These markers have shown to work well for primary prediction but possibly 
in secondary event prediction their use is limited. This shows the need for novel 
biomarkers for the accurate risk assessment of this population of patients. The 
biomarker T cell subsets that were identified here could possibly fill this role and be 
a used for prediction of secondary cardiovascular events in male patients.
It should be noted that the current study does have a few limitations. 
Primarily due to the short follow-up time of 9 months the number of MACE events 
is limited, especially in the female cohort. The current findings need to be validated 
in a cohort study specifically designed to find sex-specific differences of T cell 
distribution in CAD patients.
Our analysis in a CAD based cohort showed sex-specific effects on the T cell 
distribution in patients. Female unstable CAD patients have a significantly higher 
circulating CD4 and CD8 T cell numbers compared to female stable CAD patients, 
in contrast in males no difference was found between stable and unstable CAD 
patients. In females we find a large increase in the number of circulating CD4/CD8 
double positive T cells in unstable CAD patients compared stable CAD patients but 
no difference is found in males CAD patients. Prognostic analysis shows that classic 
blood based biomarkers LDL-C, HDL-C and hsCRP perform poorly as predictive 
biomarkers in males while in females HDL does show prognostic potential for 
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predicting secondary CAD events. Only in males do T cell subsets show prognostic 
potential for secondary CAD events, T regulatory cell subsets in particular could be 
of use as predictive CAD biomarkers.
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For T cell analysis cells were stained in 9 combinations (Table S1) with the 
following antibodies: CD127-FITC (11-1278-42; eBioscience, San Diego, USA), 
CD134-ECD (IM99512; Beckman Coulter, Fort Lauderdale, USA), CD152-PC7 
(IM99512; Beckman Coulter), CD152-PE (IM2282; Beckman Coulter), CD16-FITC 
(IM0814U; Beckman Coulter), CD25-ECD (6607112; Beckman Coulter), CD28-
ECD (6607111; Beckman Coulter), CD31-FITC (IM1431U; Beckman Coulter), 
CD3-ECD (A07748; Beckman Coulter), CD3-PC5 (A07749; Beckman Coulter), 
CD3-PC7 (737657; Beckman Coulter), CD40-PC5 (35-0409; eBioscience), CD46-PE 
(12-0469-42; eBioscience), CD49b-FITC (IM1425; Beckman Coulter), CD4-ECD 
(6604727; Beckman Coulter), CD4-PC7 (737660; Beckman Coulter), CD56-PC5 
(A07789; Beckman Coulter), CD62L-PE (IM2214U; Beckman Coulter), CD69-PC5 
(IM2656; Beckman Coulter), CD8-FITC (A07756; Beckman Coulter), CXCR4-PE 
(A07409; Beckman Coulter), ICOS-FITC (11-9948-42; eBioscience ), IL12R-PE 
(FAB839P; R and D Systems, Minneapolis, Minn., USA), IL23R-FITC (FAB14001F; 
R and D Systems), NKG2c-PE (FAB138P; R and D Systems), TCRαβ-PE (A39499; 
Beckman Coulter) and TCRγδ-PC5 (IM2662; Beckman Coulter).
Random Forest
Random forest is an ensemble learning method that generates models 
of the provided data and then uses all models combined to get better predictive 
performance. Random forest generates many decision trees based on bootstrap 
samples from the original data and for each split in a decision tree a number of 
variables are randomly selected and tested for classification performance. From these 
variables the best performing variable is selected for the split. This randomization in 
sampling and variable selection makes the model very robust and unbiased; it has 
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been shown to give good results in analyzing multivariate flow cytometry data[1,2].
As only part of the data is used to generate each individual decision tree, 
the remainder of the data can be used to test the performance of the decision tree 
and determine the importance of each variable. The importance of variables in the 
random forest is estimated by permuting one predictor variable while all else is kept 
unchanged and looking at how much prediction accuracy decreases. This is done 
per constructed decision tree and gives a mean decrease of accuracy per variable.
Because the dataset contains many hundreds of variables (all possible 
marker combinations) we first reduced the number of variables. Using random 
forest to estimate the importance of each variable and discarding variables with an 
importance of less than zero, we then generate a new random forest again discarding 
the variables with a negative importance score. This procedure is repeated until for 
a set amount of repetitions no variables with negative importance values are found. 
This technique is based on a similar technique implemented in random jungle[3].
The random forest can determine similarity between patients by looking at 
how many times two subjects fall into the same terminal node over all the decision 
trees, as it is assumed that two subjects that are similar to each other will frequently 
end up in the same terminal node. This attribute of random forest was used to impute 
missing predictor data in the database, as similar subjects were used to estimate 
the missing data.
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Table S1: Flow cytometry staining panel
FITC PE ECD PE-Cy5 PE-Cy7
CD49b TCRαβ N.A. CD56 CD3
CD16 NKG2c CD3 CD244 CD4
CD31 CXCR4 CD28 CD3 CD4
ICOS CD62L CD25 CD69 CD4
IL-23R IL-12R CD134 CD40 CD4
CD127 CD46 CD25 N.A. CD4
CD127 CD152 CD4 N.A. (CD152)
CD8 CD62L CD134 CD69 CD4
CD8 TCRαβ N.A. TCRγδ  CD4
Twenty-four marker panel used for staining T cells in whole blood.
Supplementary tables
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CD3+CD31-CD28- (cells/µL) 656 (483-880) 714 (564-941) p<0.05
CD3+CD56+TCRαβ- (cells/µL) 19 (10-37) 28 (15-42) p<0.05
CD4+CD152+ (cells/µL) 98 (60-157) 129 (75-206) p<0.05
CD4+CD25+CD62L-/low (cells/µL) 11 (6-18) 9 (4-15) N.S.
CD4+CD25+ICOS+ (cells/µL) 1 (1-3) 2 (1-3) N.S.
CD4+CD40+ (cells/µL) 7 (5-11) 8 (6-11) N.S.
CD4+CD62LhighICOS+ (cells/µL) 4 (2-6) 3 (2-7) N.S.
Circulating cell numbers for cell subsets selected by Random Forest modeling of stable and unstable 
CAD patients for the male cohort ,values are median (interquartile range).
111
CD4 and CD8 T cell subsets as biomarkers in coronary artery disease







CD4+CD127+CD46+ (cells/µL) 274 (199-382) 367 (269-483) p<0.01
CD4+CD40+ (cells/µL) 8 (6-14) 12 (9-16) p<0.01
CD4+CD8high (cells/µL) 2 (1-4) 5 (3-7) p<0.001
CD4+CD8+CD62Lhigh (cells/µL) 13 (9-19) 25 (14-39) p<0.0001
CD8+CD62Lhigh (cells/µL) 149 (95-205) 213 (167-272) p<0.0001
Circulating cell numbers for cell subsets selected by Random Forest modeling of stable and unstable 
CAD patients for the female and female cohort ,values are median (interquartile range).
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Age 62 (56-68) 64 (55-72) 64 (57-71) 62 (56-69)
BMI 27 (25-29) 28 (26-31) 27 (24-30) 27 (23-29)
SBP (mm Hg) 135 (124-145) 130 (120-140) 135 (120-150) 137 (129-149)
DBP (mm Hg) 80 (70-85) 76 (70-88) 75 (68-82) 75 (70-85)
Glucose (mmol/L) 6.00 (5.48-6.82) 5.81 (5.30-6.62) 6.15 (5.40-7.02) 5.60 (5.44-8.60)
Hemoglobin (mmol/L) 8.90 (8.58-9.40) 9.00 (8.40-9.40) 8.30 (7.75-8.60) 8.30 (7.93-8.58)
Cholesterol (mmol/L) 4.00 (3.40-4.74) 4.00 (3.58-4.94) 4.59 (3.84-5.30) 4.15 (3.60-4.73)
LDL-C (mmol/L) 2.30 (1.74-2.88) 2.40 (1.91-3.04) 2.60 (1.99-3.30) 2.65 (2.00-2.85)
HDL-C (mmol/L) 1.02 (0.86-1.21) 0.96 (0.85-1.04) 1.22 (1.01-1.47) 1.01 (0.79-1.23)†
Triglycerides (mmol/L) 1.30 (0.98-1.95) 1.30 (0.98-1.75) 1.40 (1.02-1.88) 1.42 (1.00-1.72)
hsCRP (ng/mL) 2720 (1688-6518) 3510 (1785-7683) 3626 (1889-7281) 4678 (2151-7132)
WBC (X1000 cells/µL) 7.00 (5.80-8.20) 7.10 (6.05-8.50) 7.30 (5.70-9.00) 7.40 (5.90-8.60)
Current smoker 21% (66) 14% (6) 25% (36) 21% (4)
Diabetes 20% (61) 21% (9) 23% (33) 32% (6)
Hypertension 61% (187) 77% (33) 70% (102) 79% (15)
Unstable CAD 17% (54) 33% (15)* 22% (34) 16% (3)
Beta-blocker 72% (222) 79% (34) 74% (108) 84% (16)
Ca-antagonist 30% (92) 33% (14) 23% (34) 47% (9)
Aspirin 82% (254) 72% (31) 83% (121) 95% (18)
Vitamin K antagonist 10% (31) 19% (8) 10% (14) 11% (2)
ADP receptor blocker 45% (140) 47% (20) 45% (66) 58% (11)
ACE inhibitor 35% (107) 44% (19) 29% (42) 37% (7)
ATII receptor blocker 15% (47) 23% (10) 26% (38) 32% (6)
Diuretic 17% (52) 30% (13) 26% (38) 16% (3)
Statin 82% (252) 70% (30) 71% (104) 84% (16)
Baseline characteristics of male patients that experienced major adverse cardiovascular event 
(MACE) versus control patients that did not experience MACE, values are median (interquartile 
range) or percentage (n). † p < 0.01
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Background- Numerous studies have shown differences in coronary artery 
disease (CAD) development and manifestation between males and females. The aim 
of this study was to analyse the role of sex in the association of distinct neutrophil 
and eosinophil cell subsets with coronary syndrome and the clinical outcome 
of CAD patients.
Methods and results- The Circulating Cells cohort included 470 patients 
with CAD referred to the hospital for coronary angiography. Fresh blood samples 
were analysed by flow cytometry for eosinophil and neutrophil cell subsets. Total 
neutrophil counts were significantly increased by approximately 20% in unstable 
CAD patients compared to stable CAD patients in both males (p<0.001) and 
females (p<0.001). Prospective analysis showed that in males the neutrophil cell 
subsets characterized by CD16highCD115+CD89+ and CD16highCD14- associated 
with major adverse cardiac events (MACE), with respective odds ratios (OR) of 3.34 
(1.37-9.18 CI95%; p=0.007) and 4.31 (1.57-14.43 CI95%, p=0.004). In the female 
cohort the neutrophil cell subsets CD16highCD162lowCXCR4+ (OR=6.39, 1.75-34.45 
CI95%, p=0.004) and CD16highCXCR4+ (OR=6.31, 1.73-33.95 CI95%, p=0.004) were 
strongly associated with an increased risk of MACE.
Conclusion- In the present study we show that neutrophil numbers are 
increased in unstable CAD patients in both males and females. However neutrophil 
subsets that are predictive for MACE are shown to be sex-specific. In men 
CD16highCD14- and in females CD16highCXCR4+ are potential prognostic biomarkers 
for cardiovascular events.
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Introduction
It has long been known that sex differences exist in coronary artery disease 
(CAD) manifestation and progression in men and women. Women tend to have 
approximately a 10 year delay in onset of CAD compared to men[1]. There are 
also differences in manifestation of CAD, the frequency of eroded atherosclerotic 
plaques in young women with CAD is much higher than in young men which show 
a higher frequency of ruptured atherosclerotic plaques[2,3]. Atherosclerosis is the 
primary cause of CAD and is instigated by a high lipid level in the blood leading 
to lipid accumulation in the sub-endothelial space which induces an inflammatory 
response and immune cell migration into the atherosclerotic plaque[4].
Atherosclerosis is an immune modulated disease but data on the role 
of neutrophils in atherosclerosis is limited, most likely due to the complexity of 
studying neutrophils. Neutrophils are terminally differentiated cells that have an 
extremely short lifespan and until recently markers to selectively identify neutrophils 
in tissues were unavailable. These factors made the neutrophil notoriously difficult 
to investigate and trace in vivo and in vitro. This combined with early reports of low 
numbers of neutrophils identified in atherosclerotic plaque contributed to the lack 
of interest in neutrophil research[5].
Neutrophils belong to the innate immune system and have for a long time 
been thought of as having just one basic function, to search for and kill invading 
microbes. Recent advances have changed this view on neutrophil biology and research 
has shown a role for neutrophils beyond acute inflammation and innate immunity[6].
In humans, neutrophils form the largest subset of leukocytes and account for 
50 to 70% of white blood cells (WBC). In contrast to other leukocytes the lifespan of 
neutrophils is relatively short with a half-life of approximately 8 hours[7], although 
their lifespan can be significantly expanded through activation by growth factors 
and cytokines[8]. Together with eosinophils and basophils neutrophils form the 
granulocyte subset of WBC. Neutrophils have so-called granules, and on activation 
they can rapidly excrete their content into the surrounding environment. Neutrophil 
granules contain a wide range of cytokines and chemokines and upon improper 
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activation they can cause significant collateral damage to surrounding tissue.
In experimental models for atherosclerosis, the neutrophil specific Ly6G 
staining and neutrophil depletion has led to new insight into the involvement of 
neutrophils in atherosclerotic disease. Staining with Ly6G showed an accumulation 
of neutrophils only in early and late lesions in mice, neutrophils predominantly 
accumulated in the inflamed shoulder regions of the plaque[9–11]. Depletion of 
neutrophils leads to reduced lesion formation in early atherosclerosis[9], while in 
late stage atherosclerosis neutrophils associate with rupture prone lesions[12,13]. 
The finding that circulating neutrophil numbers and lesion size directly 
correlate in atherosclerotic prone mice suggests a causal role for neutrophils in 
plaque development[9].
Observational and histochemical studies of atherosclerotic plaques have 
shown that neutrophils might play a role in later stages of atherosclerosis. Neutrophils 
were found in culprit lesions of patients with acute myocardial infarction and in 
contrast non-culprit plaques rarely show neutrophil infiltration[14]. Neutrophil 
presence in the lesions is associated with vulnerable lesion characteristics such 
as intra-plaque hemorrhage and plaque erosion[15,16]. Observational studies have 
shown that neutrophil count in the blood is a strong predictive marker for future 
cardiovascular events, as shown in the meta-analysis by Guasti et al.[17]. Little is 
known however on specific neutrophil subsets and whether differences in their 
activation or chemotactic status are associated with cardiovascular events.
Circulating Cells is a cohort study that was setup to identify cellular 
biomarkers in blood predictive of cardiac events[18]. In the present study we used a 
12-marker flow cytometry panel to identify sex-specific subsets of neutrophils and 
eosinophils that correlate with the CAD diagnosis and to identify granulocyte cell 
subsets predictive for major adverse cardiac events (MACE) that could be used as 
prognostic biomarkers in CAD.
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Methods
Study population
The study cohort consists of a total of 470 patients between the age of 31 
and 83 from the Circulating Cells Study cohort. The neutrophil flow cytometry 
panel was performed for logistic reasons only on part of the Circulating Cells Study 
cohort, therefore the study cohort is smaller than the whole Circulating Cells Study 
cohort. In brief, Circulating Cells is a multi-center study in which CAD patients 
scheduled for coronary angiography were included. Exclusion criteria were age < 18 
years, inability to give informed consent, suspected drug or alcohol abuse, serious 
concomitant disease, serious recent infectious disease in the last 6 weeks or suspected 
elevated state of the immune system and non-cooperativeness. The Circulating Cells 
protocol was approved by the review board or ethics committee of each participating 
center[18]. Nine months after inclusion in the study patients were contacted and any 
MACE that occurred in the preceding months was recorded for outcome analysis. 
MACE is the primary endpoint of this study and is defined as cardiovascular disease 
related death, myocardial infarction, percutaneous coronary intervention, coronary 
artery bypass grafting and cardiovascular accident. The cohort consists of 17 non-
significant atherosclerosis, 387 stable angina, 58 unstable angina and 44 non-STEMI 
diagnosed patients. The non-significant atherosclerosis patients were removed 
for unstable vs stable CAD analysis. For 32 patients there was no follow-up data 
available, these patients were excluded from primary endpoint MACE analysis.
Flow cytometry
Whole blood flow cytometry analyses was performed to identify and quantify 
neutrophil and eosinophil subsets with antibodies directed against the cell surface 
antigens CD14, CD16, CCR2, CX3CR1, CXCR4, CD143 (ACE), CD162, CD68, 
CD89, IL15 (membrane-bound), TIE2 and CD115. See supplementary methods for 
specifications and combinations of antibodies for staining (Table S1).
Blood was collected in EDTA-containing vacutainer blood collection tubes 
122
Chapter 4
(Becton Dickinson, Breda, the Netherlands) and 50 μl whole blood samples were 
stained with selected antibody sets for 30 minutes at 4oC. Cells were washed with 
FACS solution (1% bovine serum albumin and 0.01% Na-azide in PBS). Red blood 
cells were lysed in 8.3 g/L ammonium chloride (168320; Merck), 1.0 g/L potassium 
bicarbonate (1048540500; Merck) and 37.2 mg/L EDTA (E4884-100G; Sigma-
Aldrich) solution at 4oC for 30 minutes. Cells were then washed and fixed with 
0.2% formaldehyde and 0.9% NaCl solution immediately followed by FACS analysis 
(FC500, Beckman Coulter, Fort Lauderdale, USA) calibrated with fluorosphere setup 
kits (Beckman Coulter). Data analysis was performed on Kaluza 1.3 flow cytometer 
analysis software (Beckman Coulter).
Flow cytometry gating strategy
Neutrophils (CD16high) and eosinophils (CD16-) were defined according 
to forward and side scatter characteristics and CD16 expression and gated as 
described in Figure 1A-B. For the additional markers, subsets were defined based 
on the presence or absence of expression (e.g. CD162+ vs. CD162-) or the presence 
of distinct populations that display high (e.g. CD162high) or low expression (e.g. 
CD162low) (Figure 1C-F). The Kaluza flow cytometry analysis software was used for 
the generation of tree plots for all possible combinations of markers (Figure 1G).
Statistics
Statistical calculations were performed using R for windows (version 3.1.2). 
A P<0.05 was considered significant. Categorical data was compared using the chi-
square test. For continuous data the nonparametric Mann-Whitney U test was used. 
For logistic regression the patients were divided into 3 equal sized groups 
(tertiles) according to the measured values for each variable. Firth’s penalized 
likelihood logistic regression was used to analyze stratified data. Firth’s method was 
used to handle small sample sizes. The odds ratio (OR) was adjusted for potential 
CAD risk factors such as age (Model 1) and age, hypertension, diabetes mellitus, 
current smoker, BMI and HDL-cholesterol (HDL-C) level (Model 2).
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To identify variables that could potentially stratify patients into separate 
groups (e.g. stable vs. unstable CAD patients) we used the machine learning method 
Random Forest[19]. The Random Forest modeling method and its application in this 



























































































































































































































































































































































































































































































 Flow cytometry gating strategy for neutrophils and eosinophils. The granulocyte subset 
was first selected on the basis of forward and side scatter characteristics (A). Subsequently the CD16 
plot allowed gating of mature neutrophils (CD16high) and eosinophils (CD16-) (B). Gating of further 
markers (e.g. CXCR4, TIE2 and CD162) was based on the number of distinct populations for each 
marker (e.g. positive, negative, low, high) (C-F). Finally the tree analysis feature calculated the 
amount of cells in each possible combination of markers (G).
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Age 62(56-69) 62(56-69) 64(58-71) 63(56-71)
BMI 27(25-30) 27(25-30) 28(25-31) 25(23-28)†
SBP (mm Hg) 135(125-145) 130(120-141)* 138(125-150) 135(118-150)
DBP (mm Hg) 80(70-85) 80(70-86) 77(70-85) 76(70-80)
Glucose (mmol/L) 6.00(5.40-6.70) 6.36(5.63-7.55) 6.00(5.40-6.82) 6.70(5.47-7.80)
Hemoglobin (mmol/L) 8.90(8.50-9.30) 9.00(8.60-9.58) 8.20(7.80-8.63) 8.30(7.68-8.60)
Cholesterol (mmol/L) 3.90(3.36-4.65) 4.47(3.92-5.30)‡ 4.40(3.80-5.22) 4.66(3.90-5.37)
LDL-C (mmol/L) 2.22(1.74-2.85) 2.77(2.34-3.48)‡ 2.52(1.93-3.13) 2.71(1.99-3.50)
HDL-C (mmol/L) 1.01(0.88-1.18) 0.96(0.80-1.15) 1.16(1.00-1.44) 1.11(0.97-1.35)
Triglycerides (mmol/L) 1.30(0.94-1.80) 1.69(1.19-2.43)‡ 1.36(1.00-1.80) 1.52(1.18-2.03)
hsCRP (ng/mL) 2436(1668-5508) 5193(1865-20665)† 4028(1661-7156) 3722(2143-7227)
WBC (X1000 cells/µL) 6.80(5.75-8.00) 8.10(7.20-9.65)‡ 6.90(5.50-8.28) 9.00(7.38-9.85)‡
Current smoker 21%(60) 22%(15) 17%(17) 53%(16)‡
Diabetes 22%(63) 19%(13) 24%(25) 27%(8)
Hypertension 62%(176) 60%(40) 73%(75) 57%(17)
Beta-blocker 76%(217) 60%(40)† 84%(87) 53%(16)†
Ca-antagonist 32%(90) 22%(15) 37%(38) 17%(5)
Aspirin 83%(236) 69%(46)* 92%(95) 63%(19)‡
Vitamin K antagonist 11%(30) 21%(14)* 9%(9) 17%(5)
ADP receptor blocker 51%(145) 37%(25) 56%(58) 43%(13)
ACE inhibitor 37%(104) 28%(19) 29%(30) 30%(9)
ATII receptor blocker 16%(46) 10%(7) 32%(33) 17%(5)
Diuretic 19%(55) 16%(11) 27%(28) 13%(4)
Statin 85%(241) 67%(45)† 82%(84) 47%(14)‡
Baseline characteristics table, values are median (interquartile range) or percentage (n). Stable and 
unstable CAD was compared for males and females, categorical data was compared using the chi-





Unstable angina and non-ST elevated myocardial infarct (non-STEMI) 
are acute coronary syndromes whereas stable angina has a more chronic disease 
character, consequently there are differences in baseline characteristics of patients 
with acute or chronic coronary syndrome (Table 1). As the number of non-STEMI 
patients is low in the Circulating Cells cohort we pooled them together with the 
unstable angina patients into the unstable coronary artery disease (CAD) group and 
the stable angina patients are referred to as stable CAD patients. One of the most 
striking differences between stable and unstable CAD patients is the disparity in 
drug use. Prescription of beta-blockers, aspirin and statins was significantly higher 
in stable CAD patients compared to stable CAD both in men and women. The 
one exception is vitamin K antagonists, which were more frequently prescribed in 
unstable CAD patients but in males only. A likely consequence of the higher statin 
use is that total cholesterol, LDL-cholesterol (LDL-C) and triglyceride levels were 
significantly lower in stable CAD compared to unstable CAD in men but interestingly 
not in women. WBC count was significantly higher in unstable CAD patients both 
in men and women while hsCRP was only higher in male unstable CAD patients.
Of note is that analysis of the characteristics by sex shows differences in 
total cholesterol, LDL-C and HDL-C, which are all significantly higher in women 
compared to men (Table S2). A small but significant neutrophil count difference was 
found between men and women, men have a slightly higher number of circulating 







Neutrophils (cells/µL) 4074(3145-5080) 4048(3082-5282) p<0.001
Eosinophils (cells/µL) 141(95-226) 141(90-221) N.S.
NLR 0.63(0.55-0.70) 0.60(0.53-0.67) N.S.
Values are median (interquartile range).
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neutrophils (Table 2). The eosinophil count did not differ between sexes. The 
neutrophil-to-lymphocyte ratio (NLR), a measure often used to determine the level 
of subclinical inflammation, was not different between sexes.
Increased neutrophil count in unstable CAD patients
In the current panel CD16 expression was used to identify neutrophils and 
eosinophils in the granulocyte subset of WBC. Mature neutrophils were readily 
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 Sex-specific differences in neutrophils count (A), eosinophils count (B) and the 
neutrophil-to-lymphocyte ratio (NLR) (C) between stable and unstable CAD patients. Correlation 
matrixes of the 10 cell subsets best able to stratify stable and unstable CAD patients determined by 
Random Forest modeling for the male (E) and female (E) cohort. The variables were clustered using 
hierarchical clustering. Blue indicates a positive correlation while red indicates a negative correlation, 
the intensity of the color indicates the size of the correlation. *** p<0.001, * p<0.05.
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(e.g. asthma) a small portion of eosinophils can express CD16 to a similar degree as 
neutrophils[20]. Granulocyte cells negative for CD16 expression are largely eosinophils 
while a small remaining population of granulocytes with CD16low expression can 
be a mix of immature neutrophils, apoptotic neutrophils and CD16 expressing 
eosinophils[21]. In both the male and female cohort, we observed a higher number 
of circulating neutrophils in unstable CAD patients; the number of circulating 
neutrophils was approximately 20-25% increased in unstable CAD patients (Figure 
2A). The neutrophil-to-lymphocyte ratio was slightly but significantly increased in 
male unstable CAD patients but this was not shown for female patients (Figure 2C).
The 12 antibodies flow cytometry panel can identify up to 452 potential 
cell subsets, this poses unique challenges for analyzing the flow cytometry dataset. 
Random Forest was used to model the data for stratifying stable and unstable CAD 
patients. The Random Forest model identified 10 cell subsets which were best at 
stratifying patients into unstable and stable CAD groups. A correlation matrix was 
used to identify similar and thus correlating cell subsets (Figure 2D and 2E). Cell 
subsets were clustered using hierarchical clustering and from each cluster one cell 
subset was selected for further analysis (with the shortest combination of markers 
and the highest rank in the model).
In the male cohort the two mature neutrophil cell subsets CD16highCD14high 
and CD16highACE+CD14- showed a significantly higher number in male unstable 
CAD patients (Table S3). In particular the CD16highCD14high cell subset shows a large 
increase, which double in size (1030 cells/mL (640-2272 IQR) in stable CAD vs 1941 
cells/mL (1156-3371 IQR) in unstable CAD, p<0.001). The CD16lowCD162lowCX3CR1+ 
is a small (<0.05% of granulocytes) subset of granulocytes which is also significantly 
increased in male unstable CAD patients (Table S3).
In the female cohort the CD16highCD68- neutrophil subset is significantly 
increased in unstable CAD patients, this cell subset overlaps for 97-100% with 
the total mature neutrophil subset (CD16high) and thus shows a similar increase 
in unstable CAD compared to stable CAD patients (Table S4). The CD16highACE-
CD14high cell subset is similar to the CD16highCD14high cell subset found in males, 
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in females this small neutrophil population triples in size in unstable CAD patients 
(939 cells/mL (382-2260 IQR) in stable CAD vs 3267 cells/mL (1075-6231IQR) in 
unstable CAD). Also a small eosinophil subset (CD16-CD14+CD162+) is significantly 





























































































































































































































































 Forest plots of odds ratio for MACE in the male (A) and female (B) cohort for neutrophils, 
eosinophils and major blood based biomarkers such as hsCRP, LDL-C and HDL-C. Median value 
with corresponding 95% confidence interval for each variable, dotted vertical line indicates no 
effect. Correlation matrixes of the 10 cell subsets best able to stratify control and MACE patients 
determined by Random Forest modeling for the male (C) and female (D) cohort. The variables were 
clustered using hierarchical clustering. Blue indicates a positive correlation while red indicates a 
negative correlation, the intensity of the color indicates the size of the correlation.
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CXCR4 positive neutrophils are highly predictive of MACE in females
For the prognostic analysis of neutrophil and eosinophil subsets, MACE was 
recorded for each patient during a nine-month follow-up time. A total of 56 MACE 
incidences were observed in the cohort, 39 for male patients and 17 for female 
patients. The only significant difference in baseline characteristics can be found 
in the female cohort where the HDL-C cholesterol level was significantly lower in 
female MACE patients compared to control patients (Table S5).
Logistic regression was used to evaluate whether mature neutrophils or 
eosinophils were predictive of cardiovascular events. The subjects were divided into 
three approximately equal sized groups (tertiles) based on the relevant cell subset 
count. Logistic regression was performed by comparing odds of MACE in patients 
with the lowest cell count (first tertile) to odds of MACE in patients with higher cell 
count (second and third tertile). The regression model was adjusted for age (Model 1) 
or age, hypertension, diabetes mellitus, current smoker, BMI and HDL-C (Model 2).
Although neutrophil count and the NLR ratio have previously been described 
to be predictive of cardiovascular events, both in males and females the ORs do not 
reach significance (Figure 3A and B, Tables S6 and S7). To expand the search for 
potential prognostic granulocyte cell subsets we used Random Forest to identify 
10 cell subsets that best stratify MACE and control patients in the male and female 
cohort (Figure 3C and D).
In the male cohort two mature neutrophil subsets are associated with an 
increased risk of MACE (first compared to third tertile). With increased count of 
CD16highCD115+CD89+ (OR=3.34, 1.37-9.18 95%CI, p=0.007) and CD16highCD14- 
(OR=4.31, 1.57-14.43 95%CI, p=0.004) the risk of MACE is increased, both cell 
subsets stay significant when adjusted for other cardiovascular risk factor (Model 2, 
Table S6). The CD16lowCCR2-CD14+ cell subset also showed a significant association 
(OR=0.07, 0.01-0.26 95%CI, p=8.4*10-6) but due to more than one-third of patients 
not expressing this cell subset, subjects could not be distributed equally over three 
tertiles and the calculated OR was unreliable.
In the female cohort two cell subsets showed a significant association with 
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MACE (first compared to third tertile). The neutrophil cell subsets CD16highCXCR4+ 
and CD16highCD162highCXCR4+ are both associated with an increased chance of 
MACE with respective ORs of 6.31 (1.73-33.95 95%CI, p=0.004) and 6.25 (1.62-
35.08 95%CI, p=0.007) when adjusted for age (Model 1), ORs stayed significant 
when adjusted for additional cardiovascular risk factors (Model 2, Table S7).
HDL-C is the only classic blood based biomarker with a significant association 
with MACE in women (Figure 3B) and a trend towards significance in males (Figure 




The contribution of neutrophils to atherosclerosis has most likely been 
underestimated since early reports observed only low numbers of neutrophils in 
the plaque and further research into neutrophils was until recently complicated 
due to the rapid turnover of neutrophils and the difficulty of detecting and tracing 
neutrophils in vivo. Recent advances have made it easier to detect neutrophils in 
tissue and study their behavior in circulation. This has led to reinterpretation of the 
role of neutrophils in the development of atherosclerosis[5].
We observed a significant difference in circulating neutrophil count 
between stable and unstable patients: unstable CAD patients have an approximately 
20% higher neutrophil count both in male and females. These findings are in line 
with previous reports that suggested that circulating neutrophil count positively 
correlates with an increased number of complex lesions and degree of stenosis[22,23]. 
A particular subset of mature neutrophils which highly expressed CD14 was greatly 
increased in both male and female unstable CAD patients. Although the CD14 
expression might suggest a monocyte subset, the size and granularity of the cells 
indicated a granulocytic cell subset. CD14 expression on neutrophils can be induced 
by exposure to growth and inflammatory factors such as GM-CSF, G-CSF, TNF-α 
or LPS and could furthermore influence adhesion through CD11b integrin[24,25]. 
CD14 expression on neutrophils might thus indicate a highly activated neutrophil 
cell subset with an increased ability to adhere to the endothelial layer covering the 
atherosclerotic plaque.
While total neutrophil count and the neutrophil-to-eosinophil ratio have 
both been described to be predictive biomarkers for cardiovascular events[17,26], in 
the current cohort we find no evidence for this assumption. In contrast, sex-specific 
neutrophil subsets in males and females do show a strong association with MACE. 
Both CD16highCD115+CD89+ and CD16highCD14- associate with an increased chance 
of MACE in male subjects. Since none of the classic biomarkers such as hsCRP, 
LDL-C or HDL-C showed a significant association with MACE in males these 
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neutrophil subsets could be used as novel biomarkers for cardiovascular events in 
male CAD patients.
In the female cohort the neutrophil subset CD16highCXCR4+ and 
CD16highCD162highCXCR4+ were identified as potential prospective biomarkers for 
cardiovascular events. Interestingly increased CXCR4 expression in advanced lesion 
has previously been reported during atherosclerosis development and blockade 
of the CXCR4/CXCL12 axis has shown to increase atherosclerosis development 
in mice[11,27]. The CXCR4/CXCL12 axis has an essential role in neutrophil 
homeostasis[28,29]. Retention of neutrophils in bone marrow is orchestrated by 
CXCR4, mature neutrophils loose CXCR4 expression and leave the bone marrow 
while aged neutrophils can increase CXCR4 expression and subsequently return 
to the bone marrow[29–31]. Blockade of CXCR4 induces a large mobilization of 
neutrophils from the bone marrow resulting in a significant increase in circulating 
neutrophil numbers and blockade of CXCR4 signaling in atherosclerosis prone mice 
boosts atherosclerotic plaque development[11,27]. Alterations in CXCR4 expression 
can influence plaque development in mice as was shown by Bot et al. where a 
decrease in CXCR4 expression was induced in neutrophils without significantly 
increasing circulating neutrophils count but which did associated with an increased 
plaque development[27].
Bot et al. found that in patients suffering from acute coronary syndrome the 
CXCR4 expression on neutrophils is lower as compared to healthy individuals[27], 
while in the current study we find that higher numbers of CXCR4+ neutrophils 
associates with increased risk of MACE. This seemingly contradictory result is 
possibly due to a different setup of the study population, while Bot et al looked 
at cross-sectional cohort of healthy vs unstable CAD patients we looked in a 
prognostic cohort of patients with preexisting CAD. Research has shown that in 
humans neutrophils are mainly present in the end stage of atherosclerotic plaque 
development and primarily in vulnerable plaques with evidence of intra-plaque 
hemorrhage[14–16]. It is then interesting to speculate that neutrophils enter the 
plaque where they gradually increase CXCR4 expression which in turn induces a 
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chemotactic response reentering the blood stream and homing back to the bone 
marrow, which leads to an increase in circulating CXCR4+ neutrophils in patients 
with destabilized lesions. The fact that CXCR4+ neutrophils associate with MACE 
might indicate a role for these neutrophils in the destabilization of the atherosclerotic 
plaque, further research is needed to elucidate the mechanism by which neutrophils 
interact with a destabilizing plaque in late stage atherosclerosis.
It must be noted that due to the short follow-up time of 9 months the 
number of major adverse cardiovascular events in the female cohort and to a lesser 
extent also in the male cohort was limited. These findings thus need to be validated 
in a cardiovascular disease cohort study to specifically find sex-specific neutrophil 
subsets predictive for cardiovascular events.
In conclusion, in the current study we have identified multiple sex-specific 
neutrophil biomarkers for predicting major adverse cardiovascular events in patients 
with prevalent CAD. Classic blood based biomarkers such as hsCRP, LDL-C and 
HDL-C perform poorly as predictors of MACE in the Circulating Cells cohort, 
possibly due to the already present CAD in patients. The identified neutrophil 
subsets perform significantly better then these classic biomarkers and as such hold 
great potential for stratifying risk in patients with already prevalent CAD.
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For analyses of circulating neutrophil and eosinophil subsets, stainings were 
performed in nine combinations (Table S1) of five antibodies selected from the 
antibodies listed below. 
CD14-PC7 (A22331; Beckman Coulter, Fort Lauderdale, USA), CD16-
PC5 (A07767; Beckman Coulter, Fort Lauderdale, USA), CCR2-PE (FAB151P; 
R and D Systems, Minneapolis, Minn., USA), CX3CR1-FITC (D070-4; MBL 
International, Nagoya, Japan), CXCR4-FITC (D123-4; MBL International, Nagoya, 
Japan), CD143(ACE)-FITC (MCA2057F; AbD Serotec, Oxford, UK), CD162-
ECD (IM99512B; Beckman Coulter, Fort Lauderdale, USA), CD68-PE (12-0689-
73; eBioscience , San Diego, USA), CD89-PE (IM1614; Beckman Coulter, Fort 
Lauderdale, USA), IL15-FITC (IC2471F; R and D Systems, Minneapolis, Minn., 
USA), Tie2-PE (FAB3131P; R and D Systems, Minneapolis, Minn., USA) and 
CD115-FITC (FAB329F; R and D Systems, Minneapolis, Minn., USA). 
Random forest modeling 
Random forest is an ensemble learning method that generates models 
of the provided data and then uses all models combined to get better predictive 
performance. Random forest generates many decision trees based on bootstrap 
samples from the original data and for each split in a decision tree a number of 
variables are randomly selected and tested for classification performance. From these 
variables the best performing variable is selected for the split. This randomization in 
sampling and variable selection makes the model very robust and unbiased; it has 
been shown to give good results in analyzing multivariate flow cytometry data[1,2].
As only part of the data is used to generate each individual decision tree, 
the remainder of the data can be used to test the performance of the decision tree 
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and determine the importance of each variable. The importance of variables in the 
random forest is estimated by permuting one predictor variable while all else is kept 
unchanged and looking at how much prediction accuracy decreases. This is done 
per constructed decision tree and gives a mean decrease of accuracy per variable.
Because the dataset contains many hundreds of variables (all possible 
marker combinations) we first reduced the number of variables. Using random 
forest to estimate the importance of each variable and discarding variables with an 
importance of less than zero, we then generate a new random forest again discarding 
the variables with a negative importance score. This procedure is repeated until for 
a set amount of repetitions no variables with negative importance values are found. 
This technique is based on a similar technique implemented in random jungle[3].
The random forest can determine similarity between patients by looking at 
how many times two subjects fall into the same terminal node over all the decision 
trees, as it is assumed that two subjects that are similar to each other will frequently 
end up in the same terminal node. This attribute of random forest was used to impute 
missing predictor data in the database, as similar subjects were used to estimate 
the missing data.
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Table S1: Flow cytometry staining panel
FITC PE ECD PE-Cy5 PE-Cy7
IL-15 CD68 N.A. CD16 CD14
CX3CR1 CCR2 CD162 CD16 CD14
ACE N.A. CD162 CD16 CD14
CD115 CD89 N.A. CD16 CD14
CXCR4 Tie2 CD162 CD16 CD14












Age 62(56-69) 63(57-71) N.S.
BMI 27(25-30) 27(24-30) N.S.
Systolic blood pressure (mm Hg) 135(123-145) 137(123-151) N.S.
Diastolic blood pressure (mm Hg) 80(70-85) 77(70-85) N.S.
Glucose (mmol/L) 6.02(5.47-7.05) 6.15(5.40-7.10) N.S.
Hemoglobin (mmol/L) 8.90(8.50-9.40) 8.30(7.78-8.60) p<0.001
Cholesterol (mmol/L) 4.03(3.41-4.80) 4.54(3.80-5.26) p<0.001
LDL-C (mmol/L) 2.33(1.80-2.97) 2.60(1.95-3.21) p<0.05
HDL-C (mmol/L) 1.00(0.86-1.18) 1.14(1.00-1.43) p<0.001
Triglycerides (mmol/L) 1.30(0.98-1.90) 1.40(1.02-1.80) N.S.
hsCRP (ng/mL) 2583(1685-6728) 3975(1978-7219) N.S.
WBC (X1000 cells/µL) 7.00(5.90-8.40) 7.25(5.78-8.93) N.S.
Current smoker 21%(75) 25%(33) N.S.
Diabetes 22%(76) 25%(33) N.S.
Hypertension 62%(216) 69%(92) N.S.
Beta-blocker 73%(257) 77%(103) N.S.
Ca-antagonist 30%(105) 32%(43) N.S.
Aspirin 80%(282) 86%(114) N.S.
Vitamin K antagonist 13%(44) 11%(14) N.S.
ADP receptor blocker 48%(170) 53%(71) N.S.
ACE inhibitor 35%(123) 29%(39) N.S.
ATII receptor blocker 15%(53) 29%(38) p<0.001
Diuretic 19%(66) 24%(32) N.S.
Statin 81%(286) 74%(98) N.S.
Baseline characteristics comparison of male and female patients.
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CD16high (Mature neutrophils) (Cells/µL) 3793(3118-4875) 4835(4142-6369) p<0.001
CD16highCD14high (Cells/mL) 1030(640-2272) 1941(1156-3371) p<0.001
CD16highACE+CD14- (Cells/µL) 9(4-26) 14(7-33) p<0.05
CD16 low Granulocytes
CD16low (Cells/µL) 8(5-15) 9(6-15) N.S.
CD16lowCD162lowCX3CR1+ (Cells/mL) 378(118-1047) 622(330-1286) p<0.05
Eosinophils
CD16- (Total eosinophils) (Cells/µL) 142(98-228) 140(71-204) N.S.
Ratio
NLR 0.62(0.54-0.69) 0.65(0.55-0.74) p<0.05
Difference in total neutrophil and eosinophil cell populations and in Random Forest selected 
neutrophil eosinophil cell populations between male patients with stable coronary artery disease and 
unstable coronary artery disease, values are median (interquartile range).
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CD16high (Mature neutrophils) (Cells/µL) 3939(3019-4893) 4662(3968-6405) p<0.01
CD16highCD68- (Cells/µL) 3831(2926-4810) 4607(3918-6255) p<0.01
CD16highACE-CD14high (Cells/mL) 939(382-2260) 3267(1075-6231) p<0.01
CD16 low Granulocytes
CD16low (Cells/µL) 7(5-17) 9(5-17) N.S.
CD16lowCD162highCXCR4- (Cells/mL) 2368(1133-4832) 1967(1427-2551) N.S.
CD16lowCD115-CD14high (Cells/µL) 5(3-12) 12(4-20) N.S.
Eosinophils
CD16- (Total eosinophils) (Cells/µL) 141(88-211) 165(102-279) N.S.
CD16-CD14+CD162+ (Cells/mL) 556(379-1177) 988(564-1747) p<0.05
Ratio
NLR 0.60(0.53-0.66) 0.61(0.46-0.67) N.S.
Difference in total neutrophil and eosinophil cell populations and in Random Forest selected 
neutrophil eosinophil cell populations between female patients with stable coronary artery disease 
and unstable coronary artery disease, values are median (interquartile range).
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Age 62(56-68) 64(55-72) 63(58-71) 62(56-67)
BMI 27(24-29) 27(26-31) 27(24-30) 27(23-29)
SBP (mm Hg) 135(124-145) 132(123-140) 135(120-150) 137(127-153)
DBP (mm Hg) 80(70-85) 80(70-90) 76(67-82) 75(69-84)
Glucose (mmol/L) 6.01(5.48-6.80) 5.81(5.30-6.52) 6.10(5.40-6.92) 5.60(5.40-8.60)
Hemoglobin (mmol/L) 8.90(8.53-9.40) 8.90(8.40-9.30) 8.30(7.80-8.70) 8.25(7.85-8.53)
Cholesterol (mmol/L) 4.00(3.40-4.79) 4.16(3.63-4.94) 4.62(3.85-5.30) 4.20(3.70-4.90)
LDL-C (mmol/L) 2.30(1.75-2.89) 2.50(1.97-3.04) 2.62(1.96-3.24) 2.70(1.99-2.90)
HDL-C (mmol/L) 1.03(0.88-1.19) 0.96(0.85-1.04) 1.20(1.01-1.47) 1.02(0.77-1.25)*
Triglycerides (mmol/L) 1.30(0.97-1.90) 1.30(1.04-1.75) 1.39(1.00-1.80) 1.42(0.90-1.80)
hsCRP (ng/mL) 2470(1664-6665) 3723(1769-8053) 4001(2047-7293) 4678(2020-7224)
WBC (X1000 cells/µL) 7.00(5.80-8.20) 7.10(6.15-8.10) 7.25(5.63-9.18) 7.40(6.00-8.40)
Current smoker 34%(95) 46%(18) 25%(30) 24%(4)
Diabetes 15%(41) 23%(9) 23%(27) 35%(6)
Hypertension 10%(29) 21%(8) 67%(80) 76%(13)
Unstable CAD 17%(46) 31%(12) 23%(27) 12%(2)
Beta-blocker 47%(132) 46%(18) 73%(87) 88%(15)
Ca-antagonist 72%(201) 82%(32) 28%(33) 53%(9)
Aspirin 82%(229) 72%(28) 82%(97) 94%(16)
Vitamin K antagonist 29%(82) 36%(14) 11%(13) 12%(2)
ADP receptor blocker 62%(171) 77%(30) 48%(57) 59%(10)
ACE inhibitor 22%(60) 13%(5) 28%(33) 35%(6)
ATII receptor blocker 20%(55) 18%(7) 26%(31) 35%(6)
Diuretic 82%(228) 72%(28) 26%(31) 12%(2)
Statin 17%(47) 28%(11) 69%(82) 88%(15)
Baseline characteristics of male and female patients that experienced a major adverse cardiovascular 
event (MACE) compared to control patients that did not experience MACE, values are median 
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Background- Cytokines and chemokines function in signaling, activation 
and homing of inflammatory cells and are central mediators of the immune 
response in the atherosclerotic plaque. With sex differences shown in coronary 
artery disease (CAD) development, we examined whether the expression profile of 
plasma cytokines are different between male and female CAD patients as well as if 
cytokines expression correlated with disease manifestation and progression.
Methods and results- In unstable CAD patients an increase is seen in 
inflammatory IL-6 compared to stable CAD patients. IL-4, IL-5, IL-12, IL-13, IL-
15, IL-33, CCL2, CCL19, CCL20, CXCL4 and CXCL8 are in contrast significantly 
down-regulated in male unstable CAD patients, in female unstable CAD patients 
IL-4, CXCL8 and CXCL10 are significantly down-regulated. While some cytokines 
were predictive of major adverse cardiac events (MACE) in males or females, 
cytokine ratios were found to be stronger predictors of MACE. In females cytokine 
ratios were strongly predictive of MACE, in particular the cytokine ratio CXCL10/
CXCL1 showed a significant odds ratio (OR) in females (OR=0.10, 0.01-0.43 95%CI, 
p=0.001), also in males CXCL10/CXCL1 was predictive for MACE but interestingly 
with an inverse risk association (OR=2.54, 1.05-6.66 95%CI, p=0.038).
Conclusion- Unstable CAD patients surprisingly show a reduced cytokine 
profile compared to stable CAD patients, only IL-6 is up-regulated in unstable CAD 
patients. We find that the cytokine CCL5 is associated with MACE in males. In 
females an increased CXCL10/CXCL1 ratio is strongly associated with a decrease in 
cardiovascular events while in males it is associated with an increased risk of MACE.
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Introduction 
Coronary artery disease (CAD) is the number one cause of death worldwide 
and cerebrovascular disease is the number three cause of death, combined these two 
categories form the largest segment of cardiovascular related diseases[1]. Although 
the number of CAD deaths in the western world has decreased due to improved 
drug treatment, care and risk assessment, the number of CAD deaths in rapidly 
modernizing societies such as eastern Europe and central Asia remains high and a 
trend is observed towards a lower age in cardiovascular related deaths[2]. Projections 
show that world-wide cardiovascular disease will continue to be the number one 
cause of death in 2030[3], which indicates the urgent need for an improved risk 
stratification and treatment of CAD patients.
Atherosclerosis is the main cause of cardiovascular disease and current 
therapeutic strategies have mainly focused on management of dyslipidemia, although 
recent clinical studies have focused on the stabilization of the atherosclerotic plaque 
and ultimately on plaque regression[4]. It has been shown that inflammation plays a 
major role in the development and destabilization of the atherosclerotic plaque[5–7] 
and there is consequently a major interest in circulating markers of inflammation 
that can give an indication of atherosclerotic development[8]. Inflammation markers 
such as C reactive protein (CRP) and fibrinogen are now commonly used to aid 
in risk stratification of patients. Since these biomarkers are downstream of various 
inflammatory proteins such as cytokines, they are unlikely to be causally related to 
the development of atherosclerosis[9,10].
A number of studies have focused on upstream inflammatory cytokines 
such as IL-6 and CXCL8 but most of the studies only focused at a single cytokine 
or a small set of cytokines[11–18]. While IL-6 has shown to be predictive of coronary 
events and a mendelian randomization study has shown that IL-6 has a probable 
causal role in the development of coronary artery disease, as a biomarker the added 
benefit of IL-6 over CRP is limited as IL-6 is the main culprit for induction of CRP 
expression in the liver[19]. Similarly other cytokines have also shown only limited 
benefit when used in conjunction with commonly used biomarkers for CAD. 
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Recently it has been suggested that a number of cytokines in combination might 
benefit risk stratification for CAD patients[20].
In the current study we examined whether cytokines, alone or combined, can 
help with the diagnosis and risk stratification for future coronary events in patients 
with prevalent coronary artery disease. We determined the expression profiles for 
26 cytokines and chemokines in plasma of CAD patients scheduled for elective 
angiography. The aim of the project was to investigate whether cytokine expression 
profiles differed between the sexes in CAD patients and how these correlated with 
manifestation and progression of CAD.
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Methods
Study population
The study cohort consists of a total of 432 patients between the age of 37 and 
83, these patients form a subgroup of the Center for Translational Molecular Medicine 
(CTMM) – Circulating Cells study cohort[21]. Only for a selection of Circulating Cells 
cohort for which a full clinical parameter list was available the cytokine multiplex 
beads assay was performed, therefore the study cohort is smaller than the Circulating 
Cells study cohort. In brief, Circulating Cells is a multi-center study in which CAD 
patients scheduled for coronary angiography were included. Exclusion criteria were 
age < 18 years, inability to give informed consent, suspected drug or alcohol abuse, 
serious concomitant disease and serious recent infectious disease in the last 6 weeks 
or suspected elevated state of the immune system, and non-cooperativeness. The 
Circulating Cells protocol was approved by the review board or ethics committee of 
each participating center[21]. Nine months after inclusion in the study patients were 
contacted and any major adverse cardiovascular events (MACE) that occurred in the 
preceding months were recorded. MACE is the primary endpoint of this study and is 
defined as cardiovascular disease related death, myocardial infarction, percutaneous 
coronary intervention, coronary artery bypass grafting and cardiovascular accident. 
The cohort consists of 345 stable angina, 50 unstable angina and 37 non-STEMI 
diagnosed patients. The non-significant atherosclerosis patients were removed 
for unstable vs stable CAD analysis. For 32 patients there was no follow-up data 
available, these patients were excluded from primary endpoint MACE analysis.
Measurement of blood based cytokines
Blood was collected from patients in an EDTA BD vacutainer EDTA blood 
collection tube and blood samples were centrifuged at 156xg for 15 minutes. The 
upper layer (plasma and platelets) was transferred to a new tube and was centrifuged 
at 1000xg for 20 minutes. The upper plasma layer was collected and stored at -800C.
Plasma levels of cytokines were determined for IL-1β, IL-4, IL-5, IL-6, IL-10, 
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IL-12, IL-13, IL-15, IL-18, IL-33, IL-1RA, CCL2 (MCP1),CCL5 (RANTES), CCL17 
(TARC), CCL19 (MIP3B), CCL20 (MIP3A), CXCL1 (GRO1), CXCL4 (PF4), 
CXCL8 (IL8), CXCL10 (IP10), CXCL12 (SDF1), CX3CL1 (fractalkine), MCSF, 
INFγ, TNF-alpha and MIF. Cytokines levels were measured using a multiplex bead 
array system (Luminex; Millipore, Billerica, USA), assays were preformed according 
to manufacturer’s protocol.
Some cytokines were undetectable in a large portion of the cohort, IL-1β and 
INFγ were undetectable in more than two-thirds of the cohort and were therefore 
not included in the analysis.
Statistics
Statistical calculations were performed using R for windows (version 3.0.2). 
A P<0.05 was considered significant. Categorical data was compared using the chi-
square test. For continuous data the nonparametric Mann-Whitney U test was used. 
When comparing cytokine concentrations from the cytokine beads-array for stable 
and unstable CAD patients, false discovery rate adjustment was used to compensate 
for multiple significance testing.
While the cytokine samples were all measured at once and samples were 
randomized, the data showed a strong batch effect between samples gathered from 
different medical institutions. Z-score normalization was used to normalize data 
from each institution to the overall average for each cytokine.
For logistic regression analysis the patients were divided into 3 equal sized 
groups (tertiles) according to the measured values for each variable. Firth’s penalized 
likelihood logistic regression was used to analyze stratified data. Firth’s method was 
used because of its ability handle small sample sizes. The odds ratios were adjusted 
for age (Model 1) and age, hypertension, diabetes mellitus, current smoker, BMI and 
HDL-cholesterol (HDL-C) level (Model 2).
To identify variables that can classify patients into separate groups (e.g. 
MACE vs. control patients) we used a machine learning method called Random 
Forest[22]. Taking advantage of combinations of predictor variables this algorithm 
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classified subjects into different groups. Random forest is an ensemble learning 
method that generates models of the provided data and then uses all models 
combined to get better predictive performance. Random forest generates many 
decision trees based on bootstrap samples from the original data and for each 
split in a decision tree a number of variables are randomly selected and tested for 
classification performance. From these variables the best performing variable is 
selected for the split. This randomization in sampling and variable selection makes 
the model very robust and unbiased.
As only part of the data is used to generate each individual decision tree, 
the remainder of the data can be used to test the performance of the decision tree 
and determine the importance of each variable. The importance of variables in the 
random forest is estimated by permuting one predictor variable while all else is kept 
unchanged and looking at how much prediction accuracy decreases. This is done 
per constructed decision tree and gives a mean decrease of accuracy per variable.
We first start by reducing the number of variables to a subset of variables that 
is best for classification of the groups. Using random forest to estimate the importance 
of each variable and discarding variables with an importance of less than zero, we 
then generated a new random forest again discarding the variables with a negative 
importance score. This procedure is repeated until for a set amount of repetitions 
no variables with negative importance values are found. This technique is based on 
a similar technique implemented in random jungle[23].
The random forest can determine similarity between patients by looking at 
how many times two subjects fall into the same terminal node over all the decision 
trees, as it is assumed that two subjects that are similar to each other will frequently 
end up in the same terminal node. This attribute of random forest was used to impute 





Baseline characteristics of study cohort
The cohort consists of 345 patient with stable angina pectoris, 50 with 
unstable angina and 37 with non-ST elevated myocardial infarct (non-STEMI). Both 
unstable angina and non-STEMI are acute coronary syndromes and as the number 










Age 62(56-69) 62(56-70) 64(58-72) 63(56-71)
BMI 27(25-29) 27(26-30) 28(24-32) 25(23-28)*
SBP (mm Hg) 133(123-145) 130(115-145) 140(125-157) 133(120-147)
DBP (mm Hg) 80(72-85) 79(70-87) 77(70-85) 80(70-81)
Glucose (mmol/L) 6.00(5.49-6.70) 6.30(5.51-7.40) 6.09(5.49-6.97) 6.90(5.45-7.82)
Hemoglobin (mmol/L) 8.90(8.50-9.33) 8.90(8.60-9.50) 8.20(7.80-8.60) 8.30(7.60-8.60)
Cholesterol (mmol/L) 3.80(3.30-4.63) 4.36(3.85-5.05)‡ 4.24(3.80-5.26) 4.78(3.85-5.39)
LDL-C (mmol/L) 2.20(1.73-2.83) 2.67(2.12-3.43)‡ 2.46(1.95-3.09) 2.72(1.99-3.50)
HDL-C (mmol/L) 0.99(0.87-1.19) 0.95(0.80-1.13) 1.16(1.00-1.45) 1.05(0.95-1.31)
Triglycerides (mmol/L) 1.25(0.94-1.76) 1.59(1.24-2.18)‡ 1.34(0.96-1.80) 1.53(1.23-2.11)
hsCRP (ng/mL) 2410(1632-5805) 4977(1849-15916)† 4332(1765-7454) 4101(2165-7495)
WBC (X1000 cells/µL) 6.75(5.78-7.90) 8.10(6.85-9.55)‡ 7.05(5.53-8.28) 8.90(7.53-9.70)‡
Current smoker 20%(48) 20%(12) 15%(15) 54%(15)‡
Diabetes 19%(47) 17%(10) 24%(24) 29%(8)
Hypertension 64%(156) 59%(35) 75%(75) 61%(17)
Beta-blocker 79%(194) 61%(36)† 83%(83) 54%(15)†
Ca-antagonist 33%(81) 19%(11)* 34%(34) 21%(6)
Aspirin 84%(205) 69%(41)* 91%(91) 68%(19)*
Vitamin K antagonist 10%(24) 19%(11) 9%(9) 21%(6)
ADP receptor blocker 53%(131) 37%(22)* 57%(57) 46%(13)
ACE inhibitor 38%(94) 31%(18) 27%(27) 32%(9)
ATII receptor blocker 16%(39) 10%(6) 34%(34) 14%(4)
Diuretic 20%(50) 15%(9) 28%(28) 18%(5)
Statin 84%(206) 68%(40)† 79%(79) 50%(14)†
Baseline characteristics table for the Circulating Cells cohort, values are median(interquartile range) 
or percentage(n). * p < 0.05, † p < 0.01, ‡ p < 0.001.
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of unstable angina and non-STEMI patients was low, we combined these two groups 
to form the unstable CAD group while the stable angina group is referred to as 
stable CAD patients. Baseline characteristics of unstable and stable CAD patients 
segregated on patient sex are summarized in Table 1. The use of beta-blockers, aspirin 
and statins is significantly higher in stable CAD patients in both sexes. Use Ca-
antagonists and ADP receptor blockers are lower in unstable CAD patients but only 
in males, conversely the use of Vitamin K antagonists is significantly higher in the 
male unstable CAD group. Cholesterol, LDL-cholesterol (LDL-C) and triglyceride 
levels are significantly lower in male stable CAD patients compared to unstable CAD 
patients, possibly due to the higher prescription of statins in stable CAD patients. 
Only in males hsCRP is significantly increased in unstable CAD patients while 
both males and females show increased circulating white blood cell (WBC) count 
indicating an increased inflammatory status in unstable CAD patients compared 
to stable CAD patients[8]. In females smoking is significantly higher and BMI is 
significantly lower in the unstable CAD group compared to the stable CAD group.
A comparison of the male and female baseline characteristics showed a 
significant difference in total cholesterol, LDL-C and HDL-C levels between males 
and females; in females these levels were approximately 10-18% higher (Table S1). 
The concentration of hsCRP was 60% higher in females (4332 ng/mL, 2072-7648 
inter quartile range (IQR)) compared to males (2720 ng/mL, 1664-7327 IQR).
Decreased cytokine expression in unstable CAD patients
IL-6 expression was significantly higher in unstable male CAD patients, 
correlating with the increase in hsCRP. Due to large variance in female IL-6 levels, the 
IL-6 increase in unstable female patients was not significant (Figure 1). Unexpectedly, 
except for IL-6, the levels of the cytokines and chemokines that were differentially 
expressed in stable and unstable CAD patients were all significantly lower in unstable 
CAD patients (Figure 1 and 2, Table S2 and S3). The cytokines IL-4, IL-5, IL-12, 
IL-13, IL-15 and IL-33 all have a significantly lower plasma concentration in male 
unstable CAD patients compared to stable CAD patients, in females only IL-4 is 
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significantly lower in unstable CAD patients. In line with other cytokines, levels for 
the chemokines CCL2, CCL19, CCL20, CXCL4 and CXCL8 were significantly lower 
in male unstable CAD patients compared to stable CAD patients, while the levels 
for CCL2 and CXCL8 were significantly lower in female unstable CAD patients. 
The only chemokine/cytokine that was differentially expressed in females but not 
in males was CXCL10 which demonstrated a 25% decrease in unstable female CAD 
patients; 218.5 pg/mL (142.2-375.1 IQR) in stable CAD compared to 158.7 pg/mL 
(117.3-233.3 IQR) in unstable CAD.
To examine whether unstable and stable CAD patients clustered based on 
their cytokine profile, hierarchical clustering was performed on the differentially 





























































































Stable versus unstable CAD comparison of cytokines differentially expressed in the male 
or female cohort.* p<0.05, ** p<0.01, *** p<0.001.
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patients is found in the cluster of patients that have a substantially lowered expression 
for most cytokines, female unstable CAD patients do not cluster together (Figure 
S1). The heatmap also shows that the IL-6 expression profile differs substantially 
from other cytokine expression profiles.
CXCL10 to CXCL1 ratio is a strong predictor of MACE in female CAD patients
For the primary endpoint analysis follow up data was recorded nine months 
after inclusion. A major adverse cardiovascular event (MACE) was defined as the 
primary endpoint for the prognostic analysis which encompassed cardiovascular 
disease related death, myocardial infarction, percutaneous coronary intervention, 
coronary artery bypass grafting or cardiovascular accident. First a model was created 
to stratify patients into MACE or control patients. Random Forest was used to create 
the model for stratification of patients. The cytokines are ranked for their ability to 
stratify MACE and control patients, both for the female and the male cohort the 
top three cytokines were selected for further analysis and for each of these cytokine 






































































































Stable CAD Unstable CAD
A. B. C.
D. E. F.
 Stable versus unstable CAD comparison of chemokines differentially expressed in the 
male or female cohort. * p<0.05, ** p<0.01, *** p<0.001.
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Simple logistic regression was performed on the cytokine data to determine 
odds ratios (OR), which were adjusted for age (Model 1) or age, hypertension, 
diabetes mellitus, current smoker, BMI and HDL-C (Model 2). For the male cohort 
CCL5, CCL19 and IL-12 were selected by the Random Forest model as potential 
biomarkers while for the female cohort MCSF, MIF and IL-4 were selected. Logistic 
regression showed that CCL5 was the only cytokine to have a significant odds ratio in 
the male cohort with an OR of 3.02 (1.31-7.50 95%CI, p=0.009, Model 1) and stayed 
significant when adjusted for cardiovascular risk factors (Model 2,Table S4). In the 
female cohort MCSF showed a significant OR, 4.44 (1.34-18.68 95%CI, p=0.014, 
Model 1) and this OR also stayed significant when adjusted for cardiovascular risk 
factors(Model 2, Table S5). For both these cytokines an increase in concentration 
was associated with an increased risk of MACE (Figure 3).
Since cytokines are part of a network with extensive cross-talk, we 
reasoned that it might be informative to focus at ratios of cytokines in addition to 
cytokine concentration to show for example a switch in cellular pathways. Ratios 
were calculated for every cytokine combination and a Random Forest model was 
generated. The Random Forest model indicated that the ratios IL-10/IL-18, CXCL10/
























 Forest plots of ORs for cytokines and chemokines in the male (A) and female (B) cohort. 
Shown cytokines were selected by the Random Forest model for stratifying MACE and control 
patients. The shown OR (95% Confidence Interval (CI)) was calculated for low (first tertile) compared 
to high (third tertile) cytokine concentration. * p<0.05
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cohort and in the female cohort the ratios IL-4/CCL2, CCL2/MCSF and CXCL10/
MCSF were best able to stratify patients.
In the male cohort IL-10/IL-18 (OR=3.08,1.24-8.54 95%CI, p=0.014) and 
CXCL10/CXCL1 (OR=2.54,1.05-6.66 95%CI, p=0.038) had a significant OR in the 
age adjusted model (Model 1, Figure 4A), both stayed significant when adjusted 
for additional cardiovascular risk factor (Model 2,Table S6). In the female cohort 
CXCL10/MCSF and CXCL10/CXCL1 were associated with a decreased chance 
of developing MACE with an OR of 0.12 (0.01-0.59 95%CI, p=0.007) and 0.10 
(0.01-0.43 95%CI , p=0.001) respectively (Figure 4B), both stayed significant when 
adjusted for additional cardiovascular risk factors (Model 2, Table S7).
Note that the ratio CXCL10/CXCL1 is significant in both the female and 
male cohort but in male an increased ratio is associated with increased chance of 
MACE while in the female this is associated with a decreased chance of MACE 
(Figure 4). When we compare the ratio CXCL10/CXCL1 in male MACE patients to 
female MACE patients we observe that the ratio is approximately twice as high in 



























 Forest plots of ORs for calculated ratios of cytokines in the male (A) and female (B) cohort. 
Shown cytokines ratios were selected by Random Forest model for stratifying MACE and control 
patients. The shown OR (95%CI) was calculated for low (first tertile) compared to high (third tertile) 




The present study shows that in the current cohort of patients with prevalent 
CAD a subset of Th1 related (e.g. IL-12) as well as Th2 related cytokines (e.g. IL-4, 
IL-5) are significantly down regulated in patients with unstable CAD compared 
to stable CAD patients. Meanwhile, we also see that a subset of chemokines is 
significantly down regulated in unstable CAD patients. In contrast, a number of 
studies have shown an increase in the levels of pro-inflammatory cytokines, a 
decrease in anti-inflammatory cytokines and an increase in most chemokines in 
patients with acute coronary syndrome compared to stable angina patients[24–31].
Interestingly, most of these studies that show a significant up regulation 
of pro-inflammatory cytokines have been conducted over 10 years ago. Recent 
research, however, demonstrates that at least in the Dutch cohort of Athero-Express 
a significant change is observed in the composition of atherosclerotic plaques 
during the last decade, from an inflamed rupture prone plaque to a more stabilized 
less inflamed plaque[32]. Surprisingly the increased stability of the lesion, based on 
histological classification, is not associated with a decrease in cardiovascular events. 
The cause of this change is unclear but it is likely that changes in drug prescription and/
or lifestyle of patients might be involved, especially the use of statins has increased 
over the last decade and smoking has drastically decreased in western societies[33,34]. 
Another intriguing possibility is that the lowered cytokine levels are the results of 
T cell exhaustion, first identified in cancer it has now also been shown to correlate 
with clinical outcome in chronic viral infection and auto-immune disease[35,36]. 
When T cell exhaustion occurs in chronic viral infection multiple inhibitory factors 
are upregulated in T cells resulting in general immunosuppression[37]. In patients 
with autoimmune disease (e.g. systemic lupus, inflammatory bowel disease) a T cell 
exhaustion signature correlated with favorable outcome in auto-immune disease[36]. 
In CAD a similar mechanism might results in a decrease of cytokine levels in 
chronic CAD patients.
Some cytokines show a sex-specific association with MACE, such as MCSF 
in females and CCL5 in males. The increase in MCSF in females showed a strong 
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association with an increased incidence of MACE, MCSF has been shown to be 
one of the most strongly predictive cytokines for cardiovascular events[38,39]. The 
association of MCSF with MACE is only present in the female cohort and is not 
significant in males. In contrast CCL5 is only predictive for MACE in the male 
cohort and not for females. A previous study did not find an association between 
CCL5 levels and risk of cardiovascular events[40], but this study did not segregated 
on sex of the patient and this might have diluted the association.
It has been shown that cytokine concentration levels are highly variable over 
time potentially reducing their applicability as biomarker[17,41], to compensate for 
this variability we calculated cytokine ratios. In the male cohort IL-10/IL-18 was the 
strongest predictor of MACE, an increased IL-10/IL-18 ratio was associated with an 
increased incidence of MACE. This result is counter intuitive when considering the 
mechanistic implications for destabilization of the atherosclerotic plaque. A shift 
towards a more anti-inflammatory status (IL-10) and decreased pro-inflammatory 
status (IL-18) results in a higher incidence of MACE. Destabilization of the plaque 
is normally associated with an increased inflammation of the plaque and we would 
expect shift towards pro-inflammatory factors in MACE patients[7].
CXCL10/CXCL1 is the strongest predictor of MACE in the female cohort, 
a higher ratio is associated with a large reduction in the risk of MACE. In the male 
cohort CXCL10/CXCL1 is also predictive for MACE but is surprisingly associated 
with an increased risk of MACE. CXC chemokines are grouped in two separate sets 
by the presence of the glutamate, leucine and arginine (ELR) motif in the protein 
sequence. ELR positive chemokines are known to attract neutrophils and promote 
angiogenesis while ELR negative chemokine attract lymphocytes and are known to 
be anti-angiogenic[42,43]. CXCL1 is ELR positive while CXCL10 is ELR negative, these 
chemokines have opposing functions in the angiogenesis pathway and we propose 
that a shift in this ratio would correlate with a shift in angiogenesis. Increased 
angiogenesis could lead to structural weakening of the plaque as well as increased 
inflammatory cell recruitment.
Intriguingly, the ratio CXCL10/CXCL1 has an inverse odds ratio in 
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females compared to males. Sex-specific difference have been observed before in 
cardiovascular disease development, it is for instance well-known that women tend 
to present cardiovascular disease related complications later in life compared to 
men[44]. Also sex related differences in plaque development and composition have 
been shown, the eroded plaque phenotype is more often seen in women with an 
acute myocardial infarct and in sudden death and plaques in men have a higher 
degree of plaque hemorrhage than in women[45–47]. Progesterone has been shown 
to regulate both endothelial CXCL1 and CXCL10 in vitro, this might explain the 
difference in pre-menopausal women but as most women in the Circulating Cells 
cohort are likely to be post-menopausal (age >55) it is unknown how this translates 
to older women[48]. The CXCL10/CXCL1 ratio is a novel biomarker for CAD and 
further research is needed to confirm these findings of sex-specific risk association 
with cardiovascular events in men and women.
In conclusion, here we find that unstable CAD is surprisingly associated with 
significantly lowered concentrations of Th1 and Th2 related cytokine concentrations. 
The exception is IL-6 which is increased in unstable CAD in conjunction with 
hsCRP. We show that cytokines by themselves are mediocre prognostic biomarkers 
when adjusted for known cardiovascular risk factors. In contrast we find that the 
cytokine ratio IL-10/IL-18 is a good biomarkers in males and CXCL10/CXCL1 in 
females. Interestingly CXCL10/CXCL1 is also significant prognostic biomarkers in 
the male sex but is associated with an inverse risk of developing MACE.
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Age 64(57-72) 62(56-70) N.S.
BMI 27(24-30) 27(25-29) N.S.
Systolic blood pressure (mm Hg) 137(122-150) 133(122-145) N.S.
Diastolic blood pressure (mm Hg) 76(70-84) 80(72-85) p<0.05
Glucose (mmol/L) 6.20(5.48-7.40) 6.00(5.50-6.70) N.S.
Hemoglobin (mmol/L) 8.20(7.80-8.60) 8.90(8.50-9.40) p<0.001
Cholesterol (mmol/L) 4.40(3.80-5.30) 3.95(3.40-4.70) p<0.001
LDL-C (mmol/L) 2.60(1.96-3.26) 2.30(1.79-2.92) p<0.01
HDL-C (mmol/L) 1.16(1.00-1.44) 0.99(0.86-1.18) p<0.001
Triglycerides (mmol/L) 1.39(0.99-1.81) 1.30(0.98-1.85) N.S.
hsCRP (ng/mL) 4332(2072-7648) 2720(1664-7327) p<0.05
WBC (X1000 cells/µL) 7.30(5.60-8.93) 7.00(5.90-8.10) N.S.
Current smoker 23%(31) 20%(57) N.S.
Diabetes 24%(32) 18%(51) N.S.
Hypertension 70%(94) 63%(181) N.S.
Beta-blocker 75%(100) 75%(215) N.S.
Ca-antagonist 29%(39) 30%(86) N.S.
Aspirin 84%(112) 80%(230) N.S.
Vitamin K antagonist 12%(16) 11%(32) N.S.
ADP receptor blocker 51%(69) 49%(140) N.S.
ACE inhibitor 28%(37) 37%(105) N.S.
ATII receptor blocker 29%(39) 15%(42) p<0.001
Diuretic 25%(34) 19%(54) N.S.
Statin 71%(95) 80%(229) N.S.
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IL-4 (pg/ml) 27.6(18.2-35.7) 13.8(8.0-27.1) p<0.001
IL-5 (pg/ml) 235.0(190.3-290.6) 180.3(135.1-248.1) p<0.001
IL-6 (pg/ml) 3.2(2.3-4.9) 4.7(3.2-11.1) p<0.001
IL-10 (pg/ml) 5.5(3.3-6.5) 5.6(5.0-7.3) N.S.
IL-12 (pg/ml) 205.4(136.2-303.8) 139.4(62.4-210.9) p<0.001
IL-13 (pg/ml) 132.1(93.6-180.5) 99.2(67.9-129.2) p<0.001
IL-15 (pg/ml) 109.4(75.2-142.4) 73.7(31.1-121.8) p<0.01
IL-18 (pg/ml) 101.9(67.6-149.1) 96.6(69.5-140.3) N.S.
IL-33 (ng/ml) 69.1(49.2-104.5) 38.9(20.3-88.2) p<0.001
IL-1RA (pg/ml) 39.0(0.0-106.7) 55.1(2.7-115.3) N.S.
CCL2 (MCP1) (pg/ml) 240.7(208.0-276.5) 216.2(179.0-237.8) p<0.01
CCL5 (RANTES) (pg/ml) 80174.7(64974.1-101154.7) 87243.9(67264.0-111204.9) N.S.
CCL17 (TARC) (pg/ml) 73.6(36.7-121.1) 59.5(33.6-123.3) N.S.
CCL19 (MIP3b) (pg/ml) 16.9(12.6-23.8) 9.3(4.7-19.0) p<0.001
CCL20 (MIP3a) (pg/ml) 6.9(5.3-8.8) 5.5(4.3-7.2) p<0.01
CXCL1 (GRO1) (pg/ml) 1.1(0.5-1.9) 0.9(0.0-2.5) N.S.
CXCL4 (PF4) (pg/ml) 7443.5(6626.8-8210.2) 6392.5(5291.4-7269.7) p<0.001
CXCL8 (IL-8) (pg/ml) 54.8(43.9-67.9) 46.2(34.7-55.8) p<0.01
CXCL10 (IP10) (pg/ml) 179.5(127.3-252.5) 158.9(118.5-245.3) N.S.
CXCL12 (SDF1) (pg/ml) 78.2(65.8-95.5) 78.6(72.2-84.6) N.S.
CX3CL1 (fractalkine) (pg/ml) 1.6(0.9-2.9) 1.6(1.1-2.7) N.S.
MCSF (pg/ml) 70.0(41.6-90.1) 57.3(28.2-81.9) N.S.
TNFA (pg/ml) 3.3(2.5-6.0) 3.3(2.8-3.8) N.S.
MIF (pg/ml) 10018.0(8390.3-11190.0) 10176.5(8116.8-10840.8) N.S.
Difference in cytokine concentrations between patients with stable and unstable CAD for the male 
cohort, values are median (interquartile range).
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IL-4 (pg/ml) 30.2(20.4-40.1) 19.3(11.3-32.3) p<0.05
IL-5 (pg/ml) 244.3(197.9-319.9) 212.6(160.4-255.4) N.S.
IL-6 (pg/ml) 3.2(2.2-4.5) 3.7(1.8-6.4) N.S.
IL-10 (pg/ml) 5.5(3.9-7.7) 5.8(3.8-7.0) N.S.
IL-12 (pg/ml) 227.6(146.5-336.2) 148.1(103.5-237.9) N.S.
IL-13 (pg/ml) 129.6(92.2-193.3) 99.8(75.5-150.2) N.S.
IL-15 (pg/ml) 117.4(75.1-155.8) 113.9(71.1-146.7) N.S.
IL-18 (pg/ml) 82.6(60.0-107.9) 74.2(45.9-134.6) N.S.
IL-33 (ng/ml) 87.1(53.0-122.6) 71.4(41.0-86.7) N.S.
IL-1RA (pg/ml) 76.6(0.0-177.2) 64.6(6.9-98.8) N.S.
CCL2 (MCP1) (pg/ml) 247.0(216.2-288.6) 214.1(185.2-252.7) p<0.05
CCL5 (RANTES) (pg/ml) 88816.6(70669.6-117678.9) 85524.1(71031.1-101058.7) N.S.
CCL17 (TARC) (pg/ml) 78.6(48.5-128.9) 73.8(31.3-121.2) N.S.
CCL19 (MIP3b) (pg/ml) 19.1(14.0-25.5) 14.9(9.8-19.9) N.S.
CCL20 (MIP3a) (pg/ml) 7.4(5.5-10.0) 6.0(4.7-7.1) N.S.
CXCL1 (GRO1) (pg/ml) 1.1(0.5-2.2) 1.3(0.5-2.2) N.S.
CXCL4 (PF4) (pg/ml) 7514.2(6519.2-8315.8) 7207.2(6095.0-7831.4) N.S.
CXCL8 (IL-8) (pg/ml) 57.4(46.0-75.1) 47.7(31.7-58.8) p<0.05
CXCL10 (IP10) (pg/ml) 218.5(142.2-375.1) 158.7(117.3-233.3) p<0.05
CXCL12 (SDF1) (pg/ml) 79.3(69.6-90.1) 77.3(68.0-82.1) N.S.
CX3CL1 (fractalkine) (pg/ml) 1.6(1.1-3.0) 2.0(1.4-3.0) N.S.
MCSF (pg/ml) 70.1(42.1-95.7) 71.0(7.3-90.9) N.S.
TNFA (pg/ml) 3.3(2.3-5.3) 3.3(2.8-4.3) N.S.
MIF (pg/ml) 10512.1(9327.4-12249.8) 9960.7(8907.9-10432.3) N.S.
Difference in cytokine concentrations between patients with stable and unstable CAD for the female 
cohort, values are median (interquartile range).
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Cytokines as biomarkers in coronary artery disease
Figure S1: Heatmap of cytokine 
concentrations for male and female 
cohort. Cytokine values were 
distributed into deciles (10 quantiles) 
to enforce equal range, both cytokines 
and patients were clustered with 
hierarchical clustering. Two clusters 
for both male and female patients can 
be identified which are marked with 
red and blue color. On the right of 
the heatmap each individual unstable 
CAD (USC) patient is marked by a 
black line, the percentage indicates the 
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Background- Smoking may influence coronary artery disease (CAD) 
progression in multiple ways, one of which is the modulation of the immune response. 
The aim of this study was to identify the influence of smoking on circulating white 
blood cells (WBC), miRNA and cytokine expression in patients with CAD.
Methods and results- The current study used a cohort of 363 CAD patients 
referred for coronary angiography from the Circulating Cells study. Flow cytometry 
analysis was used to determine monocyte, T cell and neutrophil count in the blood 
of smokers and non-smokers. For CD4+ and CD8+ T cells miRNA expression of a 
selected subset of 92 miRNAs was evaluated for differentially expressed miRNAs 
between smokers and non-smokers. Furthermore the concentration of 24 cytokines 
was determined in blood of smoking and non-smoking patients.
CCL2 and MIF had a significantly higher concentration in blood of 
smokers compared to non-smokers, whereas CXCL10 concentration was 
significantly decreased in smokers. Compared to non-smokers, smokers display 
an increase in circulating WBCs including T cells, Treg cells, classical monocytes 
and predominantly neutrophils whereas they display a decrease in circulating cell 
count for non-classical monocytes. More so Treg cells increased with pack-years 
irrespective of smoking cessation. 
Conclusion- Smokers have an increased circulating WBC count, primarily 
caused by an increase in neutrophils. Circulating Treg cells are increased in current 
smokers and are shown to be dose dependently increased with increased smoking 
pack-years. The increase in smoking induced circulating Treg count is shown to be 
persistent even after smoking cessation.
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Introduction
It is well known that (cigarette) smoking increases the risk of developing 
several diseases, including COPD, cancer and cardiovascular disease[1]. Since two 
out of three smokers die as the result of smoking related diseases[2,3], smoking is 
recognized as one of the most important factors adding to preventable illness in 
the world. Numerous epidemiological studies have shown that smoking increases 
the incidence of myocardial infarction and cardiovascular related death and the 
World Health organization estimates that 10% of cardiovascular related deaths is 
attributable to smoking[4].
Smoke contains approximately 4000 different compounds, which 
complicates conclusions on the mechanisms by which smoking effects coronary 
artery disease (CAD) and its underlying metabolic pathways[5]. Smoking influences 
the development of CAD in multiple ways. Firstly smoking can induce endothelial 
cell dysfunction through reactive oxygen species[6], secondly it has a pro-thrombotic 
effect[7], thirdly it modifies lipids via oxidation and lastly smoking modulates the 
immune system[8,9]. Several studies have shown that smoking induces an increase in 
circulating white blood cell (WBC) count, which is primarily caused by an increase 
in the number of neutrophils[10–12]. Other inflammatory markers such as hsCRP and 
fibrinogen are also known to be increased in smokers, which indicates that smoking 
causes a chronic increase in the inflammatory status[13–16]. As it has become clear 
in the last decennia that inflammation is a central mechanism of atherosclerotic 
disease progression, increased systemic inflammation through smoking could be 
one of the ways by which smoking aggravates CAD.
Although smoking induces increased WBC count in smokers, smoke and 
smoke extract can also have an anti-inflammatory or Th2 skewing effect on T cells 
cytokine production. NK cells, dendritic cells, alveolar macrophages as well as 
monocytes are reported to suppress pro-inflammatory cytokine production upon 
exposure to smoke extracts or specific compounds found in smoke[17–21]. In contrast 
neutrophils, mast cells and endothelial cells are activated by exposure to cigarette 
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smoke conditioned medium and their production of pro-inflammatory cytokine 
is increased[22–25]. 
In the Circulating Cells study the blood of CAD patients scheduled for 
coronary angiography was analyzed for their WBC subset distribution, miRNA 
expression in various white blood cell subsets and plasma cytokine levels. In the 
current study we investigate the influence of smoking on WBC counts, cytokine 
levels and miRNA expression of T cells; furthermore we investigate whether the 
degree of smoking has a dose dependent effect on circulating inflammatory factors.
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Methods
Study population
The study cohort consists of a total of 363 CAD patients between the age of 
37 and 82, these patients form a subgroup of the Center for Translational Molecular 
Medicine (CTMM) – Circulating Cells study cohort. The Circulating Cells study was 
setup to find novel biomarkers for CAD, here we use the cohort to study the effect 
of smoking on the immune system. The Circulating Cells cohort consist of stable 
angina patients and patients with acute coronary syndrome (ACS), ACS is known 
to instigate an acute increase in systemic inflammation. In the current study we 
investigated the impact of smoking on inflammatory factors, to reduce the effect 
of the coronary syndrome on study results we limited the studied cohort to stable 
angina patients only. In brief, Circulating Cells is a multi-center study in which CAD 
patients scheduled for coronary angiography were included. Exclusion criteria were 
age < 18 years, inability to give informed consent, suspected drug or alcohol abuse, 
serious concomitant disease, serious recent infectious disease in the last 6 weeks 
or suspected elevated state of the immune system, and non-cooperativeness. The 
Circulating Cells protocol was approved by the review board or ethics committee of 
each participating center[26].
Measurement of blood based cytokines
Blood was collected from patients in an EDTA BD vacutainer blood collection 
tube and blood samples were centrifuged at 156xg for 15 minutes. The upper layer 
(plasma and platelets) was transferred to a new tube and was centrifuged at 1000xg 
for 20 minutes. The upper plasma layer was collected and stored at -800C. 
Plasma levels of cytokines were determined for IL-4, IL-5, IL-6, IL-10, IL-
12, IL-13, IL-15, IL-18, IL-33, IL-1RA, CCL2 (MCP1),CCL5 (RANTES), CCL17 
(TARC), CCL19 (MIP3B), CCL20 (MIP3A), CXCL1 (GRO1), CXCL4 (PF4), 
CXCL8 (IL8), CXCL10 (IP10), CXCL12 (SDF1), CX3CL1 (fractalkine), MCSF, 
TNF and MIF. Cytokines levels were measured using a multiplex bead array 
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system (Luminex; Millipore, Billerica, USA), assays were preformed according to 
manufacturer’s protocol.
Flow cytometry
Whole blood flow cytometry analysis was performed to identify and quantify 
leukocyte cell subsets. Cells were stained with the following antibodies: CD3-PC7 
(737657; Beckman Coulter, Fort Lauderdale, USA), CD4-PC7 (737660; Beckman 
Coulter), CD8-FITC (A07756; Beckman Coulter), CD14-PC7 (A22331; Beckman 
Coulter), CD16-PC5 (A07767; Beckman Coulter), CD25-ECD (6607112; Beckman 
Coulter), CD28-ECD (6607111; Beckman Coulter), CD56-PC5 (A07789; Beckman 
Coulter), CD62L-PE (IM2214U; Beckman Coulter), CD69-PC5 (IM2656; Beckman 
Coulter), CD127-FITC (11-1278-42; eBioscience, San Diego, USA), TCRαβ-PE 
(A39499; Beckman Coulter). First, blood was collected in an EDTA BD vacutainer 
blood collection tube and 50 μl whole blood was stained with the respective 
antibodies for 30 minutes on 4oC. Red blood cells were lysed and afterwards cells 
were analyzed by flow cytometry. Each center was equipped with an identical 
flow cytometer (FC500, Beckman Coulter) and before each run cytometers were 
calibrated with fluorosphere setup kits (Beckman Coulter). Analysis was performed 
on Kaluza 1.3 flow cytometer analysis software (Beckman Coulter). 
Flow cytometry gating strategy
First the forward/side scatter plot was used to select lymphocyte, monocyte 
and granulocyte population. Next for each individually marker the positive and 
negative population was gated (e.g. CD62L+, CD62L-) and if distinct low and high 
populations were present these were separately gated (e.g. CD62Llow, CD62Lhigh).
microRNA assay
Magnetic beads were used to isolate CD4+ and CD8+ T cells from whole 
blood (BD Biosciences cat # 557767 and cat # 557766) according to manufacturer’s 
protocol, all steps were done on ice and the first incubation step was extended to 
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60 min. RNA was isolated from samples and spotted on custom MicroRNA Array 
(Taqman, Life technologies) and analysis was done according to manufacturer’s 
protocol (part num.:439972, rev.:C).
Statistics
Statistical calculations were performed using R for windows (version 
3.1.2). A P<0.05 was considered significant. Categorical data was compared 
using the chi-square test. For continuous data if two groups were compared the 
nonparametric Mann-Whitney U test was used, for comparison of more than two 
groups the nonparametric Kruskal-Wallis ANOVA test was used. False discovery 
rate adjustment was used to compensate for multiple significance testing.
A strong batch effect was observed between institutions for miRNA samples 
and cytokine samples, z-score normalization was used to compensate for this effect. 





Baseline characteristics for smokers and non-smokers are shown in Table 
1. All patients in this cohort were diagnosed with stable angina pectoris and all 
are treated for CAD, 83% of non-smokers and 87% of smokers were on statins but 
was not significantly different between smokers and non-smokers. Smokers were 
slightly but significantly younger than non-smokers. Triglycerides were significantly 
increased in smokers, total cholesterol and HDL-cholesterol (HDL-C) are also 







Male 71%(208) 77%(53) N.S.
Age 64(58-70) 59(50-71) p<0.01
BMI 27(25-30) 26(24-29) N.S.
Systolic blood pressure (mm Hg) 135(124-147) 138(124-150) N.S.
Diastolic blood pressure (mm Hg) 80(70-85) 80(70-85) N.S.
Glucose (mmol/L) 6.00(5.50-6.80) 5.93(5.37-6.87) N.S.
Hemoglobin (mmol/L) 8.65(8.10-9.10) 8.80(8.40-9.30) N.S.
Cholesterol (mmol/L) 3.96(3.40-4.77) 4.12(3.46-4.99) N.S.
LDL-C (mmol/L) 2.20(1.80-2.83) 2.33(1.75-2.97) N.S.
HDL-C (mmol/L) 1.05(0.89-1.26) 1.00(0.90-1.16) N.S.
Triglycerides (mmol/L) 1.26(0.94-1.71) 1.43(1.04-2.28) p<0.05
hsCRP (ng/mL) 2486(1620-5220) 4621(1715-8786) p<0.05
WBC (X1000 cells/µL) 6.50(5.40-7.70) 7.90(7.15-9.10) p<0.001
Diabetes 22%(64) 25%(17) N.S.
Hypertension 67%(197) 57%(39) N.S.
Beta-blocker 81%(239) 72%(50) N.S.
Ca-antagonist 32%(93) 39%(27) N.S.
Aspirin 85%(250) 84%(58) N.S.
Vitamin K antagonist 11%(32) 9%(6) N.S.
ADP receptor blocker 53%(155) 52%(36) N.S.
ACE inhibitor 35%(103) 32%(22) N.S.
ATII receptor blocker 23%(68) 17%(12) N.S.
Diuretic 23%(69) 20%(14) N.S.
Statin 83%(243) 87%(60) N.S.
Baseline characteristics table for cohort, values are median (interquartile range) or percentage (n).
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trending towards higher concentrations in smokers, which is consistent with 
previous reports[27]. Also in accordance with previous studies we see a significant 
(approximately 86%, p<0.05) increase in the inflammatory marker hsCRP and an 
increase in the number of WBC (approximately 22%, p<0.001) in smokers compared 
to non-smokers[12,28–33].
Lymphocyte, monocyte and granulocyte subsets
When we analyzed the nature of the changes in the WBCs, we found 
that monocytes showed a mixed picture. Classical monocytes increased with 
approximately 20% in smokers while circulating non-classical monocytes showed 
a decrease in smokers by approximately 18% (Table 2). Except for non-classical 






CD4+ 846.5 +/-353.2 1115.7 +/-424.7 p<0.001
CD4+CD69-CD62Lhigh (naive) 560.2 +/-285.7 715.9 +/-302.7 p<0.001
CD4+CD69+CD62L-/low (activated) 5.0 +/-7.6 4.6 +/-3.1 N.S.
CD4+CD28- 68.2 +/-83.2 59.5 +/-56.4 N.S.
CD4+CD127-CD25+ (Treg) 30.6 +/-19.1 46.7 +/-36.0 p<0.001
CD4+CD8+ 2.1 +/-2.7 6.4 +/-23.1 p<0.001
CD8+ 345.0 +/-293.5 468.2 +/-222.4 p<0.001
CD8+CD69-CD62Lhigh (naive) 92.8 +/-69.2 155.4 +/-97.4 p<0.001
CD8+CD69+CD62L-/low (activated) 11.6 +/-16.9 9.7 +/-8.3 N.S.
Natural killer cells
CD56+ CD3-TCRαβ- 259.0 +/-137.2 239.9 +/-153.5 N.S.
Monocytes
CD14highCD16- (classical) 498.0 +/-171.9 596.7 +/-172.0 p<0.001
CD14highCD16+ (intermediate) 46.0 +/-28.8 46.3 +/-26.6 N.S.
CD14lowCD16+ (non-classical) 57.5 +/-28.4 47.1 +/-23.9 p<0.01
Granulocytes
CD16high (neutrophils) 3927.0 +/-1349.5 4788.5 +/-1416.1 p<0.001
CD16- (eosinophils) 166.7 +/-126.5 222.8 +/-159.0 p<0.01
Circulating cell count for select WBC subsets. Data are presented in cells/µL as mean +/- SD.
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monocytes we see a general increase in WBC numbers. In absolute terms the 
largest difference is seen in neutrophils where we observed 20% more circulating 
neutrophils in smokers; 3927 (+/-1350 S.D.) cells/µL in non-smokers compared to 
4789 (+/-1416 S.D.) in smokers (p<0.001). CD4+ T cells increased on average with 
32% which was primarily caused by an increase in naïve CD4+ T cells which increased 
by 28%, whereas in contrast there was no significant difference in activated CD4+ T 
cell number. We observed a large increase in regulatory T cells (Treg, CD4+CD127-
CD25+), which was increased by approximately 52% in smokers. CD8+ T cell count 
is 36% higher in smokers which is comparable to what is seen for CD4+ T cells, there 
is a larger increase in naïve CD8+ T cells which increased by approximately 67%. The 
largest relative change is seen in the double positive CD4+CD8+ T cell subset, which 
was on average increased by 200% in smokers (Table 2).
Table 3: Differentially expressed miRNAs in CD4+ and CD8+ cells from smokers 
and non-smokers





miR-212 CD4+ 2.06 31.3 +/-2.6 30.3 +/-1.5 p<0.05
miR-1979 CD4+ 1.82 20.6 +/-2.1 19.7 +/-1.8 p<0.05
miR-1308 CD4+ 1.56 29.1 +/-1.8 28.5 +/-1.1 p<0.05
miR-132 CD4+ 1.54 26.2 +/-1.2 25.5 +/-1.0 p<0.01
miR-486-3p CD8+ 2.18 29.2 +/-2.1 28.0 +/-1.4 p<0.01
miR-31 CD8+ 1.58 24.1 +/-1.5 23.4 +/-1.1 p<0.01
miR-24 CD8+ 1.57 21.8 +/-1.6 21.1 +/-0.9 p<0.01
miR-150 CD8+ 1.53 16.3 +/-1.2 15.7 +/-0.8 p<0.01
miR-132 CD8+ 1.53 26.3 +/-1.1 25.6 +/-1.1 p<0.01
miR-146b-5p CD8+ 1.53 19.6 +/-1.0 18.9 +/-0.8 p<0.01
miR-19a CD8+ 1.52 21.3 +/-1.3 20.7 +/-0.9 p<0.01
miR-345 CD8+ 1.51 28.1 +/-1.9 27.5 +/-1.3 p<0.05
Differentially expressed miRNAs with a fold change >1.5 in CD4+ and CD8+ cells, data are presented 
as mean Ct +/- SD.
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MicroRNA expression in CD4+ and CD8+ T cells
Smoking has been found to substantially alter miRNA profiles in alveolar 
macrophages, epithelial cells, spermatozoa as well as in plasma resident vesicles[34–38]. 
Since we observed significant changes in T cell subsets in smokers, we hypothesized 
that smoking might induce changes in the miRNA profile in CD4+ and CD8+ T 
cells. We selected a set of 92 miRNAs on basis of a review of published data about 
the expression of miRNAs in T cells and a pilot study in which we analyzed the 
miRNA profile in CD4+ and CD8+ T cells from healthy and CAD patients. Table 3 
lists those miRNAs that were significantly up-regulated in smokers by more than 
1.5 in either CD4+ or CD8+ T cells, no significantly down-regulated miRNAs were 
found. miR-132 is the only miRNA that is up-regulated in both CD4+ and CD8+ 
T cells. Note that we find substantially more differentially expressed miRNAs in 
CD8+ T cells than in CD4+ T cells. Compared to the large changes that were seen in 
the miRNA profile in plasma of people that smoke[34], we see comparatively modest 
changes in miRNA expression between smokers and non-smokers. We found only 
two miRNAs that were increased by more than 2-fold in smokers, in CD4+ T cells 
miR-212 was 2.06-fold up-regulated (p<0.05) and in CD8+ T cells miR-486-3p was 








































 CXCL10 (A), MIF (B) and CCL5 (C) were differentially expressed between smokers and 
non-smokers. Data are presented as mean and the error bar represents the SEM. *p<0.05, **p<0.01.
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Cytokine expression in plasma
Previous research has shown that the influences of smoking on cytokine 
production is dependent on the cell type that is treated with smoke, both anti-
inflammatory as well as pro-inflammatory effects have been reported[17–25]. Here we 
tested in plasma 24 cytokines and chemokines for differential expression in smokers 
and non-smokers (Table S1). Three cytokines showed a differential expression 
in smokers compared to non-smokers; the plasma levels of CCL5 and MIF were 
significantly increased in smokers by approximatley 21% (non-smokers: 87.69 ng/
mL, +/-36.13  S.D. compared to smokers: 106.0 ng/mL, +/-44.92 S.D., p<0.05) and 
30% (non-smokers:10.6 ng/mL, +/-4.62 S.D. vs smokers: 13.8 ng/mL, +/-9.13 S.D., 
p<0.01) respectively, whereas a significant reduction in CXCL10 plasma level was 
shown in smokers by on average 28% in smokers (non-smokers: 248.2 pg/mL, +/-
165.0 S.D. compared to smokers: 177.5 pg/mL, +/-115.5 S.D., p<0.01) (Figure 1).
Dose dependent increase in Treg cells
To investigate whether smoking may exert a dose dependent effect on 











































 Dose dependent effect of smoking on CD4+ T cells (A) and Treg cells (B). Cohort 
participants were distributed in 5 groups dependent on their smoking pack-years (PY), groups 
were comprised of never-smokers (PY=0, n=62), low smoking (PY=1-14, n=52), medium smoking 
(PY=15-24, n=50), high smoking (PY=24-35, n=59) and very high smoking (PY > 35, n=56). Data 
are presented as mean and the error bar represents the SEM. *p<0.05, **p<0.01, ***p<0.001.
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the relation between smoking pack-years (PY) and cell count, miRNA expression 
and cytokine level. Smoking pack-year is a way to quantify the degree of smoking 
that a person has done over his lifetime; it is calculated by multiplying the number of 
cigarette packs smoked per day by the number of years a person has smoked. Groups 
were comprised of never-smokers (PY=0, n=62), light smoking (PY=1-14, n=52), 
medium smoking (PY=15-24, n=50), heavy smoking (PY=24-35, n=59) and very 
heavy smoking (PY > 35, n=56). ANOVA analysis showed a significant difference 
between groups for Treg (CD4+CD127-CD25+) cells, CD4+CD8+ double positive cells 
and naive CD8+ cells (CD8+CD69-CD62Lhigh), though CD4+CD8+ double positive 
cells and naive CD8+ cells show a significant difference in the ANOVA test there was 
no consistent trend towards an increase or a decrease with increasing pack-years. 
Consequently CD4+CD8+ double positive cells and naive CD8+ cells do not show 
a strong correlation with PY (Rho<0.2), in contrast a strong correlation between 
Treg cell count and PY was observed in the study cohort, Rho=0.29 (p<0.001; 
Spearman correlation). Heavy smokers and very heavy smokers had significantly 
higher numbers of circulating Treg cells as compared to never-smokers and light 
smokers (Figure 2): very heavy smokers had 52% more circulating Treg cells then 
never-smokers. Removal of the current smokers from the cohort does not affect the 
correlation, which remains significant (Rho=0.26, p<0.001). Moreover if only the 
people that have smoked in the past but quit are taken into account the correlation 
remains significant with Rho=0.23 (p<0.01). To control for a possible correlation 
between age and PY, we checked the correlation for these parameters (Rho=-0.05, 
p=0.4) and found no significant correlation. Finally, we did not find a significant 




In this study we analyzed the effect of current smoking and the dose of 
smoking as expressed in pack-years on blood derived biomarkers in a cohort of 
patients suffering from stable angina pectoris. One of the most striking findings of 
this study is that we show a dose dependent increase of smoking on the number of 
circulating regulatory T cells in the blood. This effect of smoking is independent of 
smoking cessation. To the best of our knowledge this is the first time that a correlation 
is shown between smoking pack-years and circulating Treg count. In addition, we 
show an increase in circulating T cells, neutrophils and classical monocytes while 
we see a decrease in non-classical monocytes in smokers.
Numerous reports have shown an increase in WBC in current smokers, we 
specifically analyzed which cell subsets are responsible for the increase in WBC. We 
now show a large increase in the number of circulating CD4+ and CD8+ T cells in 
smoking patients. The largest increases were observed in the Treg cell population, the 
CD4+CD8+ double positive T cell population and in the naive CD8+ T cell population. 
Both in a mouse smoking model as well as in human smokers an oligoclonal 
expansion has been shown primarily in the CD8 compartment of T cells and this 
could account for the increase in naïve CD8+ T cells[39,40]. CD4+CD8+ double positive 
T cells are common in the thymus as immature T cells express both CD4 and CD8 
but in circulation less than 5% of T cells are both CD4+CD8+ double positive[41–43]. 
Very little is known about the functionality of CD4+CD8+ double positive cells and 
even less about the effect smoking has on these cells. Data pertaining to Treg cell 
expansion in PBMC is limited, though it has been shown that the Treg cell number 
increases in bronchoalveolar lavage fluid in the lungs of smokers compared to never 
smokers[44]. In the current cohort of cardiovascular disease patients an increase in 
Treg cells would be considered beneficial for its repressive effect on inflammation 
and consequently repressing atherosclerotic plaque development. Likely other effects 
like an increase in oxidized lipid moieties and increased endothelial cell dysfunction 
would outweigh the otherwise beneficial effects of increased Treg count.
Concomitant with these changes in the T cell population we see an increase 
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in classical monocytes, eosinophils and neutrophils but in contrast a decrease in 
circulating non-classical monocytes. Recent evidence indicates that non-classical 
monocytes are derived from classical monocytes which likely differentiate in the 
circulation[45,46]. As such it is surprising that we see a decrease in non-classical 
monocytes while at the same time seeing an increase in classical monocytes. Two 
scenarios may explain this phenomenon, first differentiation of classical monocytes 
could be blocked or second a higher percentage of non-classical monocytes 
show patrolling behavior and consequently lowering the percentage of measured 
circulating non-classical monocytes. In a mouse model it has been shown that one-
third of the non-classical monocytes in the vascular compartment are patrolling the 
vasculature, during which they crawl along the vascular wall surveying endothelial 
integrity[47]. This patrolling behavior primarily involves the interaction of ICAM on 
endothelial cells with LFA on non-classical monocytes, blocking this interaction 
all but abolishes this behavior[48]. Smoke extract is known to induce expression of 
VCAM and ICAM on endothelial cells and thus a larger portion of the non-classical 
monocytes might be patrolling the vascular wall in smokers and consequently a 
decrease in the number of circulating non-classical monocytes is measured by 
flow cytometry[49].
The changes in miRNA expression in circulating CD4+ and CD8+ T cells 
are modest compared to changes seen in the plasma of smokers, where up to 8-fold 
changes in the expression of miRNA were seen[34]. Fichtlscherer et al. saw a large 
down regulation of plasma resident miRNAs in CAD patients, in the present study 
we are using a CAD cohort and this might reduce the effect we see of smoking on 
miRNA expression[50]. One noteworthy change seen in miRNA expression is the up 
regulation of miR-212 and miR-132 in CD4 T cells and miR-132 in CD8+ T cells. 
miR-212 and miR-132 are processed from the same non-coding RNA sequence and 
share the same seed region, they are known to target IRAK4[51]. TLR signaling and 
possibly TCR signaling is modulated by IRAK4 and a reduction in IRAK4 activity 
could lead to repressed TCR signaling[52–54]. Decreased TCR signaling through miR-
212 and miR-132 up regulation could consequently play a part in the apparent 
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anergic and immune suppressed response of T cells observed in smokers[55–59].
Previous reports have shown an increase in the level of inflammation 
markers in the blood of smokers, we observed a significant increase in hsCRP but no 
concomitant increase in IL-6 which has been described previously[28,32]. We did find a 
significant increase in the chemokine CCL5 and chemokine-like protein MIF, which 
might induce increased inflammatory cell recruitment towards the atherosclerotic 
plaque. In contrast we see a decrease in CXCL10, CXCL10 functions as a chemokine 
attractant for lymphocytes, in addition to its chemotactic function CXCL10 can 
reduce angiogenesis[60]. Nicotine agonist was shown to decrease CXCL10 plasma 
concentration in a sepsis mouse model which confirms the current findings of 
decreased CXCL10 concentration in smokers, furthermore nicotine is also known 
to increase angiogenesis in a atherosclerosis model[61,62]. The second hand smoke 
induced increase in angiogenesis seen in a lung cancer model could thus be caused 
by a nicotine mediated decrease in CXCL10[63].
A large portion of the non-smokers in the current cohort have smoked in 
the past and subsequently quit smoking. To assess the lasting effect of smoking 
has on inflammatory markers a comparison was made between pack-years and 
inflammatory factors. In contrast to the large differences between smokers and non-
smokers we see very little correlation with smoking pack years and inflammatory 
markers. The one exception is the significant correlation (Rho>0.2) we find with 
Treg (CD4+CD127-CD25+) cells, which increases with the number of pack-years. 
Even when we only looked at people that have quit smoking, the correlation between 
pack-years and the increased number of Tregs remains significant. In COPD 
patients a similar correlation was found for pack-years and Treg (CD4+CD25bright) 
count in bronchoalveolar lavage fluid, in the current study we can expand this to 
Treg cells in blood[64].
In conclusion, we describe that smoking induces a large increase in classical 
monocytes, neutrophils, CD4+ and CD8+ T cells and T regulatory cells while there 
is a reduction in circulating non-classical monocytes. Concomitant with these 
changes in circulating immune cells we see increases in CCL5 and MIF while there 
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is a significant decrease in CXCL10 in smokers. Importantly we find that even after 
cessation of smoking there remains a correlation between smoking pack-years and 
circulating Treg cell numbers in blood. Further research is needed to show what 
consequences this has for development of atherosclerosis or other smoking related 




1.  Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002; 2(5): 372–377. 
doi:10.1038/nri803.
2.  Jha P et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 
2013; 368(4): 341–350. doi:10.1056/NEJMsa1211128.
3.  Banks E et al. Tobacco smoking and all-cause mortality in a large Australian cohort study: findings 
from a mature epidemic with current low smoking prevalence. BMC Med 2015; 13: 1–10. doi:10.1186/
s12916-015-0281-z.
4.  Word Health Organization. Mortality attributable of tobaco: WHO Global Report. WHO Libr Cat Data 
2012: 4.
5.  Burns DM. Cigarettes and cigarette smoking. Clin Chest Med 1991; 12(4): 631–642.
6.  Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction 
and early atherogenesis. Arterioscler Thromb Vasc Biol 2014; 34(3): 509–515. doi:10.1161/ATVBA-
HA.113.300156.
7.  Barua RS, Ambrose JA. Mechanisms of coronary thrombosis in cigarette smoke exposure. Arterioscler 
Thromb Vasc Biol 2013; 33(7): 1460–1467. doi:10.1161/ATVBAHA.112.300154.
8.  Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12(3): 204–
212. doi:10.1038/ni.2001.
9.  Goncalves RB et al. Impact of smoking on inflammation: overview of molecular mechanisms. Inflamm 
Res 2011; 60(5): 409–424. doi:10.1007/s00011-011-0308-7.
10.  Yarnell JW et al. Lifestyle and hemostatic risk factors for ischemic heart disease : the Caerphilly Study. 
Arterioscler Thromb Vasc Biol 2000; 20(1): 271–279. doi:10.1161/01.ATV.20.1.271.
11.  Van Eeden SF, Hogg JC. The response of human bone marrow to chronic cigarette smoking. Eur Respir 
J 2000; 15(5): 915–921.
12.  Wannamethee SG et al. Associations between cigarette smoking, pipe/cigar smoking, and smoking 
cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J 2005; 
26(17): 1765–1773. doi:10.1093/eurheartj/ehi183.
13.  Rohde LE et al. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. 
Am J Cardiol 1999; 84(9): 1018–1022.
14.  Mendall MA et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardio-
vascular risk factors in men. Eur Heart J 2000; 21(19): 1584–1590. doi:10.1053/euhj.1999.1982.
15.  Frohlich M et al. Independent association of various smoking characteristics with markers of systemic 
inflammation in men. Results from a representative sample of the general population (MONICA Augs-
burg Survey 1994/95). Eur Heart J 2003; 24(14): 1365–1372. doi:10.1016/S0195-668X(03)00260-4.
16.  Bazzano LA et al. Relationship between cigarette smoking and novel risk factors for cardiovascular dis-
ease in the United States. Ann Intern Med 2003; 138(11): 891–897. doi:10.1016/j.accreview.2003.08.037.
17.  Arimilli S et al. Combustible and non-combustible tobacco product preparations differentially reg-
ulate human peripheral blood mononuclear cell functions. Toxicol In Vitro 2013; 27(6): 1992–2004. 
doi:10.1016/j.tiv.2013.06.015.
18.  Shimada ALB et al. In vivo hydroquinone exposure impairs MCP-1 secretion and monocyte recruit-
ment into the inflamed lung. Toxicology 2012; 296(1-3): 20–26. doi:10.1016/j.tox.2012.02.012.
19.  Gaschler GJ et al. Cigarette smoke exposure attenuates cytokine production by mouse alveolar mac-
195
Smoking and coronary artery disease
rophages. Am J Respir Cell Mol Biol 2008; 38(2): 218–226. doi:10.1165/rcmb.2007-0053OC.
20.  Mian MF et al. Impairment of human NK cell cytotoxic activity and cytokine release by cigarette 
smoke. J Leukoc Biol 2008; 83(3): 774–784. doi:10.1189/jlb.0707481.
21.  Mortaz E et al. Cigarette smoke attenuates the production of cytokines by human plasmacytoid den-
dritic cells and enhances the release of IL-8 in response to TLR-9 stimulation. Respir Res 2009; 10: 47. 
doi:10.1186/1465-9921-10-47.
22.  Orosz Z et al. Cigarette smoke-induced proinflammatory alterations in the endothelial phenotype: role 
of NAD(P)H oxidase activation. Am J Physiol Heart Circ Physiol 2007; 292(1): H130–9. doi:10.1152/
ajpheart.00599.2006.
23.  Nordskog BK et al. Matrix-degrading and pro-inflammatory changes in human vascular endotheli-
al cells exposed to cigarette smoke condensate. Cardiovasc Toxicol 2003; 3(2): 101–117. doi:10.1385/
CT:3:2:101.
24.  Iho S et al. Nicotine induces human neutrophils to produce IL-8 through the generation of perox-
ynitrite and subsequent activation of NF-kappaB. J Leukoc Biol 2003; 74(5): 942–951. doi:10.1189/
jlb.1202626.
25.  Mortaz E et al. Cigarette smoke stimulates the production of chemokines in mast cells. J Leukoc Biol 
2008; 83(3): 575–580. doi:10.1189/jlb.0907625.
26.  Hoefer IE et al. Circulating cells as predictors of secondary manifestations of cardiovascular disease: 
design of the CIRCULATING CELLS study. Clin Res Cardiol 2013; 102(11): 847–856. doi:10.1007/
s00392-013-0607-9.
27.  Craig WY et al. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of pub-
lished data. BMJ 1989; 298(6676): 784–788.
28.  Jefferis BJ et al. Secondhand smoke (SHS) exposure is associated with circulating markers of inflam-
mation and endothelial function in adult men and women. Atherosclerosis 2010; 208(2): 550–556. 
doi:10.1016/j.atherosclerosis.2009.07.044.
29.  Holt PG, Keast D. Environmentally induced changes in immunological function: acute and chronic 
effects of inhalation of tobacco smoke and other atmospheric contaminants in man and experimental 
animals. Bacteriol Rev 1977; 41(1): 205–216.
30.  Tollerud DJ et al. The effects of cigarette smoking on T cell subsets. A population-based survey of 
healthy caucasians. Am Rev Respir Dis 1989; 139(6): 1446–1451. doi:10.1164/ajrccm/139.6.1446.
31.  Tracy RP et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovas-
cular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc 
Biol 1997; 17(10): 2167–2176.
32.  Bermudez EA et al. Relation between markers of systemic vascular inflammation and smoking in 
women. Am J Cardiol 2002; 89(9): 1117–1119. doi:10.1016/S0002-9149(02)02284-1.
33.  Price JF et al. Relationship between smoking and cardiovascular risk factors in the development of pe-
ripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J 1999; 20(5): 
344–353. doi:10.1053/euhj.1998.1194.
34.  Takahashi K et al. Cigarette smoking substantially alters plasma microRNA profiles in healthy subjects. 
Toxicol Appl Pharmacol 2013; 272(1): 154–160. doi:10.1016/j.taap.2013.05.018.
35.  Momi N et al. Smoking and microRNA dysregulation: a cancerous combination. Trends Mol Med 
2014; 20(1): 36–47. doi:10.1016/j.molmed.2013.10.005.
36.  Schembri F et al. MicroRNAs as modulators of smoking-induced gene expression changes in human 
196
Chapter 6
airway epithelium. Proc Natl Acad Sci U S A 2009; 106(7): 2319–2324. doi:10.1073/pnas.0806383106.
37.  Marczylo EL et al. Smoking induces differential miRNA expression in human spermatozoa: a potential 
transgenerational epigenetic concern? Epigenetics 2012; 7(5): 432–439. doi:10.4161/epi.19794.
38.  Graff JW et al. Cigarette smoking decreases global microRNA expression in human alveolar mac-
rophages. PLoS One 2012; 7(8): e44066. doi:10.1371/journal.pone.0044066.
39.  Korn S et al. Characterization of the interstitial lung and peripheral blood T cell receptor repertoire in 
cigarette smokers. Am J Respir Cell Mol Biol 2005; 32(2): 142–148. doi:10.1165/rcmb.2004-0239OC.
40.  Motz GT et al. Persistence of lung CD8 T cell oligoclonal expansions upon smoking cessation in a 
mouse model of cigarette smoke-induced emphysema. J Immunol 2008; 181(11): 8036–8043.
41.  Blue ML et al. Coexpression of T4 and T8 on peripheral blood T cells demonstrated by two-color fluo-
rescence flow cytometry. J Immunol 1985; 134 (4 ): 2281–2286. Available at: http://www.jimmunol.org/
content/134/4/2281.abstract.
42.  Ortolani C et al. Cytofluorimetric identification of two populations of double positive (CD4+,CD8+) 
T lymphocytes in human peripheral blood. Biochem Biophys Res Commun 1993; 191(2): 601–609. 
doi:http://dx.doi.org/10.1006/bbrc.1993.1260.
43.  Ghia P et al. Age-dependent accumulation of monoclonal CD4+CD8+ double positive T lympho-
cytes in the peripheral blood of the elderly. Br J Haematol 2007; 139(5): 780–790. doi:10.1111/j.1365-
2141.2007.06867.x.
44.  Barcelo B et al. Phenotypic characterisation of T-lymphocytes in COPD: abnormal CD4+CD25+ 
regulatory T-lymphocyte response to tobacco smoking. Eur Respir J 2008; 31(3): 555–562. 
doi:10.1183/09031936.00010407.
45.  Yona S et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under 
homeostasis. Immunity 2013; 38(1): 79–91. doi:10.1016/j.immuni.2012.12.001.
46.  Varol C et al. Monocytes give rise to mucosal, but not splenic, conventional dendritic cells. J Exp Med 
2007; 204(1): 171–180. doi:10.1084/jem.20061011.
47.  Auffray C et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling 
behavior. Science 2007; 317(5838): 666–670. doi:10.1126/science.1142883.
48.  Carlin LM et al. Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate 
their disposal. Cell 2013; 153(2): 362–375. doi:10.1016/j.cell.2013.03.010.
49.  Giunzioni I et al. Cigarette smoke condensate affects monocyte interaction with endothelium. Athero-
sclerosis 2014; 234(2): 383–390. doi:10.1016/j.atherosclerosis.2014.03.029.
50.  Fichtlscherer S et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010; 
107(5): 677–684. doi:10.1161/CIRCRESAHA.109.215566.
51.  Nahid MA et al. Regulation of TLR2-mediated tolerance and cross-tolerance through IRAK4 modula-
tion by miR-132 and miR-212. J Immunol 2013; 190(3): 1250–1263. doi:10.4049/jimmunol.1103060.
52.  Lye E et al. IRAK-4 kinase activity is required for IRAK-4-dependent innate and adaptive immune 
responses. Eur J Immunol 2008; 38(3): 870–876. doi:10.1002/eji.200737429.
53.  Kawagoe T et al. Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-medi-
ated immune responses but not in TCR signaling. J Exp Med 2007; 204(5): 1013–1024. doi:10.1084/
jem.20061523.
54.  Suzuki N et al. A critical role for the innate immune signaling molecule IRAK-4 in T cell activation. 
Science 2006; 311(5769): 1927–1932. doi:10.1126/science.1124256.
55.  Lambert C et al. Acrolein in cigarette smoke inhibits T-cell responses. J Allergy Clin Immunol 2005; 
197
Smoking and coronary artery disease
116(4): 916–922. doi:10.1016/j.jaci.2005.05.046.
56.  Chang JC et al. Tobacco smoke suppresses T cells but not antigen-presenting cells in the lung-associat-
ed lymph nodes. Toxicol Appl Pharmacol 1990; 102(3): 514–523. doi:10.1016/0041-008X(90)90046-W.
57.  Kalra R et al. Effects of cigarette smoke on immune response: chronic exposure to cigarette smoke im-
pairs antigen-mediated signaling in T cells and depletes IP3-sensitive Ca(2+) stores. J Pharmacol Exp 
Ther 2000; 293(1): 166–171.
58.  Geng Y et al. Effects of nicotine on the immune response. II. Chronic nicotine treatment induces T cell 
anergy. J Immunol 1996; 156(7): 2384–2390.
59.  Ouyang Y et al. Suppression of human IL-1beta, IL-2, IFN-gamma, and TNF-alpha production by 
cigarette smoke extracts. J Allergy Clin Immunol 2000; 106(2): 280–287. doi:10.1067/mai.2000.107751.
60.  Van den Borne P et al. The multifaceted functions of CXCL10 in cardiovascular disease. Biomed Res 
Int 2014; 2014: 893106. doi:10.1155/2014/893106.
61.  Heeschen C et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. 
Nat Med 2001; 7(7): 833–839. doi:10.1038/89961.
62.  Chatterjee PK et al. Nicotinic acetylcholine receptor agonists attenuate septic acute kidney injury in 
mice by suppressing inflammation and proteasome activity. PLoS One 2012; 7(5): e35361. doi:10.1371/
journal.pone.0035361.
63.  Zhu B et al. Second hand smoke stimulates tumor angiogenesis and growth. Cancer Cell 2003; 4(3): 
191–196. doi:10.1016/S1535-6108(03)00219-8.









IL-4 (pg/ml) 1.15 27.5 +/-13.9 31.8 +/-15.6 N.S.
IL-5 (pg/ml) 1.12 240.4 +/-114.7 269.8 +/-126.7 N.S.
IL-6 (pg/ml) 1.20 4.1 +/-5.2 4.9 +/-6.6 N.S.
IL-10 (pg/ml) 0.71 7.5 +/-13.7 5.3 +/-3.2 N.S.
IL-12 (pg/ml) 1.15 217.9 +/-117.8 251.1 +/-138.5 N.S.
IL-13 (pg/ml) 1.22 142.8 +/-92.5 174.6 +/-140.8 N.S.
IL-15 (pg/ml) 1.17 111.3 +/-55.0 130.1 +/-63.2 N.S.
IL-18 (pg/ml) 0.88 112.2 +/-72.5 98.8 +/-59.2 N.S.
IL-33 (ng/ml) 1.15 80.4 +/-48.4 92.8 +/-53.0 N.S.
IL1RA (pg/ml) 1.15 93.7 +/-166.8 107.8 +/-220.5 N.S.
CCL2 (MCP1) (pg/ml) 1.04 242.9 +/-56.7 253.0 +/-55.0 N.S.
CCL5 (RANTES) (ng/ml) 1.21 87.69 +/-36.13 106.0 +/-44.92 p<0.05
CCL17 (TARC) (pg/ml) 1.33 92.9 +/-103.1 123.2 +/-111.5 N.S.
CCL19 (MIP3b) (pg/ml) 1.18 18.1 +/-9.1 21.4 +/-10.2 N.S.
CCL20 (MIP3a) (pg/ml) 1.20 7.9 +/-5.0 9.4 +/-9.4 N.S.
CXCL1 (GRO1) (pg/ml) 1.29 2.1 +/-4.1 2.8 +/-5.7 N.S.
CXCL4 (PF4) (pg/ml) 1.04 7219.3 +/-1544.8 7498.3 +/-1249.6 N.S.
CXCL8 (IL8) (pg/ml) 1.17 59.0 +/-41.0 68.8 +/-52.9 N.S.
CXCL10 (IP10) (pg/ml) 0.72 248.2 +/-165.0 177.5 +/-115.5 p<0.01
CXCL12 (SDF1) (pg/ml) 0.98 83.5 +/-35.3 82.2 +/-31.8 N.S.
CX3CL1 (fractalkine) (pg/ml) 0.64 3.0 +/-6.3 1.9 +/-2.0 N.S.
MCSF (pg/ml) 1.07 65.1 +/-38.1 69.7 +/-34.3 N.S.
TNFA (pg/ml) 1.53 8.7 +/-25.6 13.4 +/-34.9 N.S.
MIF (ng/ml) 1.30 10.6 +/-4.62 13.8 +/-9.13 p<0.01









The primary aim of the Circulating Cells study was to find novel biomarkers 
in circulating whole blood which improve on the current biomarkers for risk 
stratification in cardiovascular disease patients. During the course of the Circulating 
Cells study it became clear that there were substantial differences in immune responses 
during cardiovascular disease in males and females. Stratification of patients 
was impossible without taking into account the major sex-specific differences in 
immune biology. It has long been known that sex has an effect on the development 
of atherosclerosis, but little is known about role of sex-specific difference in immune 
response to coronary artery disease (CAD).
Sex differences in cardiovascular disease
Differences in symptoms, risk factors and the underlying pathology of 
cardiovascular disease are well known in men and women. New insights into sex-
specific differences in cardiovascular disease have led to adaptations in diagnostic 
testing and treatment regiments[1].
Cardiovascular disease development in women generally lags 7 to 10 
years behind compared to men in the expression of clinical symptoms[2]. It is not 
fully understood what causes this delay but it is suggested that sex steroids have a 
protective effect on cardiovascular disease development during the pre-menopausal 
years of a woman’s life[3]. Cardiovascular disease greatly increases in women 
after starting menopause, 14% of women in the age of 30 to 44 have obstructive 
cardiovascular disease, 29% of women from 45 to 54, 48% of women from 55 to 
64, 65% of women from 65 to 74 and 79% of women over 75[4]. Due to this delayed 
development cardiovascular disease has been described as a “males disease”. In 
Europe 41% of males die of cardiovascular disease while 52% of women die from 
cardiovascular disease clearly contradicting the view that cardiovascular disease is 
a males disease[5,6]. At lower ages cardiovascular disease is more prevalent among 
men but during menopause the occurrence of cardiovascular disease among women 
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quickly increases, eventually outnumbering the men.
Younger women have a better/healthier atherosclerotic lipid profile compared 
to men, but this changes after menopause at which point total cholesterol levels start 
to increase and at the same time HDL-cholesterol (HDL-C) levels which are higher 
in young women start to decrease[7,8]. Large scale meta-analyses have reported that 
there are no significant differences in risk association between major lipids subsets 
and cardiovascular disease for men and women[9–11]. Although some studies suggest 
triglycerides are a stronger cardiovascular risk predictors for women than for men[12]. 
In the Circulating Cells study women had significantly higher total cholesterol and 
HDL-C levels compared to men, while the difference in LDL-cholesterol (LDL-C) 
was close to significant (p=0.06) and triglyceride level was comparable in both 
sexes (Table 1). 89% of women participants in the Circulating Cells study are over 
the age 50 and likely post-menopausal, as such the higher total cholesterol level is 
not surprising.
Type 2 diabetes, hypertension, metabolic syndrome and obesity are all 
stronger predictors of cardiovascular disease in women than in men. A meta-
analysis including more than 850.000 people shows that diabetes mellitus tripled 
the risk of cardiovascular disease in women while it doubled the risk in men[13], 
another large scale meta-analysis showed an increased risk in women with diabetes 
of 27% compared to men with diabetes[14]. Smoking has recently also been shown 
to confer a 25% greater risk of cardiovascular disease on women than on men[15]. 
Inflammation markers such as C-reactive protein have been used in addition to 
Table 1: Comparison of lipid levels between males and females in the 
circulating cells study
Female (n=126) Male (n=330) p value
Age 63(57-71) 62(56-69) N.S.
Total cholesterol (mmol/L) 4.4(3.8-5.3) 4.0(3.4-4.8) p<0.001
LDL-C (mmol/L) 2.6(1.9-3.2) 2.3(1.8-3.0) N.S.
HDL-C (mmol/L) 1.1(1.0-1.4) 1.0(0.9-1.2) p<0.001
Triglycerides (mmol/L) 1.4(1.0-1.8) 1.3(1.0-1.9) N.S.
Mann-Whitney U test was used to compare male and female subjects.
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traditional risk factors to stratify patients for cardiovascular disease risk. Starting 
from puberty women have systematically higher CRP values compared to men, 
and women with hsCRP values equal to men are at lower risk for cardiovascular 
disease[16]. Other risk markers that differ between men and women are acute phase 
brain natriuretic peptide, which is higher in women with acute coronary syndrome 
while creatine kinase-MB and cardiac troponin are lower in women with acute 
coronary syndrome[17].
In 2007 the American Heart Association issued an update to the guidelines 
for prevention of cardiovascular disease in women, the update altered the risk 
assessment in women in acknowledgement of limitations of the then current risk 
prediction algorithms, like the Framingham risk score[18]. The Framingham risk score 
and other similar risk prediction algorithms are largely age dependent and limited 
to a 10 year risk prediction, this could underestimate the lifetime risk of women and 
especially of young women. The new risk prediction method is mainly based on risk 
factor burden in women, instead of an age dependent risk stratification.
Women with cardiovascular disease have a greater burden of risk factors, 
but despite the increased number of risk factors the extent of atherosclerotic 
plaque burden is less in women than in men[19–21]. In post-menopausal women 
significant changes take place in plaque composition, post-menopausal women 
with cardiovascular disease have plaques with significantly thinner fibrous caps 
and bigger necrotic cores than pre-menopausal women[22]. These changes make the 
plaque more vulnerable to rupture leading to acute clinical complication such as 
acute thrombus formation. There are two main causes of acute thrombus formation 
instigated by atherosclerosis, plaque rupture and plaque erosion[23]. Plaque rupture 
is caused by thinning of the fibrous cap and subsequent rupture of the cap depositing 
thrombotic material into the lumen. Plaque rupture is both in men as well as in 
women the main cause of an acute coronary events. Erosion of the plaque happens 
when the endothelial layer covering the plaque is lost and the layer of smooth 
muscle cells and collagen structure underneath is exposed to the lumen. In general 
plaque erosion is more often seen in women especially in young women than in 
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men [24]. Eroding plaques are most often described as significantly less inflamed 
then ruptured plaques, with a lower macrophage and lymphocyte content[23]. Studies 
have shown that the myeloperoxidase level in plasma is higher in people with plaque 
erosion in combination with an increase in the number of myeloperoxidase positive 
cells in eroding plaques[25]. A recent paper by Quillard et al. showed a possible 
mechanism in which neutrophils cause endothelial desquamation leading to erosion 
of the plaque[26].
Sex differences in cardiovascular disease pathology may be explained by 
several different causes, the most likely of which are sex hormones, genetics and 
gender (environmental) factors. Biological factors such as genetics and primarily 
sex hormones can have substantial impact on immune responses and this in turn 
can influence the development of cardiovascular disease possibly leading to the 
differences observed between the sexes.
Sex differences in the immune response
The pathogenesis of viral, fungal and bacterial infections differs significantly 
between sexes. Infection rate is higher in men and moreover women have a better 
survival rate after infection[27,28]. Vaccination is generally more effective in females 
than in males and higher antibody titers are achieved after vaccination against 
certain antigens[28]. At the same time side effects of vaccination can be more 
severe in women.
In contrast, most autoimmune diseases are more prevalent among 
women[29]. A severe sex bias is found in autoimmune diseases such as systemic lupus 
erythematosus, Sjogrens disease and thyroiditis in which more than 85% of the cases 
are found in women. A less severe but still significant sex bias is seen in rheumatoid 
arthritis and multiple sclerosis in which 60-75% of cases are in women. The cause of 




Monocyte count is significantly lower in women compared to men in the 
Circulating Cells cohort, this is in accordance with other studies that found higher 
monocyte counts in men[30]. Upon start of menopause circulating monocyte count 
significantly increases in women and this increase can be abrogated by hormone 
replacement therapy, as such it is likely that the difference in circulating monocyte 
count seen in the current study would be larger in younger males and females[31]. 
Estrogen could influence monocyte homeostasis through cell survival and 
chemotaxis, both these routes can be influenced by estrogen modulation. Estradiol 
treatment has been shown to down regulate vascular CCL2 expression a potent 
monocyte chemoattractant and has an important function in the homeostasis 
of monocytes in ovariectomized mice[32]. Estrogen can also influence monocyte 
cell survival by modulating the Fas/Fas Ligand system that induces apoptosis in 
monocytes which could consequently influence circulating monocyte count[33].
Not only circulating monocyte count but also the monocyte function is 
influenced by sex. Significant sex-specific alterations in aging have been shown 
in monocyte cytokine expression profiles[34]. Estrogen significantly affects the 
expression of CD16 and cytokine expression of monocytes upon LPS stimulation, 
resulting in a lower IL-1β ,IL-6 and TNFα expression by monocytes[35,36] via 
an inhibition of NF-κB[37,38]. In contrast, prolonged estradiol administration to 
ovariectomized mice increased IL-1β, IL-6 and IL-12p40 expression by peritoneal 
Table 2: Comparison of circulating immune cells between males and females
Female (n=126) Male (n=330) p value
Classical monocytes 472(378-599) 525(430-652) p<0.05
Intermediate monocytes 40(28-55) 41(28-63) N.S.
Non-classical monocytes 48(35-64) 48(35-69) N.S.
Neutrophils 4012(3128-5219) 4010(3132-4933) N.S.
CD4 T cells 1024(804-1332) 809(610-1078) p<0.001
Cytotoxic T cells 295(214-452) 299(203-467) N.S.
T regulatory cells 33(26-48) 26(16-40) p<0.001
Mann-Whitney U test was used to compare male and female subjects.
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macrophages by inhibiting the PI3K/Akt pathway which enhances the response to 
TLR4 signalling[39].
While many studies have examined the impact of estrogen replacement 
therapy on inflammation less is known about the influence of testosterone on the 
immune system. Testosterone replacement therapy in type-2 diabetic men suffering 
from testosterone deficiency lead to a significant decrease in IL-1β, IL-6 and TNFα 
secretion by monocytes [40]. Testosterone has also been shown to induce changes in 
leukotriene synthesis in human monocytes, leukotriene is a potent chemoattractant of 
immune cells and has been shown to be important in atherosclerosis development[41]. 
Leukotriene B4 has been shown to contribute to monocyte recruitment to the 
plaque as well as stimulate foam cell differentiation[42]. Interestingly dual knockout 
of 12/15-LO and 5-LO ,which are involved in the synthesis of leukotrienes, had an 
attenuating effect on atherosclerosis development in female mice but not in male 
mice[43]. Estrogen has both pro- as well as anti-inflammatory effects on monocytes 
while testosterone seems to have mostly repressive effects on monocyte and 
macrophage inflammation. 
In chapter 2 we show that classical monocytes are more numerous in unstable 
CAD compared to stable CAD in both men and women. Breaking up the unstable 
CAD clinical category into unstable angina and non-ST elevated myocardial infarct 
(NSTEMI) an association is seen between classical monocyte count and the CAD, 
gradually increasing from stable angina to unstable angina and reaching the maximum 
level in NSTEMI patients (Table 3). In all clinical categories (stable angina, unstable 
angina and NSTEMI) women have approximately 10% less circulating classical 
monocytes compared to men. In contrast to classical monocytes, intermediate and 
non-classical monocyte count are comparable between women and men. 
Substantial sex-specific differences are found in prognostic monocyte 
subsets. In women classical monocytes are the strongest predictors of CAD events, 
whereas in men intermediate monocytes show a predictive tendency for CAD events 
(Chapter 2). These results are confirmed by two studies, Berg at al. found classical 
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found intermediate monocyte to be predictive in a male dominated cohort[44,45]. This 
shows that women have a ‘classical monocyte predictive phenotype’ and males an 
‘intermediate predictive phenotype’.
T cells
Women tend to have a higher number of circulating CD4 T cells, a higher 
immunoglobulin level and a higher CD4 to CD8 T cell ratio[46–49]. In the Circulating 
cells cohort CD4 T cell numbers are approximately 20% higher in women compared 
to men, confirming these earlier reports (Table 2). Not only are circulating CD4 T 
cells more numerous in women they are also reported to have a stronger response 
to immune stimuli, cytokine production by cytotoxic T cells as well as differentiated 
CD4 T cells is higher in females compared to males[50,51].
Many studies have shown that estrogen can influence T cell differentiation 
toward effector T cell subsets[52–57]. Although effects were observed in these studies 
with T cell skewing towards specific T cell effector subsets, the results conflicted on 
the affected T helper subset. The general consensus is that estrogen has a bimodal 
effect on T cell function, low levels of estrogen skew towards a Th1 response while 
high levels of estrogen result in a Th2 response. The high levels of estrogen during 
pregnancy correlate with the Th2/humoral skewed response[58]. Th2 mediated 
autoimmune diseases flare up during pregnancy and Th1 mediated autoimmune 
diseases report decreased disease severity[59]. Low levels of estrogen lead to increased 
IL-12 responsiveness and induce T-bet expression, the transcription factor 
regulating Th1 differentiation[53,60]. Increased T-bet expression leads to increased 
IFNγ production and inhibition of IL-4 expression, repressing Th2 differentiation[61]. 
High doses of estrogen lead to diminished IFNγ induction of Interferon Regulatory 
Factor-1 (IRF-1) which opens the way to Th2 differentiation[62]. 
In addition to regulating Th1 and Th2 differentiation estrogen can also 
influence Treg cell responses. During the menstrual cycle changing estrogen levels 
can influence the number of circulating Treg cells, Treg numbers increase during 
the follicular phase and decrease during the luteal phase[63]. During pregnancy the 
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number of Treg cells increases and is likely necessary for the immune cell tolerance 
of the allograft expressing paternal antigens (fetus)[64,65]. The importance of Tregs 
during pregnancy is shown in women with SLE ,which have lower number of 
circulating Treg cells. These women have difficulty getting pregnant and maintaining 
pregnancy[66]. Estrogen also influences functionality of Treg, in a mice model of MS 
estrogen treatment induced Programmed Death-1 (PD-1) expression, potentially 
increasing Treg cells suppressive capacity[67]. Furthermore in vitro estrogen increased 
production of IL-10 and TGFβ by Treg cells thus increasing their capacity to regulate 
osteoblast differentiation in a bone resorption model[68].
Not only does estrogen increase T cell number and skew T cell differentiation 
but estrogen also influences trafficking of T cells. CCR1, 2, 3, 4 and 5 are selectively 
upregulated on T cells by administration of estrogen to ovariectomized mice, both 
Th1 as well as Th2 cell showed increased expression chemokine receptors[69].
In males it has been shown that blockade or deprivation of testosterone 
signaling increases thymic emigration of CD4 and CD8 T cells, significantly 
increasing the number of circulating T cells[70–72]. Furthermore, proliferation of 
T cells after TCR stimulation was significantly increased in castrated mice[71,72]. 
Testosterone seems to have a repressive effect on both Th1 as well as Th2 differentiation 
in different disease models, which could explain the higher infection rate seen in 
males[73–75]. The influence of testosterone on Tregs is unclear as reports in different 
disease models show conflicting results on Treg number after administration 
or deprivation of testosterone[76,77]. In general it is clear that testosterone has a 
suppressive effect on T cell numbers and T cell activation.
In the Circulating Cells cohort male patients have a lower number of circulating 
CD4 and regulatory T cells, possibly caused by the repressive effect of testosterone 
as estrogen levels in post-menopausal women are close to or even lower than those 
in men. Strikingly a significant sex-specific difference is shown with regard to the 
effect of the coronary syndrome on CD4 T cell numbers (Chapter 3). While in males 
circulating numbers of CD4 T cells do not differ between stable angina, unstable 
angina and NSTEMI, in females the number of CD4 T cells in unstable angina and 
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NSTEMI is significantly increased compared to stable angina patients (Table 2). The 
difference between males and females in circulating T cell number becomes even 
more exaggerated in the unstable angina and NSTEMI group, females with unstable 
angina or NSTEMI have approximately 50% more circulating CD4 T cells compared 
to males with the same conditions. Possibly testosterone blocks the T cell expansion 
seen in women resulting in a primarily innate response in males while in females 
both an innate and adaptive response occurs.
Neutrophils
It is known that during the menstrual cycle circulating neutrophil counts 
change and are increased during the luteal phase and during pregnancy suggesting 
a role of estrogen and progesterone in neutrophil homeostasis[78]. Delayed apoptosis 
of neutrophils might cause the increase in circulating neutrophils as it has been 
shown that estrogen and progesterone delay apoptosis of neutrophils in a dose 
dependent manner[79]. Testosterone may also play a role in neutrophil homeostasis, 
as castration leads to reduced circulating neutrophil counts in males both in humans 
as well as in mice[80]. In both women and girls circulating neutrophil count is higher 
than in their male counterparts, although it has been reported that this difference 
decreases after menopause[81,82]. In the Circulating Cells study the neutrophil count is 
not significantly different between men and women, possibly due to most women in 
this study being post-menopausal (Table 2).
Compared to T cells few studies have examined sex-specific differences in 
neutrophil function. A study using a mouse model for trauma (hemorrhage shock 
and burn model) shows that testosterone potentiates neutrophil activation while 
estrogen represses activation of neutrophils[83]. Female sex hormones also influence 
chemotaxis of neutrophils in response to fMLP (a chemoattractant) and while 
estrogen reduces chemotaxis, progesterone has the opposite effect of increasing 
chemotaxis[84]. Not only does estrogen impact chemotaxis but also cellular adhesion 
by inducing nitric oxide (NO) synthesis consequently reducing CD18 expression 
and thereby limiting the ability of neutrophils to adhere to endothelial cells[85]. 
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NO expression will also induce vasodilation and reduce adhesion molecule 
expression on endothelial cells limiting overall cell migration. The expression of NO 
is synchronized with the estrogen cycle in women thus further confirming the link 
between NO expression and estrogen[85]. In contrast to these anti-inflammatory effects 
of estrogen one study found that neutrophils in women are myeloperoxidase (MPO) 
enriched compared to neutrophils in men and the MPO concentration correlated 
with the circulating estrogen concentration, thus indicating that female neutrophils 
are potentially more inflammatory than male neutrophils when activated[86].
A recently discovered anti-inflammatory cell subset the myeloid derived 
suppressor cell (MDSC) has been shown to be more numerous in male mice 
circulation compared to female mice in multiple mice strains[87]. There are two 
MDSC subsets the monocytic and the granulocytic MDSC subset, the granulocytic 
MDSC have similar cellular markers as neutrophils. The MDSC cell subset is very 
effective in suppressing inflammation and is well known in the cancer field to limit 
anti-cancer immune responses and thus promote cancer progression. Not only 
do male mice have more circulating MDSCs but in a mouse model of lupus the 
number of MDSCs also correlated with testosterone concentration in the plasma of 
these mice[88].
In the Circulating cells study neutrophil counts are increased with 
increasingly severe cardiovascular disease diagnosis (stable angina, unstable angina, 
NSTEMI), the increase in circulating neutrophil count is comparable between males 
and females (Table 3).A substantial sex-specific effect was found for neutrophil 
subsets prognostic for cardiovascular events, specific subsets were found that were 
predictive for males or for females (Chapter 4). The potential prognostic neutrophil 
subsets were stronger predictors of cardiovascular events than the subsets found in 
the T cell (Chapters 2) and monocyte (Chapter 3) studies described in this thesis.
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Sex differences in cytokine expression
The differences in cytokine production seen between the sexes may be 
related to modulation of the transcription factor NF-κB by sex hormones[89]. 
NF-κB is a central regulator of transcription for many cytokine and chemokine 
genes and by modulating NF-κB activity sex hormones can impact the transcription 
of a broad range of cytokines. Estrogen receptor (ER) can form a complex with 
NF-κB often leading to inhibition of transcriptional activation of both ER as well as 
NF-κB [90]. Activation of the androgen receptor by testosterone down regulates NF-κB 
expression, inversely NF-κB can also modulate androgen receptor expression[91–93].
Table 4: Comparison of cytokine concentrations in blood between males and females
Female (n=106) Male (n=265) p value
IL-1RA (pg/ml) 76.4(0.00-155) 39.0(0.00-107) p<0.05
IL-4 (pg/ml) 28.2(17.4-36.5) 25.0(15.6-34.5) N.S.
IL-5 (pg/ml) 237(193-298) 228(172-278) N.S.
IL-6 (pg/ml) 3.22(1.77-4.63) 3.25(2.95-5.22) N.S.
IL-10 (pg/ml) 5.54(4.32-7.62) 5.50(4.11-6.66) N.S.
IL-12 (pg/ml) 200(136-312) 190(120-285) N.S.
IL-13 (pg/ml) 124(86.8-172) 120(85.1-166) N.S.
IL-15 (pg/ml) 116(75.0-153) 104(65.5-140) N.S.
IL-18 (pg/ml) 82.6(57.1-118) 102(70.4-153) p<0.001
IL-33 (ng/ml) 76.1(45.8-115) 65.1(41.0-101) N.S.
TNFα (pg/ml) 3.32(2.82-5.29) 3.32(2.82-5.52) N.S.
CCL2 (MCP1) (pg/ml) 242(208-282) 233(201-269) N.S.
CCL5 (RANTES) (ng/ml) 87.3(71.1-110) 80.5(65.2-102) p = 0.05
CCL17 (TARC) (pg/ml) 71.7(40.7-128) 69.8(34.0-115) N.S.
CCL19 (MIP3b) (pg/ml) 18.6(12.5-24.8) 16.3(9.87-23.4) p = 0.08
CCL20 (MIP3a) (pg/ml) 6.75(5.15-8.85) 6.74(5.13-8.42) N.S.
CXCL1 (GRO1) (pg/ml) 1.06(0.51-2.07) 1.06(0.46-1.99) N.S.
CXCL4 (PF4) (ng/ml) 7.33(6.28-8.31) 7.25(6.39-8.1) N.S.
CXCL8 (IL-8) (pg/ml) 52.0(41.1-66.8) 52.5(40.8-64.5) N.S.
CXCL10 (IP10) (pg/ml) 195(137-316) 179(128-259) p = 0.09
CXCL12 (SDF1) (pg/ml) 78.5(68.5-85.9) 78.3(67.5-90.6) N.S.
CX3CL1 (fractalkine) (pg/ml) 1.57(1.06-2.92) 1.57(1.06-2.62) N.S.
MCSF (pg/ml) 70.1(40.3-90.0) 68.9(40.0-88.5) N.S.
MIF (ng/ml) 10.3(9.23-11.2) 10.0(8.24-10.9) p = 0.09
Mann-Whitney U test was used to compare male and female subjects.
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Estrogen receptor can influence NF-κB activity in several different ways. 
Estrogen receptor can displace CBP, a coactivator, in the NF-κB promotor complex 
leading to repression of the CCL2 gene[94]. Estrogen receptor can also recruit 
corepressors, as in the case of induction of TNFα where presence of ligand bound 
ER leads to recruitment of GRIP1 to the NF-κB complex blocking of TNFA gene 
transcription[95]. Furthermore ER can block nuclear translocation of NF-κB and 
indirectly affect NF-κB activity by modulating transcription of other factors (e.g. 
IκBα, NF-κB essential modulator) that in turn regulate NF-κB activity[96–98]. In 
general high levels of estrogen lead to inhibition of NF-κB ultimately decreasing 
pro-inflammatory cytokine production, in contrast studies have also shown that 
lower levels of estrogen can increase NF-κB activity compared to controls indicating 
a possible bimodal response[99].
Interferon type I and type II
Studies have also shown that ER can strongly stimulate the type I interferon 
pathway, this view is confirmed by the fact that female mice have a higher expression 
of genes associated with the interferon pathway, such as interferon regulatory factor 
5 and interferon inducible Ifi202[100–102]. Estrogen can also influence expression 
IRF-1 which regulates translation of the type II interferon IFNγ, estrogen at high 
concentrations (pregnancy level) reduced IRF-1 expression in T cells which is 
associated with IFNγ expression[62]. Various reports have shown that the IFNγ 
levels are similar or slightly increased in men compared to women, while IFNγ 
levels significantly change during the menstrual cycle[47,103,104]. In vitro observations 
show that that progesterone and testosterone have no effect on IFNγ production 
indicating that the primary source of variation is likely the estrogen cycle[105,106].
Interleukin 12
Little is known about the effect of estrogen on IL-12 production, reports 
on estrogen levels during pregnancy are inconsistent and in vitro studies on IL-12 
production by CD4 T cells also show inconsistent results[107–109]. Testosterone on the 
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other hand seems to have a potentiating effect on IL-12 production by monocytes as 
LPS stimulated monocytes from men produced more IL-12 then from women and 
confirming these results physiological levels of testosterone also increased production 
of IL-12 in monocytes after LPS stimulation[47,105]. This stands in contrast to reports 
that testosterone represses Th1 differentiation, which is modulated by IL-12.
Interleukin 6
During atherosclerosis development IL-6 has many different functions from 
activating endothelial cells to inducing T cell differentiation[110]. IL-6 is also the 
primary cytokine inducing the hepatic acute phase proteins, acute phase proteins 
such as hsCRP and fibrinogen are used as biomarkers for CAD disease development. 
Sex-differences in IL-6 could have consequence both for the development as well as 
the treatment of atherosclerosis. A multitude of papers have shown a significant 
increase in IL-6 plasma levels after menopause[111–114]. In contrast most papers do 
not show any change during the menstrual cycle, although one paper did show a 
decreased in IL-6 concentration during the luteal phase[115–121]. Reports on the effect 
of hormone replacement therapy on IL-6 levels are inconsistent, one shows an 
increased IL-6 level, two show no change in IL-6 and another two show a decrease 
in IL-6 levels[122–127]. It has been suggested that the discrepancy in effect could be 
due to hepatic effects induced by orally administered conjugated equine estrogen in 
contrast to administering estradiol transdermally[128]. In contrast to humans, animal 
models overwhelmingly show inhibition of IL-6 due to estrogen treatment[129]. 
Testosterone replacement therapy in men with type 2 diabetes showed 
that testosterone reduced pro-inflammatory cytokine production (e.g. IL-6, IL-1β 
and TNFα) in DCs[130]. Generally it is thought that both estrogen and testosterone 
reduce IL-6 expression. A mendelian randomization study has shown that IL-6 
receptor and CAD are causally linked[131], sex hormone induced skewing of IL-6 





Il-4 is the primary cytokine involved in the differentiation of Th2 cells and 
are also one of the cytokines produced by Th2 cells and are thus intimately linked 
with the Th2 cell fate. The data concerning IL-4 and atherosclerosis development 
are inconsistent[132,133] but in a prolonged hyperlipidemic model in advanced 
stages of atherosclerosis development absence of IL-4 decreased atherosclerotic 
development[134]. During menstrual cycle there are significant changes in the number 
of circulating Th2 cells together with an increase in IL-4 production by T cells[104]. 
This could be an effect of an increase in progesterone which has been shown to 
induce IL-4 production in T cells[106]. Women with surgically induced menopause 
(ovariectomy) showed a significant decrease in IL-4 which was not abrogated by 
estrogen replacement therapy [135]. In contrast, there is no significant difference in IL-4 
levels between men and women, also between fertile women and post-menopausal 
women there are no significant differences in IL-4 levels[103,111,136]. In the Circulating 
cells study we also see no significant differences in IL-4 plasma concentration 
between men and women (Table 4). These results show that testosterone and 
estrogen have no effect on IL-4 production while progesterone potentially induces 
IL-4 production in T helper cells. It is unknown what effect the temporal increase in 
Th2 and IL-4 during the menstrual cycle has on atherosclerosis development.
Interleukin 10
Estrogen as well as progesterone has not been shown to induce changes in 
IL-10 plasma levels. IL-10 levels between men and women do not significantly differ 
and also there is no significant difference between fertile and post-menopausal 
women, furthermore IL-10 levels do not change during the menstrual cycle[47,103]. 
There are some indication that testosterone might induce IL-10 production in 
T cells. In an experimental model of lupus it was shown that splenocytes from 
mice treated with a testosterone derivate secrete significantly larger amounts 
of IL-10, as well as CD4 T cells directly treated with testosterone significantly 
increased IL-10 secretion[137,138].
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CCL2
There is very little information on effects of sex on chemokine expression, the 
single exception is CCL2. Estrogen has been shown to inhibit monocyte migration 
by CCL2 and studies in multiple cell types have shown that estrogen represses CCL2 
production[129]. Post-menopausal women on hormone replacement therapy showed 
a gradual decrease of plasma CCL2 level over a 12 month period and cessation of 
treatment resulted in an increased CCL2 plasma level[139]. Ablation of CCL2 receptor 
CCR2 results in a decrease in circulating monocytes and consequently a decrease 
in monocyte infiltration in the plaque[140], as such reduced CCL2 could decrease 
atherosclerosis progression in women.
Sex-specific differences in cytokine expression in the Circulating Cells cohort
Studies on sex-specific effects on other cytokines or chemokines are 
inconsistent (IL-1β, IL-2) or not available. In the Circulating Cells cohort we see 
only few significant differences in cytokine concentration between men and 
women, IL-1RA is significantly higher in women while IL-18 is significantly higher 
in men. Interestingly it has been shown that IL-18 is significantly increased in 
post- menopausal women while IL-18 has also been shown to be increased during 
pregnancy[111,141]. These results indicate that sex hormones but possibly also genetic 
factors modulate sex differences in IL-18 expression.
In the Circulating cells cohort there are few differences in cytokine expression 
pattern between male and female stable and unstable CAD patients, the exception 
is CXCL10 which is significantly lower in female unstable CAD patients while 
expression in male unstable CAD patients is not different from stable CAD patients 
(Chapter 5). As we have seen before in the analysis of monocytes and neutrophils in 
the prospective analysis we again see a substantial difference between sexes, while 
CCL5 is predictive of CAD related events in men this is not the case in women and 
in women MCSF is predictive whereas it is not in men. Even more curious is the fact 
that the CXCL10 to CXCL1 ratio is predictive of CAD related events in both men 
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and women but while an increase is associated with a protective effect in women 
these levels are associated with a higher risk in men (Chapter 5).
Association of inflammation factors with sex-specific changes in immune cells
The large differences in development of immune diseases between men 
and women shows that the regulation of the immune system is likely substantially 
different between sexes. The Circulating Cells database has an extensive with 
CAD related inflammatory factors which we can use to examine the sex-specific 
interactions of inflammatory factors with cell count. HDL-C is lipoprotein and is 
well known to have an anti-inflammatory effects. In the Circulating Cells cohort 
the number of circulating neutrophils, CD4 T cells, CD8 T cells and Treg cells is 
decreased when HDL-C concentration is increased but only in males, surprisingly 
females show no significant association between HDL-C levels and circulating 
immune cells (Table 5). Acute-phase proteins are often used to show changes in 
inflammation, these proteins are produced by the liver in large quantities in response 
to pro-inflammatory cytokines secreted by a local inflammatory reaction. hsCRP is 
such an acute-phase protein and in the Circulating Cells cohort both in males and 
females the immune cell distribution significantly changes with increasing hsCRP 
concentration, although the pattern of changes is substantially different between 
sexes. With increasing hsCRP concentration in males the number of circulating 
neutrophils and monocyte increases significantly subsets, instead in females the 
number of circulating T cell, eosinophils and neutrophils increases significantly and 
not monocytes (Table 6). Acute phase proteins are an upstream reaction to changes 
in cytokine concentrations and one of the main cytokines known to induce hsCRP 
production is IL-6. While in both males and females we see a significant increase 
in neutrophil count with increasing IL-6 concentration other changes in immune 
cell distribution seem to be sex-specific (Table 7). Females show a large increase in 
classical monocytes while males show large decreases in CD4 and CD8 T cells with 
increasing IL-6 concentration. The sex-specific associations between inflammation 
217































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































factors and immune cells suggests that regulation of immune cells in males and 
females are considerably different between the sexes.
Future perspectives
Sex-specific differences in biomarker have been shown, from differences 
in baseline value to differences in biomarker potential. Still most biomarkers are 
used without taking sex differences into account, target values or cut-off points for 
biomarkers are identical for both sexes. By taking into account the sex of the patient, 
current biomarkers target values can be improved to increase accuracy of diagnosis 
as well as prognosis. Prognostic biomarkers seem to be especially dependent on 
the sex of the subject and we show here that many prognostic biomarkers that are 
valid for one sex will not be valid or even have an opposing effect in the other sex. 
Taking into account the large sex-specific differences in immune diseases, from 
auto-immune responses to infection, the potential for sex-specific biomarkers in 
these diseases is most likely even more pronounced.
Currently in the research field of cardiovascular disease there is great interest 
in the effect the sex of the patient has on the development and progression of CAD, 
but this has not yet translated into changes in clinical practice. A better understanding 
of the specific differences in CAD development in males and females will lead to 
better targeted treatment of CAD in patients but could potentially also lead to 
discovery of novel treatment targets in the different sexes. The studies described in 
this dissertation show a clear advantage in the use of biomarkers specifically tailored 
to the sex of the patient and shows the need for further research into sex-specific 
pathology as well as sex-specific treatment of cardiovascular disease.
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Circulerende immuun cellen als biomarkers in hart- en vaatziekte: 
het verschil tussen mannen en vrouwen
In het begin van de 20ste eeuw waren coronaire hartziekten in Amerika 
de vierde doodsoorzaak na longontsteking, tuberculose en diarree; in de 
daaropvolgende jaren zou dit snel veranderen. In het begin van de vorige eeuw 
was de levensverwachting van een 20-jarige man slechts 41 jaar, de impact die 
een leeftijd gerelateerde aandoening zoals coronaire hartziekten kon krijgen was 
hierdoor beperkt. Maar in de daaropvolgende decennia nam de leeftijdsverwachting 
dramatisch toe en door de gemiddeld hogere leeftijd nam ook de kans toe om te 
overlijden aan coronaire hartziekten, maar ook de dramatische afname van andere 
ziekten zoals tuberculose en diarree droegen hieraan bij. Tegen het einde van de 
tweede wereld oorlog vormden coronaire hartziekten doodsoorzaak nummer 1 in 
Amerika en dat is sindsdien niet meer veranderd. In Nederland wordt pas sinds 
1936 bijgehouden hoeveel mensen overlijden aan hart- en vaatziekten (HVZ), en 
direct was HVZ in 1936 de grootste doodsoorzaak in Nederland. Momenteel is 
HVZ de primaire doodsoorzaak wereldwijd en voorspellingen wijzen erop dat dit 
nog wel een tijd zo zal blijven.
De primaire oorzaak van HVZ is atherosclerose ook wel aderverkalking 
genoemd. Atherosclerose is een proces waarbij verdikking plaatsvindt van de 
slagaderwand voornamelijk op plaatsen waar de slagader zich vertakt. De eerste 
stadia van atherosclerose zijn al zichtbaar bij tieners en jongvolwassenen. In dit 
stadium vindt er ophoping plaats van lipoproteïnen (cholesterol) in de aderwand, 
deze ophoping is met het blote oog te zien als een gele “vettige” verdikking en 
wordt dan ook wel een “fatty streak” genoemd. De lipoproteïnen, “Lage Dichtheid 
Lipoproteïne” (LDL) genoemd, kunnen worden gemodificeerd en dit zorgt voor 
een verergering van de plaatselijke ontstekingsreactie. De endotheelcellen, die de 
fatty streak scheiden van het lumen waar het bloed door stroomt, raken geïrriteerd 
door het gemodificeerde LDL en gaan eiwitten/proteïnen produceren waardoor 
immuuncellen blijven “plakken” en in de vaatwand infiltreren. Risico factoren voor 
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HVZ zoals roken, diabetes en hoge bloeddruk zorgen onder andere voor een hogere 
mate van irritatie van de endotheelcellen wat de vorming van een atherosclerotische 
plaque versnelt. Monocyten (een type immuun cel) zijn de eerste cellen die 
migreren naar de (zogenaamde) atherosclerotische plaque. Zo gauw de monocyten 
in de plaque zijn gaan ze ongeremd gemodificeerd LDL opnemen maar doordat ze 
slecht in staat zijn deze lipiden weer uit te scheiden veranderen ze in zogenaamde 
schuimcellen, grote cellen met vet ophopingen in de cel. Dit eerste stadium van 
atherosclerose is nog volledige reversibel door verlaging van het LDL gehalte in het 
bloed, dus door een aanpassing van het dieet of door het gebruik van medicijnen.
Veel vroege atherosclerotische plaques zullen zich niet verder ontwikkelen 
dan het stadium van een fatty streak, maar sommige plaques voornamelijk op 
specifieke plekken in de kransslagader, dijslagader en halsslagader zullen zich 
verder ontwikkelen tot een complexe plaque. Immuun cellen zoals macrofagen, 
neutrofielen en T cellen, die gemigreerd zijn naar de plaque zullen ontsteking 
versterkende proteïnen gaan produceren zoals cytokinen. Dit zorgt voor een vicieuze 
cirkel waarbij meer immuun cellen worden gerekruteerd die dan weer de lokale 
ontsteking versterken waardoor weer meer immuun cellen worden aangetrokken. In 
dit stadium gaan gladde spiercellen migreren vanuit de wand van de slagaderen en 
gaan de plaque bedekken met een beschermende laag fibroblast-achtige spiercellen. 
Gladde spiercellen produceren extracellulaire matrix proteïnen die voor een “fibrous 
cap” zorgen op de plaque, deze beschermt de plaque tegen schade en stabiliseert de 
structuur van de plaque. Intussen zullen sommige schuimcellen en gladde spiercellen 
in de kern/het binnenste van de plaque doodgaan, de cellen die doodgaan kunnen 
niet goed worden opgeruimd waardoor een necrotische kern ontstaat waarin zich 
afbraakmateriaal van cellen en lipiden verzamelt. De necrotische kern zorgt voor 
een verergering van de ontstekingen en door stresssignalen vanuit het binnenste 
van de plaque kunnen er nieuwe vaatjes worden gevormd die voornamelijk vanaf 
de buitenkant van de ader zorgen voor extra toevoer van immuun cellen. Op dit 
punt in de ontwikkeling van de atherosclerotische plaque wordt de plaque een 
“fibroatheroma” genoemd. De ontwikkeling van de fibroatheroma gebeurt niet bij 
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iedereen even snel, hoewel mannen evenveel fatty streaks hebben op jongere leeftijd 
als vrouwen, hebben mannen veel meer fibroatheromas tegen de tijd dat ze 30 worden.
Door toename van de grote van de plaque kan de plaque een obstructie 
vormen voor de bloed circulatie, in eerste instantie kan de ader dit opvangen door 
verwijding van het bloedvat waardoor de oppervlakte van het lumen niet veranderd. 
Zo gauw de ader dit niet meer kan opvangen doordat de plaque te groot is geworden 
zal het lumen nauwer worden en kunnen er klinische klachten ontstaan. Ernstige 
stenose, zoals vernauwing van het lumen door een plaque genoemd wordt, kan 
resulteren in pijn op de borst die voornamelijk bij lichaamsinspanning wordt 
gevoeld, dit wordt ook wel angina pectoris genoemd.
Een myocard infarct is in bijna alle gevallen een gevolg van een bloedstolsel 
(een zogenaamde trombus) dat de bloed toevoer in de slagader blokkeert. Er 
zijn twee grote oorzaken van trombus vorming: het scheuren van de plaque en 
zogenaamde erosie van de plaque. Scheuren van de plaque is de meest voorkomende 
vorm en is in 75% van de gevallen de oorzaak van trombus formatie. Onderzoek 
heeft uitgewezen dat plaques die scheuren een dunne fibrous cap hebben, de laag 
met spiercellen en extracellulaire matrix proteïnen die de plaque bedekt is dunner 
geworden. Deze kwetsbare atherosclerotische plaques worden in het Engels “thin 
cap fibroatheroma” (TFCA) genoemd, deze plaques worden getypeerd door een 
dunne fibrous cap en een grote necrotische kern. Het dunner worden van de fibrous 
cap wordt veroorzaakt door sterfte van gladde spiercellen die de extracellulaire 
matrix proteïnen produceren, de sterfte van gladde spiercellen wordt op zijn beurt 
veroorzaakt door ontstekingsfactoren die worden geproduceerd door geïnfiltreerde 
immuuncellen. Autopsie bij mensen heeft uitgewezen dat TFCA plaques in ruime 
mate zijn geïnfiltreerd door immuuncellen zoals monocyten. In 95% van de gevallen 
van een gescheurde plaque blijkt het om een TCFA te gaan maar onderzoek heeft ook 
uitgewezen dat maar een klein percentage van de TFCAs in het lichaam uiteindelijk 
werkelijk scheuren. Blijkbaar zijn er meer factoren van belang bij het destabiliseren 
van de plaque, maar welke dat zijn is nog onduidelijk.
Het scheuren van de plaque is niet de enige oorzaak van trombus formatie, 
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zogenaamde erosie van de plaque kan ook zorgen voor trombus formatie. In 
vergelijking met het scheuren van de plaque is er vrij weinig bekend over erosie 
van de plaque. Bij erosie is er geen scheur in de plaque zichtbaar maar is er wel 
trombus formatie, de endotheelcellen die normaal de binnenkant van het bloedvat 
bedekken zijn bij erosie van de plaque verloren gegaan. Hoewel het scheuren van de 
plaque voor zowel mannen als vrouwen de voornaamste oorzaak zijn voor trombus 
formatie komt erosie van de plaque veel vaker voor bij vrouwen, voornamelijk bij 
premenopauzale vrouwen.
In dit proefschrift wordt gebruik gemaakt van de data die verkregen zijn uit 
de Circulating Cells studie, die is opgezet om te zoeken naar factoren in het bloed 
die kunnen voorspellen of iemand die al last heeft van HVZ een cardiovasculair 
ongeluk krijgt zoals hartinfarct. In de hoofstukken 2, 3 en 4 van dit proefschrift werd 
er gekeken of circulerende immuuncellen een voorspellende waarde hebben voor 
het optreden van complicaties van HVZ. In hoofdstuk 2 en 4 worden respectievelijk 
naar monocyten en neutrofielen gekeken, dit zijn cellen die bij het aangeboren 
immuunsysteem horen. Het aangeboren immuunsysteem kan een breed scala 
aan lichaamsvreemde elementen zoals bacteriën meteen herkennen en opruimen. 
Dit gebeurt zeer snel maar kan door het ongerichte karakter van het mechanisme 
soms tot schade leiden bij gezonde cellen. Als de reactie voortduurt, kan dit tot 
escalatie leiden van de immuun reactie en kunnen negatieve gevolgen hebben voor 
de omringende weefsels. Bij atherosclerose leidt de voortdurende ontstekingsreactie 
voornamelijk tot over activatie van het aangeboren immuun systeem. In hoofdstuk 3 
werd gekeken naar T cellen, dit zijn cellen die in adaptieve immuun systeem werken. 
Het adaptieve immuun systeem leert de lichaamsvreemde elementen te herkennen 
dit kan in eerste instantie tijd kosten maar als het adaptieve immuun systeem 
eenmaal heeft geleerd een bepaald lichaamsvreemd element te herkennen kunnen 
bij een volgende infectie snel een immuun reactie op gang worden gebracht. Dit is 
bijvoorbeeld noodzakelijk bij het griepvirus dat elk jaar verandert, waardoor het 
aangeboren immuun systeem het virus deeltje niet herkent, het adaptieve immuun 




In hoofdstuk 2 tot en met 4 keken we naar bijvoorbeeld het aantal monocyten, 
neutrofielen en T cellen dat er in de bloedsomloop is, maar daarnaast analyseerden 
we ook wat de activatie status van een cel was. De activatie, migratie of regulatie 
status van een cel kunnen we aflezen aan de expressie van bepaalde proteïnen op 
de celwand, hierdoor kunnen we de cellen opdelen in subsets van monocyten, 
neutrofielen of T cellen. Een bekende subset van T cellen bijvoorbeeld die niet 
zozeer in de actieve afweer van lichaamsvreemde elementen meedoet maar een rol 
heeft bij het regelen van de immuunreactie, de zogenaamde T-remmercel. Deze 
T-remmercel cel kan bijvoorbeeld een immuunreactie verminderen of stoppen door 
in te grijpen bij de lokale immuuncellen. T-remmercellen brengen een zeer specifiek 
patroon van eiwitten op hun celoppervlak tot expressie (CD4, CD25 en niet CD127) 
aan de hand waarvan ze geïdentificeerd kunnen worden.
Het eerste wat opviel tijdens de analyse van de verkregen data was dat er 
grotere verschillen waren tussen mannen en vrouwen. Mannen hebben bijvoorbeeld 
meer circulerende monocyten (hoofdstuk 2) terwijl vrouwen daarentegen veel meer 
circulerende T cellen (hoofdstuk 3) hebben. Zowel voor monocyten (hoofdstuk 2) 
als neutrofielen (hoofdstuk 4) vonden we cel subsets die alleen voor vrouwen of 
alleen voor mannen voorspellend waren voor het ontstaan van cardiovasculaire 
complicaties (ongelukken).
Daarnaast hebben we ook gekeken naar circulerende ontstekingsfactoren 
(cytokinen) om te bepalen of deze kunnen voorspellen of het waarschijnlijk is dat een 
cardiovasculair complicatie binnenkort ontstaat (hoofdstuk 5). Bij cytokinen vinden 
we dat de verschillen tussen man en vrouw nog extremer zijn dan de gevonden seks-
gebonden verschillen bij de immuuncellen. Bij cytokinen hebben we een cytokinen 
ratio (de ene cytokine concentratie gedeeld door een andere cytokine concentratie) 
die tegengesteld voorspellend is bij mannen en vrouwen. Dat wil zeggen een hoge 
CXCL10/CXCL1 ratio is goed voor vrouwen want die hebben dan een kleinere 
kans op het ontwikkelen van cardiovasculaire complicaties, daartegenover staat dat 
mannen met een hoge CXCL10/CXCL1 verhouding juist een grotere kans hebben op 
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het krijgen van een cardiovasculaire complicatie. Het is onduidelijk wat de oorzaak 
is van deze verschillen maar mogelijk heeft dit te maken met immuun regulatie door 
seks hormonen, zoals estrogeen en testosteron.
Hoofdstuk 6 heeft een wat afwijkend onderwerp en gaat over het effect 
van roken op het immuunsysteem. We zien dat als mensen roken de hoeveelheid 
circulerende monocyten, neutrofielen en T cellen sterk toeneemt en ook andere 
inflammatie factoren (cytokinen) nemen sterk toe vergeleken met mensen die 
niet roken. Ook kijken we of het verschil maakt hoeveel men rookt, bij de meeste 
inflammatie factoren en immuun cellen is dit niet het geval. T-remmercellen nemen 
daarentegen toe naarmate mensen meer roken, opvallend genoeg is dit ook het geval 
bij mensen die al gestopt zijn met roken. Dus bij mensen die roken is het aantal 
T-remmercel cellen blijvend verhoogd. Over het algemeen worden T-remmercel 
cellen als gunstig gezien voor de ontwikkeling van atherosclerose omdat ze de 
ontstekingsreactie onder controle houden, maar daarentegen is er ruimschoots 
aangetoond dat roken de ontwikkeling van atherosclerose bevordert. De negatieve 
effecten van roken overschaduwen hoogstwaarschijnlijk de positieve effecten van de 
toename van het aantal T-remmercellen.
De overkoepelende conclusie uit dit proefschrift is dat er een groot 
verschil bestaat tussen mannen en vrouwen wat besterft de immuunregulatie 
tijdens atherosclerose. Mogelijk zijn niet alleen de voorspellende immuunfactoren 
verschillend maar ook de processen die tot de ontwikkeling en progressie bijdragen 
aan atherosclerose. Niet alleen blijken factoren die een cardiovasculair ongeluk 
voorspellen verschillend tussen mannen en vrouwen, maar verschillen in de effecten 
van medicatie op atherosclerose progressie kunnen ook een rol spelen. Er is meer 
onderzoek nodig om een beter inzicht te krijgen in de overeenkomsten en in de 
verschillen bij de ontwikkeling van HVZ in mannen en vrouwen. Dit kan uiteindelijk 
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